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Abstract                                                                              
  
DNA damage transactivates TP53-regulated surveillance mechanisms that are crucial in 
maintaining cellular integrity and suppressing tumorigenesis. TP53 mediates this 
directly by transcriptionally modulating gene and microRNA (miRNA) expression and 
by regulating miRNA biogenesis through interaction with the DROSHA complex. 
However, the regulative mechanism of miRNA-AGO2 loading and the global change in 
AGO2 binding to its gene targets in response to DNA damage have not been investigated 
yet. In addition, the role of other non-coding RNAs, such as snoRNAs, in the TP53-
mediated response to DNA damage has not yet been defined. Here we identify a novel 
group of TP53-regulated miRNAs and show that DNA damage induces and reduces the 
loading of a subset of miRNAs, including the let-7 family members onto AGO2, in a 
TP53-dependent manner and that this previously undescribed process is most likely the 
result of TP53 binding to AGO2.  These findings indicate that TP53 control of AGO2 
loading is a new mechanism of miRNA regulation in carcinogenesis. Using AGO2 RIP-
Seq and PAR-CLIP we also show that TP53 modulates the reduction, induction and 
remodelling of AGO2 binding to the 3’UTR of different mRNA targets at specific RNA 
motifs. Furthermore, we determine on a transcriptome-wide level the miRNA-mRNA 
interaction networks involved in the response to DNA damage both in the presence or 
absence of TP53. We also show that those miRNAs whose cellular abundance or 
differential loading onto AGO2 is regulated by TP53, are involved in an intricate 
network of regulatory feedback and feedforward circuits that fine tune gene expression 
levels in response to DNA damage to permit DNA repair or the initiation of 
programmed cell death. Finally, we demonstrate a relationship between TP53 and the 
GAS5-derived snoRNAs both in cancer cell lines and human tissue samples which 
implies that this class of non-coding RNAs might also be involved in coordinating the 
TP53-mediated response. These findings provide a novel insight into the complexities 
surrounding the role of non-coding RNAs in the TP53 response to DNA damage and 
their relevance to carcinogenesis. 
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1.1 MicroRNAs and their biogenesis   
 
MicroRNAs (miRNAs) are small endogenous non-coding RNAs ~17 – 25 nucleotides 
(nt) in length that play an important role in post-transcriptional regulation of gene expression 
by targeting mRNAs for cleavage or translational repression.
2
 The first miRNA gene, Lin-4, 
was identified in 1993 in the nematode Caenorhabditis elegans and was implicated in 
postembryonic development.
3
 
4
  miRNAs were subsequently identified in other species 
including plants, animals and even viruses.
5
 Early estimates grouped miRNAs into 48 
families, based on similarities in nt 2–8 at their 5’ end, referred to as the ‘seed sequence’, and 
at least a third of miRNA families are highly conserved across species.
6,7
 Currently around 
1900 mature human miRNA sequences have been identified and the genes that encode them 
have been found in intergenic regions and within introns and exons of other genes. miRNAs 
can be transcribed from their own promoters, promoters of nearby genes or from promoters 
of ‘host’ genes. Furthermore, they can be expressed as single genes (monocistronic) or as 
clusters of miRNAs situated within one specific locus (polycistronic).
4
 
 
MiRNA gene transcription is predominantly regulated by transcription factors (TF) 
responding to multiple stimuli.
8
 Most miRNAs are transcribed in the nucleus by RNA 
polymerase II (Pol II) to produce primary transcripts (pri-miRNAs).
9-11 Some miRNAs 
associated with Alu repeats are transcribed by Pol III, which is also responsible for 
transcription of other small non-coding RNAs such as the U6 small nuclear RNAs (snRNA).
2
 
Pri-miRNAs are several kbs long, contain a local hairpin “stem- loop” structure and are 
capped and polyadenylated (Figure 1).
9-11
  
 
Pri-miRNA processing involves “cropping” of the upper part of the pri-miRNA stem–loop by 
an RNaseIII enzyme called DROSHA, to form the 60-70-nt precursor-miRNA (pre-
miRNA).
12,13
 Drosha is a 160kDa protein containing two RNase III domains (RIIIDs) and a 
double-stranded RNA-binding domain (dsRBD).
5,14
 It forms two types of complex, a small 
650 kDa microprocessor complex that contains only Drosha and DiGeorge syndrome critical 
region gene 8 (DGCR8) that processes the majority of pri-miRNAs, and a larger complex that 
contains the Dead-Box RNA helicases (p72 and p68; also known as DDX17 and DDX5), 
heterogeneous nuclear ribonucleoproteins and Ewing's sarcoma proteins.
15
 p72 and p68 may 
act as a “scaffold” to recruit other factors (e.g. SMADs & p53) for the processing of a subset 
22 
 
of pri-miRNAs whose pre-miRNA  and mature miRNA levels are reduced in homozygous 
p72 or p68 knockout mice.
16-18
   
 
Drosha cleaves the 5' and 3' arms of the pri-miRNA hairpin, and DGCR8 determines the 
exact cleavage site. Intron-derived miRNAs (mirtrons) bypass Drosha-mediated processing 
and form a hairpin structure resembling a pre-miRNA after splicing and debranching, prior to 
further processing by Dicer in the cytoplasm.
19,20
 Pre-miRNAs can also be generated from 
short introns, which are referred to as mirtrons. They are Drosha-independent and are 
liberated during splicing by the spliceosome.
21
 
 
Pre-miRNAs comprise of a short double-stranded RNA (dsRNA) stem with a base-paired 5′ 
end and a 1–8 nt protruding 3′ end ("minihelix motif").9,22 Export of pre-miRNAs is mediated 
by a nuclear transport receptor called exportin-5, encoded by the XPO5 gene.
23
 Exportin-5 
binds cooperatively to pre-miRNAs and the guanosine triphosphate (GTP) bound form of its 
cofactor Ran GTPase in the nucleus, and releases the pre-miRNA following the hydrolysis of 
Ran-GTP to Ran-GDP in the cytoplasm.
23
 Pre-miRNAs are then processed by the 
cytoplasmic RNase III Dicer which cleaves off the loop to form into 22 nt miRNA duplex 
(miRNA-miRNA*) that have 2 nts overhanging at each 3' end.
5,20
  
 
Dicer is a 200 kDa multi-domain protein containing two RIIIDs, a dsRBD and a long N-
terminal segment with a Dead-Box RNA Helicase domain, a DUF283 domain and a PAZ 
domain. The Dead-Box RNA Helicase domain uses ATP hydrolysis to unwind RNA 
duplexes.
5
 Human Dicer next interacts with 2 proteins, TRBP (TAR RNA-binding protein) 
and PACT (protein activator of PKR), neither of which are required for the cleavage reaction 
itself, but contribute to the formation of the RNA-induced silencing complex (RISC) by 
recruiting the final core component protein Argonaute-2 (AGO2).
24,25
 The RISC is the 
cytoplasmic effector machine of the miRNA pathway and contains a single-stranded miRNA 
guiding it to its target mRNAs. Cytoplasmic miRNA processing and RISC assembly are 
mediated by the RISC loading complex (RLC).
20
 The RLC complex is initiated by the 
assembly of Dicer, TRBP and AGO2, and the exported pre-miRNA only joins the RLC after 
this is complete.
26
  
 
Mature miRNAs that are incorporated into the effector complex are termed 'miRNP' 
(miRNA-containing ribonucleoprotein complex), “mirgonaute” or “miRISC” (miRNA-
23 
 
containing RNA-induced silencing complex).
5
 Their function requires separation of the 
miRNA/miRNA* duplex into the functional guide strand, which is complementary to the 
mRNA target, and the passenger strand (miRNA
*
), which is subsequently degraded.
5,20
 The 
strand selected for incorporation into the miRISC is determined by the thermodynamic 
stability of the base pairs at the two ends of the duplex. Generally the strand with the weakest 
5’-end base pairing is selected as the functional strand and loaded onto AGO2. The miRISC 
then binds by imperfect or perfect base pair complementarity to the 3'UTR of the target 
mRNA in a sequence-specific manner, inducing mRNA cleavage (in cases of perfect base 
pair complementarity), cleavage-independent mRNA degradation through deadenylation or 
translational repression (in cases where the interaction contains bulges).
18
  MiRNAs generally 
bind via their 5’ part, termed the ‘seed region’ (nucleotides 2–8 of the miRNA), to the 
complementary motif located on the target mRNA using Watson–Crick consecutive base 
pairing.
27
 The 3’ part of the miRNA also interacts with the target thus forming an an 
imperfect interaction with it. It  has been predicted that a single miRNA can therefore target 
many mRNAs.
28
 The choice between translational suppression or mRNA degradation is 
largely affected by the degree of complementarity with the mRNA target.
28
 
 
Although in plants, miRNAs generally target transcripts through perfect complementarity, in 
humans, targeting is predominantly through imperfect base-pairing to multiple sites in 3′ 
UTRs. Watson–Crick base-pairing to the 5′ end of miRNAs, especially to the ‘seed region’ is 
crucial for miRNA-target regulation. However, 3′-end pairing might also contribute to target 
recognition, especially when sites have weaker miRNA seed matches. Imperfect miRNA–
mRNA hybrids with central bulges at nucleotides 9–12, drive repression of gene expression 
through translational inhibition or exonucleolytic mRNA decay. Several studies in various 
systems have proposed mechanisms of miRNA-mediated translational repression.
29-31
 They 
include repression at the initiation and post-initiation stage of translation,
31,32
 as well as rapid 
degradation of target mRNAs.
33-35
 GW or P-bodies in the cytoplasm appear to play a vital 
role in miRNA-mediated translational repression and mRNA decay,
29-31
 and GW182 is a 
particularly important component of this process in various orgnaisms including humans.
34-36
 
Wakiyama et al. (2009) demonstrated that let-7 miRNPs directed the deadenylation of target 
mRNAs and impaired the synergistic enhancement of translation by the 5’-cap and 3’-
poly(A) tail and that this resulted in translational repression and was dependent on AGO and 
GW182.
37
 Furthermore, Meijer  et al. (2013) demonstrated a linear model for miRNA-
mediated gene regulation in which translational repression via the RNA helicase eIF4A2 was 
24 
 
required initially and this was subsequently followed by mRNA decay.
38
 Perfectly 
complementary target sites with central pairing are rarely demonstrated in humans but 
generally result in target regulation through mRNA degradation/slicing rather than 
transcriptional repression.
39
 Target site multiplicity has been shown to enhance the degree of 
repression by animal miRNAs, each of which might have hundreds of target transcripts, 
owing to their imperfect base-pairing requirements. Although miRNAs predominantly target 
evolutionarily conserved sites on the 3’UTRs of mRNA, studies have shown that target sites 
also exist on the open reading frames (ORFs) as well as on the 5’ UTRs and that miRNA-
guided gene repression via these sites can be equally efficient.
40-43
 Accordingly, two recent 
studies in human cells have identified functional miRNA target sites in the ORFs of DNA 
methyltransferase 3b and of the cell-cycle inhibitor p16INK4A (CDKN2A).44,45 Conversely, 
recent evidence from genome wide studies argues against miRNAs having the capability to 
regulate targets through an interaction with their ORFs region.
46
 Although miRNA regulated 
gene targeting relies predominantly on the miRNA-mRNA interaction sites within the 
primary structures of both elements, it is probable that secondary structure of the mRNA and 
its association with RNA-binding proteins (RBPs) could also influence target site 
accessibility, and hence modulate miRNA regulation of gene expression. For example, 
folding within the mRNA secondary structure (for example forming a stem loop) may 
conceal its 3’UTR target site and prevent the RISC from binding.47 Furthermore, if the 
miRNA target site overlaps with an RBP binding site then, when bound to the RBP, the 
mRNA would be protected from miRNA targeting.
48
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1.1.1 AGO2 and miRNA loading on the RISC complex 
 
AGO proteins are the direct binding partners of small RNAs and are crucial components of 
all of the small-RNA-guided gene-regulatory processes that have been identified to date.
49
 
They are highly conserved in all eukaryotes, except in Saccharomyces cerevisiae, where the 
small RNA machinery is lost.
50
 In eukaryotes, the AGO family can be divided into AGO and 
PIWI proteins. AGO proteins mainly interact with miRNAs or short interfering RNAs in the 
cytoplasm where they are involved in post-transcriptional gene-silencing. 
51
 PIWI proteins 
silence transposable genetic elements through binding to PIWI-interacting RNAs (piRNAs) 
especially in germ line cells.
52
 In mammals, the AGO subfamily consists of four distinct 
proteins (termed AGO1-4), and although all four appear to bind miRNAs, only AGO2 is 
catalytically active and functions as an endonuclease.
53
 However studies do suggest that the 
Figure 1: miRNA processing. 
The primary miRNA transcript (pri-miRNA) 
is synthesised by RNA polymerase II or III. 
Cleavage occurs in the nucleus by the 
microprocessor complex Drosha–DGCR8 to 
produce a precursor stem-loop structure 
termed the pre-miRNA. This is exported 
from the nucleus into the cytoplasm by 
Exportin-5–Ran-GTP where the RNase 
Dicer in complex with the double-stranded 
RNA-binding protein TRBP cleaves the pre-
miRNA hairpin into its mature form. The 
functional strand of the miRNA/miRNA* 
duplex is loaded with Argonaute (AGO2) 
proteins into the RNA-induced silencing 
complex (RISC), and guides the RISC to 
silence target mRNAs through various 
mechanisms. The passenger strand 
(miRNA*) is degraded. Modified from 
Winter et al. Nature Cell Biology 11, 228 - 
234 (2009) 20  
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non-catalytic AGO proteins (AGO1, 3 and 4) may not be completely redundant and that they 
may play a role in processes such as spermatogenesis
54
 and Alu RNA-guided mRNA decay 
during stem cell proliferation.
55
  
 
AGO2 consists of four distinct domains: the amino- or N‑terminal, PAZ (PIWI–
ARGONAUTE–ZWILLE), Mid (middle) and PIWI domains, that form a two lobed structure 
with one lobe comprising the N and PAZ domains and the other containing the MID and 
PIWI domains. The two lobes are connected via a hinge that allows structural rearrangements 
to occur upon RNA binding. The N domain facilitates small RNA loading onto AGO2 and 
assists in unwinding the small RNA duplex.
56
 Furthermore it contains an unstructured loop 
that is important for mRNA cleavage.
57
 The PAZ domain binds the miRNA 3′ end into a 
specific binding pocket and thus anchors it in place, whilst the MID domain anchors the 5′ 
end through specific contacts with uridine or adenine residues.
58
 This means that small RNAs 
with Gs or Cs at their 5′ end will only bind weakly to human AGO2.59 The PIWI domain 
contains an RNase-H-like fold, consisting of an Asp-Asp-Glu/Asp motif that is crucial for the 
endonuclease action of AGO2 and is responsible for target mRNA cleavage following fully 
complementary binding to the RISC.
58
  
 
The process of miRNA loading onto AGO in the RISC complex starts at the Dicer stage. 
Dicer binds pre-miRNAs and, via its two RNase III domains, cleaves both strands to form a 
dsRNA approximately 21 nt in length, which subsequently dissociates from and re-associates 
with Dicer at a different position. The dsRNA-binding protein, TRBP, is a crucial component 
in this step as it senses asymmetry and positions the dsRNA in a specific orientation that 
allows correct strand selection and loading. Therefore, Dicer contains two distinct RNA-
binding sites: one that positions long dsRNA for cleavage, and one that rebinds the siRNA 
after cleavage, aided by TRBP.
49
 The dsRNA is then transferred to a bound AGO2 with the 
assistance of a chaperone protein called heat shock protein 90 (HSP90). HSP90 hydrolyses 
ATP and with the aid of other co-chaperones keeps AGO2 in an open state which allows it to 
accommodate the dsRNA. Following this, the passenger or miRNA* strand is removed, and 
the AGO protein loaded with the single-stranded miRNA transitions into a closed 
conformation.
49
 In humans, the miRNA* strand cleaved by AGO2 is removed from the 
RISC-loading complex by the endonuclease C3PO, which also activates the RISC, priming it 
27 
 
to be able to cleave complementary target mRNAs. 
49
 Once bound, the miRNA then guides 
the RISC complex to its mRNA target.  
 
1.1.2 The let-7 family of miRNAs 
 
Lethal-7 (let-7) was the second miRNA ever to be discovered (Lin-4 being the first) and was 
originally demonstrated as a heterochronic gene in the nematode Caenorhabditis elegans, 
where it was shown to control the timing of stem-cell division and differentiation.
60
 Let-7 
subsequently became the first known human miRNA,
61
 and studies have shown that let-7 and 
its family members are highly conserved across species in both sequence and function.
7,62
 
Furthermore, in humans, aberrant expression of let-7 creates a less differentiated cellular state 
and promotes the development of a number of diseases such as cancer.
7
  
 
The let-7 family of miRNAs is often present in multiple copies in a genome although this 
varies between organisms. For example, although there is only one let-7 in Drosophila, there 
are 11 mature let-7 sequences in the Zebrafish and 14 let-7 family members in mice.
7
 To 
distinguish between multiple isoforms, a letter is placed after let-7 to indicate a slightly 
different nucleotide sequence, and a number at the end denotes that the same sequence is 
present in multiple genomic locations. In humans, there are 10 mature let-7 family sequences 
(let-7a to g, let-7i, mir-98, and mir-202) that are produced from 13 closely related 
genes/precursor sequences (let-7a-1, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-f7-1, 
let-7f-2, let-7g, let-7i, mir-98, and mir-202).
7
 Therefore, 3 separate precursors (let-7a-1, let-
7a-2 and let-7a-3) produce the mature let-7a sequence and precursors from two different 
genomic locations produce the let-7f (let-7f-1 and let-7f-2) sequence. 
 
Let-7 is an important regulator of seam cell differentiation and development in C. elegans and 
in particular the transition from the larval 4 to adult stage, which is the point at which these 
cells stop dividing and terminally differentiate.
60,63
 Let-7 mutant worms display abnormalities 
in temporal development patterns and many die, thus giving the let-7 gene its name, lethal-
7.
60
 Interestingly, let-7 expression levels vary at the different stages of C.elegans 
development and this regulation appears to occur at the transcriptional level. This is crucial 
for regulating the proper timing of seam cell development especially at the last larval stage; 
let-7 is only detectable from the L3 stage of development and reaches maximal expression 
28 
 
during the L4 stage,
60
 consistent with its role in promoting cell-cycle exit and terminal 
differentiation of seam cells at the end of the L4 stage. This temporal pattern of let-7 
expression during development has also been reported in other organisms, 64-66 although the 
direct contribution of let-7 in development in vertebrates has not yet been demonstrated.
65,67
 
This relates to the fact that in vertebrates some let-7 family members are probably redundant, 
and the fact that it is technically challenging to knock out all let-7 family members in the 
same animal at the same time.
7
 However, let-7 has been shown to play a role in 
embryogenesis and cerebral development in mammals
65,67
 and expression levels are 
undetectable in human and mouse embryonic stem cells but increase with cellular 
differentiation.
7,65
 Conversely, low let-7 levels have been linked to a number of human 
malignancies which is consistent with the process of cellular de-differentiation that is 
commonly associated with tumorigenesis.
68-70
 However, some let-7 family members appear 
to have an oncogenic role in certain tumour types which suggests that the function of this 
family of miRNAs may be sequence and cell-type specific. For example, in lymphoma, 
upregulation of let-7b and let-7i was associated with high grade transformation and hence a 
worse outcome.
71
   
 
Although let-7 expression is regulated at the transcriptional level in C.elegans, in humans it 
has been shown to be under the control of both transcriptional and post-transcriptional 
mechanisms. Here, let-7 genes are generally transcribed by Pol II leading to the formation of 
pri-let-7. The transcription of let-7a, let-7d, let-7f and let-7g, is directly repressed by MYC,
72
 
although in humans, few transcription factors have been identified that promote let-7 
transcription.
7
 In contrast a number of transcription factors, including temporal regulatory 
element-binding protein and DAF-12 are thought to regulate the transcription of let-7 in 
C.elegans.
73,74
 However, human let-7 is also post-transcriptionally regulated by the RNA-
binding protein, LIN28, which binds to the stem loops of pri-let-7a and pri-let-7g,
75,76
 and 
inhibits the Drosha complex from processing them.
76,77
 In some cases let-7a processing is 
inhibited by LIN28 at the Dicer level rather than the Drosha level, through the direct binding 
of LIN28 to the pre-let-7a stem, which prevents the production of mature let-7a.
78
 
Interestingly, as cells differentiate, the expression of LIN28 decreases and this enables the 
Drosha complex to bind to and process pri-let-7 into pre-let-7, which is then processed by 
Dicer into the mature let-7.
77
 This is then incorporated into the RISC where it can post-
transcriptionally repress its gene targets. A number of let-7 targets have been identified and 
include the cell-cycle regulators cyclin D,
79
 TLX,
79
 CDC25A,
80
 RAS,
81
 MYC
82
 and the high 
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mobility group AT-hook 2 (HMGA2),
83
 and it is regulation of these genes that enables cells 
to terminally differentiate. In targeting such genes let-7 appears to have an important tumour 
suppressor role and this is supported by the fact that decreased expression of many let-7 
family members has been associated with a number of malignancies and a poor prognosis in 
many cases.
68,70
 Therefore improving our knowledge of how let-7 expression is regulated and 
identifying, in greater detail, the network of let-7 regulated genes may enable a better 
understanding of its role in tumorigenesis.   
 
1.2 miRNAs and cancer 
 
Over 50% of miRNA-encoding loci reside in chromosomal regions altered by 
tumorigenesis
84
 and a number of miRNAs function as classical oncogenes or tumor 
suppressor genes.
85
 The first study to demonstrate a link between miRNAs and cancer 
identified both miR-15a and miR-16-1 were down-regulated or absent in most patients with 
B-cell chronic lymphocytic leukemia, which resulted from a deletion at 13q14 where the 
genes encoding these miRNAs are located.
86
 Extensive tumor profiling studies have 
implicated many miRNAs in the development, progression and metastasis of many tumour 
types (Table 1). Their discovery goes someway to explaining the gap that frequently exists 
between tumour genotype and phenotype, and has furthered our understanding of post-
transcriptional regulation of gene expression in which they play a critical role. The functional 
importance of miRNAs in both healthy and pathological states has exposed their notable 
potential as disease biomarkers and therapeutic targets.  
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Tumour type miRNA Expression in 
pathological state 
Reference 
Breast cancer miR-155 
miR-21 
miR-17-92 
miR-9 
miR-31 
let-7 
miR-126 
Overexpressed 
Overexpressed 
Overexpressed 
Overexpressed 
Down-regulated 
Down-regulated 
Down-regulated 
87
 
88
 
89
 
90
 
91
 
92
 
93
 
 
Colorectal cancer miR-155 
miR-21 
miR-34 
Overexpressed 
Overexpressed 
Down-regulated 
94
 
95
 
96
 
 
Lung cancer miR-21 
miR-17-92 
miR-155 
let-7 
miR-1 
Overexpressed 
Overexpressed 
Overexpressed 
Down-regulated 
Down-regulated 
97
 
98
 
99
 
99
 
100
 
 
Hepatocellular carcinoma miR-221 
miR-21 
miR-151 
miR-26a 
Overexpressed 
Overexpressed 
Overexpressed 
Down-regulated 
101
 
102
 
103
 
104
 
 
Prostate cancer miR-21 
miR-34a 
miR-15a/16-1 
miR-143 
Overexpressed 
Down-regulated 
Down-regulated 
Down-regulated 
105
 
106
 
107
 
108
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Pancreatic cancer miR-21 
miR-34 
let-7 
Overexpressed 
Down-regulated 
Down-regulated 
109
 
110
 
22
 
 
AML miR-29a 
miR-10a/b 
miR-29b 
Overexpressed 
Overexpressed 
Down-regulated 
111
 
112
 
113
 
 
CLL miR-155 
miR-15a/16-1 
miR-34a 
Overexpressed 
Down-regulated 
Down-regulated 
114
 
86
 
115
 
 
 
Table 1: miRNAs implicated in the pathogenesis of human malignancies 
 
1.2.1 MiRNAs as biomarkers 
1.2.1.1 Diagnostic biomarkers 
 
Cancers are often diagnosed at a late stage, with associated poor prognosis. The oncogenic 
and tumor suppressive nature of miRNAs, and the discovery of tumour-specific miRNA 
signatures suggests a potentially important role for these molecules as early diagnostic 
biomarkers. In a study of 104 matched pairs of primary malignant and non-malignant lung 
tissue, Yanaihara et al.
99
 identified a group of 43 differentially expressed miRNAs that could 
successfully discriminate between the two groups. Gee et al.
116
 found a panel of miRNAs 
(including the miR-200 family) that were down-regulated in malignant pleural mesothelioma 
compared to lung adenocarcinoma, and could be used consistently to distinguish between 
these two tumors.
116
 A tissue profiling study demonstrated a role for miRNAs in 
distinguishing primary brain tumours from secondary metastases originating from distant 
sites
117
 and other studies have identified panels of potential diagnostic biomarkers in 
hepatocellular carcinoma,
118
 breast carcinoma
90
 and pancreatic endocrine and acinar 
tumours.
119
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Current diagnostic methods are usually invasive and technically challenging, indicating a 
substantial need for novel non-invasive biomarkers for early tumor detection. The ability to 
profile miRNAs in the circulation represents a less invasive method of investigating disease-
specific miRNAs and is a promising alternative approach to tumor tissue profiling 
techniques. An essential requirement for developing circulating miRNA-based diagnostics is 
the ability to accurately isolate and measure miRNA species. Chen et al.
120
 was one of the 
first studies to demonstrate the presence of miRNAs in human serum and plasma. Using 
Solexa sequencing they identified approximately 100 circulating miRNAs in healthy Chinese 
subjects and subsequently studied specific expression patterns of serum miRNAs in lung and 
colorectal cancer patients, comparing them to healthy subjects. In lung cancer patients, 28 
miRNAs were absent and 63 new miRNA species were detected, and in the colorectal cohort 
69 serum miRNAs were detected that were not present in the healthy cohort, which included 
miR-221, previously shown to be increased in colorectal tumour specimens.
121
 Interestingly, 
despite the high concentration of RNAses in plasma and serum, circulating miRNAs were 
resistant to RNase A digestion.  
 
Evidence for the role of secretory miRNAs as diagnostic tools is growing. Elevated plasma 
miR-155, miR-197, and miR-182 levels accurately discriminated lung cancer patients from 
healthy controls (81.33% sensitivity and 86.76% specificity). miR-155 and miR-197 levels 
were higher in patients with metastasis than those without, and were significantly decreased 
in responsive patients during chemotherapy.
122
 Shen et al.
123
 demonstrated that patients with 
malignant solitary pulmonary nodules had elevated plasma levels of miR-21 and miR-210 but 
lower miR-486-5p levels compared to those with benign lesions or healthy controls. A 
comparison of plasma miRNA expression levels between 20 early breast cancer patients and 
20 healthy controls identified 31 differentially expressed miRNAs in Caucasian patients and 
18 in African American patients.
124
  Liu et al.
125
 used logistic modeling to show plasma miR-
16 and miR-196a levels could discriminate pancreatic cancer from chronic pancreatitis and 
normal controls. This was even more sensitive with the inclusion of serum CA19-9 in the 
logistic model, and was even effective at identifying stage I disease.  
 
Despite this growing evidence, the use of plasma miRNAs as diagnostic tools in clinical 
practice remains sparse. Although there have been advancements in isolation techniques and 
despite the apparent stability of circulating miRNAs, their measurement may be confounded 
by variability in the levels of cellular miRNAs from hematological origins and from 
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circulating tumor cells. To truly gain a greater understanding of the relevance of free 
circulating miRNA levels, fractionation processes must be employed to differentiate between 
those derived from tumor tissue and circulating cells. This should improve the sensitivity of 
these methods, as microdissection has in tissue-based miRNA biomarker studies. 
Furthermore, miRNA levels in other bodily fluids may play a future role in cancer diagnosis. 
Studies have identified miRNAs as potential diagnostic biomarkers in human bile
126
, sputum 
127
 and faeces
128
 although further studies are required to validate this. 
1.2.1.2 Prognostic biomarkers 
 
miRNA profiling studies have demonstrated a number of correlations between differentially 
expressed miRNAs and prognosis in various tumour types. In lung adenocarcinoma, low let-
7a and elevated miR-155 expression was associated with poor survival,
99
 and miR-137 and 
miR-372 levels correlated with increased risk of relapse and worse survival.
129
 
Overexpression of miR-155 and miR-21 correlated with poor outcome in early-breast cancer 
and dysregulated expression of miR-9, miR-10b, miR-21 are miR-315 was associated with an 
increased risk of metastasis.
90,91,93,130
 Schetter et al.
131,132
 demonstrated in two independent 
cohorts that elevated miR-21 levels correlated with poor survival in colorectal cancer, and the 
same miRNA has been implicated in predicting survival in localised pancreatic cancer, as has 
miR-196a-2.
109
 In hepatocellular carcinoma decreased miR-122
133
 and miR-26
104
 correlated 
with poor patient survival and miR-151-5p with an increased risk of intrahepatic 
metastasis.
134
 Historically, factors such as tumor grade, size and lymph node involvement 
have been used in early stage disease to determine treatment strategies, however there is 
sufficient evidence to suggest that miRNAs would serve as useful adjuncts or even 
alternatives to such methods.  
 
1.2.1.3 Predictive biomarkers  
 
Despite the development of novel targeted anti-cancer therapies, chemotherapy represents the 
foundation for treatment regimens for most hematological and solid malignancies. However, 
resistance of tumor cells to chemotherapy, and to a lesser extent targeted therapies, remains a 
major obstacle to effective treatment. Recent studies postulate that aberrant miRNA 
expression might be involved in tumor resistance to current therapies. This suggests a role for 
34 
 
miRNAs as predictive biomarkers, and that modulation of tumor miRNAs may be exploited 
to improve treatment response in addition to producing direct anti-tumor effects. 
 
miR-155 knockdown increased sensitivity of breast cancer cells to chemotherapy through 
regulation of FOXO3a
87
 and down-regulation of miR-21 augmented breast cancer cell 
response to taxol.
135
 Multidrug-resistance in specific MCF-7 cell lines is associated with 
reduced levels of miR-326
136
 and miR-451
137
 leading to upregulated expression of the multi-
drug resistance-associated protein 1 (MRP-1/ABCC1) and the multi-drug resistance 1 protein 
(MDR1) respectively. Furthermore, reconstitution of miR-451 expression sensitised cells to 
doxorubicin. Inhibition of miR-21 increased sensitivity of pancreatic adenocarcinoma cells to 
gemcitabine.
138
 Two clinical studies provide further evidence that miR-21 affects 
chemosensitivity in pancreatic cancer. The first study using 81 pancreatic ductal 
adenocarcinoma (PDAC) samples from patients treated with gemcitabine, found high miR-21 
expression was associated with poorer overall survival in both the adjuvant and metastatic 
settings,
139
 and a subsequent study demonstrated a correlation between low miR-21 
expression and improved outcome (disease-free and overall survival) in patients with 
localised PDAC treated with adjuvant gemcitabine or 5-fluorouracil chemotherapy.
140
  
 
Cisplatin resistance has been linked to miR-214 overexpression via targeting of PTEN.
141
 Li 
et al.
142
 demonstrated an association between taxol-resistance in human ovarian cancer cells 
lines and increased expression of MDR1/P-gylcoprotein due to down-regulation of miR-27a, 
and transfection with pre-miR27a re-sensitized these cells to taxol. Furthermore, in a study of 
37 stage III ovarian cancer patients, seven miRNAs, including miR-27a, were significantly 
differentially expressed in tumors from platinum-resisitant versus –sensitive patients. High 
miR-27a expression was associated with a particularly poor prognosis in terms of OS.
143
  
 
Response to fludarabine therapy in CLL is associated with differential miRNA expression. In 
a study of fludarabine-treated CLL patients, Ferracin et al.
144
 identified 37 miRNAs that 
distinguished responders from non-responders, with miR-21, miR-148a and miR-122 being 
more highly expressed in non-responding patients. In a similar study involving 50 CLL 
patients, fludarabine resistance was associated with decreased miR-29a and increased miR-
181a expression.
145
 The Let-7 family targets Bcl-XL in hepatocellular carcinoma cell lines, 
and overexpression of these miRNAs increased sorafenib-induced apoptosis in cell culture 
experiments.
146
 Furthermore, in a miRNA expression analysis involving over 200 HCC 
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patients treated with interferon-, Ji et al.104 demonstrated an association between improved 
response and low miR-26 expression.  
 
Although these data are promising, larger prospective trials are required to validate the role of 
miRNAs as predictive biomarkers, but such studies may lead to significant changes in 
treatment algorithms for certain tumour types. 
 
1.2.2 MiRNA-modulating agents as cancer therapeutics  
1.2.2.1 Theory versus reality 
 
A greater understanding of miRNA expression and function, and the growing evidence that 
miRNA deregulation is involved in cancer development and progression supports their role as 
potential therapeutic targets in cancer. Down-regulation of target oncogenes by re-expression 
of tumor suppressor miRNAs, or re-expression of tumor suppressor genes by silencing an 
oncomir could impair tumour growth and metastasis.  
 
A single miRNA can target many mRNAs suggesting that miRNA-modulating therapy could 
simultaneously modify a number of relevant gene networks within a tumour, leading to 
significant biological effects on phenotype and possibly a reduction in the emergence of 
therapy-resistant clones. Furthermore, we have recently shown for the first time  that in 
situations where multiple miRNAs co-operatively inhibit a network of tumour suppressor 
genes to promote tumorigenesis, co-targeting more than one miRNA is more effective in 
suppressing tumorigenesis tumour growth than targeting just a single miRNA.
147
 
Accordingly, a new class of drugs that specifically target small RNA pathways via 
replacement of tumor suppressive miRNAs with synthetic or viral vector encoded miRNA 
mimics or antisense-mediated inhibition of oncogenic miRNAs are currently in development. 
Hypothetically, such approaches should be well tolerated by non-target cells, because 
pathways within them that are affected by miRNA-modulating therapy are already controlled 
by the endogenous miRNA. However, a number of concerns must be addressed before such 
therapies can be safely applied to the clinic. Off-target effects provide a major obstacle, 
although utilizing a number of miRNAs at lower concentrations to target a single mRNA may 
enhance the specificity of silencing, and selecting a miRNA which targets multiple genes 
within a pathway may consolidate silencing and reduce off-target effects.
148
 Furthermore, 
36 
 
although double-stranded RNA-based therapies have been shown to be more effective than 
single stranded mimetics, they trigger a greater innate immune response through activation of 
double-stranded RNA-dependent protein kinase R.
149
 This effect can be reduced by the 
careful design of double-stranded based therapies less than 30 nucleotides in size that are 
relatively deplete in uracil or guanine sequences. 
 
The development of approaches to deliver miRNA-modulating agents to target tissues is also 
a major difficulty. Barriers to systemic delivery include degradation by serum and tissue 
nucleases, failure to cross the capillary endothelium due to size, uptake by scanvenger 
macrophages and ineffective endocytosis and endosomal release in target cells.
150
 
Additionally, intracellular RNA-binding proteins may further limit the activity of miRNA-
modulating agents within target cells. The strategies employed to modulate miRNA activity 
for therapeutic purposes and measures utilised to overcome potential obstacles are discussed 
below.   
1.2.2.2 miRNA inhibition  
 
miRNA antagonists must selectively hybridize with their endogenous miRNA target via 
partial or complete complementarity, thereby preventing interactions between the miRNA 
and its target mRNA.
151
 The most basic examples are anti-miRNA oligonucleotides (AMOs) 
which consist of a ‘naked’ single-stranded molecule that inhibits miRNAs via complementary 
binding. An early example of their use in vivo demonstrated that intravenous (i.v.) injection 
of an AMO into mice silenced hepatocyte expression of Fas and protected against fulminant 
hepatitis.
152
  
 
However ‘naked’ oligomers are relatively unstable and are easily degraded by endogenous 
RNases, resulting in their limited efficacy by systemic administration. To overcome this, 
oligomers can be modified by the addition of cholesterol conjugated 2’-O-methyl groups to 
produce more stable ‘antagomirs’. Krutzfelt et al.153 demonstrated that a single i.v. injection 
of an antagomir designed to target cholesterol-regulating miR-122 in mice, resulted in 
prolonged miR-122 silencing in the liver and a significant decrease in serum cholesterol 
levels. Ma et al.
154
 showed the systemic delivery of an antagomir to miR-10b in a mouse 
mammary tumour model prevented metastasis formation. Furthermore, a single intratumoral 
injection of antagomir-221/222 into Me665/1 melanoma xenografts in nude mice, 
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significantly inhibited tumour progression for one week with no documented toxicity,
155
 and 
intraperitoneal (i.p.) injection of antagomir-182 reduced hepatic metastasis of melanoma cells 
in a mouse model.
156
  
 
Further adaptations led to the development of ‘locked nucleic acid’ (LNA) oligomers. Such 
oligonucleotides contain a ribose moiety that is functionally locked into a C3’-endo 
conformation via the addition of a methylene bridge, that confers greater stability, increased 
miRNA-binding affinity and lower toxicity.
151
 LNA antisense oligomers to miR-122 have 
been shown to reduce serum cholesterol levels in healthy and obese mice as well as healthy 
non-human primates. MiR-122 is also essential for Hepatitis C virus (HCV) RNA replication 
and systemic delivery of an LNA antisense oligomer to miR-122 (SPC3649, Santaris 
Pharma) in HCV-infected chimpanzees led to prolonged 300-fold suppression in HCV 
viremia.
157
 In a subsequent Phase I single-dose safety study in humans, SPC3649 
demonstrated limited toxicity and a clear dose-dependent pharmacology and has now entered 
into Phase II, making it the first miRNA-modulating therapy to reach this stage.
158
 Such 
agents are yet to show similar success in the cancer setting. 
 
Vector-encoded RNA molecules, termed ‘miRNA sponges’, represent a novel approach to 
miRNA-modulating therapy. Containing multiple complimentary 3’UTR binding sites, they 
competitively bind to miRNAs thus liberating their mRNA targets. They can be designed to 
carry a number of different binding sites, enabling simultaneous inhibition of multiple 
members of a miRNA cluster or different miRNAs acting on the same target. This is an 
advantage over ASOs which only target single miRNAs. Furthermore they can be stably 
integrated into the genome, enabling the development of transgenic animals and stable cell 
lines that are functionally deficient in certain miRNAs. Valastyan et al.
91
 orthoptically 
implanted MCF7-Ras cells expressing a sponge vector targeting the anti-metastatic miR-31 
into mice, resulting in a significant induction of lung metastases. Gentner et al.
159
 
demonstrated that expression of an anti-miR-223 vector in hematopoietic stem cells, resulted 
in the functional knockdown of miR-223 when these cells were transplanted into lethally 
irradiated mice. However, a number of factors make miRNA sponges unsuitable for 
therapeutic use in humans and therefore no such approaches have been trialed yet. Firstly 
there is the risk of insertional mutagenesis in target cells, and vector size and poor 
biodistribution limits their systemic use. The future design of small-molecule drugs targeting 
miRNAs (SMIRs) may overcome this. 
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1.2.2.3 miRNA replacement/mimics 
 
Although studies directed at inhibiting oncogenic miRNAs have shown promise, the 
restoration of tumour suppressive miRNAs using miRNA replacement or mimics may be a 
more efficacious, less toxic strategy. They are likely to have less off-target effects, as miRNA 
mimics should have a similar sequence to the naturally occurring depleted miRNA and 
therefore target identical mRNAs. Developing a miRNA mimic requires the design of 
structures able to interact with the RISC and target the same mRNA as the endogenous 
miRNA. Such approaches have utilised chemically modified miRNAs, viral vectors and 
nanoparticle delivery systems in pre-clinical, and more recently, clinical models. 
 
Chemical adaptations to miRNAs mimics have, as with miRNA antagonists, allowed more 
effective administration to their target tissue. Takeshita et al.
160
 used tail vein injections to 
administer a chemically modified miR-16 precursor (a tumor suppressor known to be down-
regulated in prostate cancer) or ‘scrambled mimic’ to a murine model of bony metastatic 
prostate cancer. The miRNA was complexed with atelocollagen, which promoted uptake into 
the bone metastases and was effectively and persistently detected in target tissue for >3 days. 
Growth of the bone metastases was significantly lower in miR-16-treated mice than those 
administered the ‘scrambled mimic’. 
 
Adeno-associated viruses (AAVs) allow the persistent transcription and expression of 
miRNAs at high levels in target tissues with a low risk of insertional mutagenesis compared 
to other viral delivery systems.
161
 Down-regulation of miR-26a is associated with HCC and 
tail vein delivery of a miR-26a-expressing AAV into a murine HCC model suppressed 
tumorigenesis.
162
 Furthermore, although approximately 90% of hepatocytes were transduced 
with miR-26a in this model, there were no signs of hepatotoxicity or dysregulation of 
endogenously expressed miRNAs.
162
 Another murine model utilised the intranasal instillation 
of an adenovirus encoding let-7 or a negative control (n.c.) miRNA, and the cre recombinase 
in transgenic K-RAS G12D mice (which induces expression of the K-RAS mutant G12D and 
the formation lung tumors). Following surgical removal of the lungs, histology revealed mice 
that received cre/let-7 developed far fewer and smaller tumors than those that received 
cre/n.c., further establishing a role for let-7 as a tumor suppressor.
163
 A previous study had 
shown that the intratumoral injection of let-7 directly into murine non-small cell lung cancer 
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xenografts caused tumor shrinkage,
164
 demonstrating two methods of replacing this down-
regulated miRNA. AAVs may carry the risk of undesired immune responses and to date, no 
such therapeutic strategies have been employed in human cancer trials.  
 
Nanoparticles are positively charged structures with diameters of 45-70nm that can be used to 
administer negatively charged miRNAs/mimics to target tissues. This structure confers 
greater miRNA stability, allows their slow release for prolonged mRNA targeting and avoids 
the possible immunogenicity associated with AAVs. These characteristics suggested their 
potential to be administered intravenously to humans. Davis et al.
165
 recently published the 
preliminary results of the first human clinical trial using this delivery system. This Phase I 
study of patients with advanced solid tumors used the iv administration of an RNAi 
encapsulated in nanoparticles that targets the mRNA of ribonucleotide reductase (RRM2), a 
protein overexpressed in many solid tumors. The nanoparticles also contained surface 
transferrin protein targeting ligands (present on tumor cell surfaces) allowing specific 
delivery to tumors. The study demonstrated effective uptake of the RNAi to target tissue and 
efficient knockdown of its target gene. Response data are not yet mature.  
 
The clinical relevance of miRNAs is clearly reflected by the fact that in the ten years since 
initially being linked to malignancy, they have progressed from discovery to biomarker and 
drug development programs and remain at the forefront of research into tumour biology. 
Their role as biomarkers is promising particularly with regards to circulating miRNAs, which 
offer a potentially less invasive method of diagnosing cancer, assessing risk of relapse, and 
predicting and potentially following response to therapy. Guidance regarding the design of 
biomarker studies is rightly becoming more stringent and additional appropriately planned 
studies involving larger sample sizes will be vital before specific miRNAs can be utilised 
clinically in this manner. miRNA-modulating agents represent a new class of therapeutics, 
encompassing a wide range of mechanistic approaches including RNA interference and gene 
therapy, as well as complex delivery and tissue-targeting strategies. It is these last two points 
that have proved the biggest obstacle in the development of such agents. The human body’s 
natural barriers have hampered the systemic delivery of these drugs although this is being 
slowly overcome by innovative modifications to current agents and the design of new 
therapeutic structures. The generally widespread expression of many pertinent miRNAs has 
required the design of novel delivery systems to ensure tissue-specific targeting. Initial results 
from work by Davis et al.
165
 and developments in delivery systems by the pharmaceutical 
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industry suggest that before long, the use of miRNA-based therapies may become common 
practise in the cancer clinic. Furthermore, linking evidence from prognostic and predictive 
biomarker studies with clinical trials involving miRNA-modulating therapies could lead to 
combined treatment strategies involving the use of such therapies with current treatments to 
maximise response and improve outcome.  
 
1.3 The importance of regulatory relationships between p53 and 
miRNAs in the p53-mediated cellular response to DNA damage 
 
p53 is one of the most frequently mutated tumour suppressors, and functions 
predominantly as a transcription factor by regulating target gene expression and to a lesser 
extent through non-transcriptional processes such as those mediated by protein-protein 
interactions or by its direct binding with the mitochondria.
166,167
 It regulates the expression of 
protein-coding genes and non-coding RNAs involved in apoptosis, senescence, DNA repair, 
cell-cycle arrest, cell differentiation, metabolism and angiogenesis,
168
 thereby coordinating 
cellular response to stresses, such as oncogene activation and DNA damage. Whether the cell 
enters growth arrest or undergoes apoptosis ultimately depends on the integration of 
incoming signals with antagonistic effects on cell growth.
168
 Mutations or inactivation in p53 
are the most frequent abnormalities observed in cancer cells.
169
 Furthermore, aberrant 
expression of proteins involved in the p53 pathway such as murine double minute 2 
(MDM2),
170
 Jun-NH2-terminal kinase-1 (JNK1),
171
 hypoxia-inducible factor 1 (HIF-1)172 
and imbalances in Rb-E2F1 and Bax/BCL-2 ratios are commonly observed in malignant 
cells.
168
 Such mutations have significant implications in terms of tumor growth and response 
to current treatment modalities. Many chemotherapeutic agents, in particular anthracyclines 
and platinum-containing compounds, as well as radiotherapy, induce cancer cell death or 
senescence via DNA damage and the subsequent activation of p53-mediated pathways. 
Resistance to such treatments can occur due to mutations in components of the p53-signalling 
networks. A better understanding of the role of the various components within these 
pathways and their interactions with each other may allow modifications and improvements 
to current anti-cancer treatments and the design of novel therapies. Refining our knowledge 
of the role of miRNAs in such p53-signalling networks may be crucial to achieving this. 
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1.3.1 p53 activation and its regulation of downstream signaling pathways 
following DNA damage.  
 
In humans, the TP53 gene is located on the short arm of chromosome 17 (17p13.1) 
and spans 20 kb, with a non-coding exon 1 and a very long first intron of 10 kb.
173
 The 
coding regions are highly conserved between vertebrates. TP53 encodes a protein that in 
humans comprises of 393 amino acids and is separated into 7 domains consisting of folded 
DNA-binding and tetramerization domains, flanked by intrinsically disordered regions at 
both the amino- and carboxy-termini each of which has a specific function.
174-176
 The first 63 
residues form the natively unfolded amino-terminal transactivation domain (TAD), which is 
subdivided into the subdomains TAD1 (residues 1-42) and TAD2 (residues 43-61), which are 
primarily responsible for activating transcription factors and connect target gene recognition 
with target gene expression by direct binding to the transcriptional coactivators p300/CBP 
and components of the basal transcription machinery.
174-176
 The TAD region is followed by a 
proline-rich region (PRR; residues 61-94) which is important in apoptotis.
174
 Next comes the 
central DNA-binding core domain (DBD; residues 94-292) that consists of a central 
immunoglobulin-like β-sandwich scaffold and additional elements that form the DNA-
binding surface, which include a loop-sheet-helix motif and two large loops stabilized by a 
zinc ion.
177-179
 Residues 316-325 comprise the nuclear localization signaling domain and 
residues 307-355 contain the homo-oligomerisation domain (OD) that is connected to the 
DBD through a flexible linker region. The C-terminal is located between residues 356-393 
and contains sequences involved in nuclear localisation, tetramerisation and the regulation of 
specific and non-specific DNA binding.
180
 This regulatory region, along with the amino-
terminal, undergo a variety of post-translational modifications including ubiquitylation, 
phosphorylation, methylation and SUMOylation that regulate activity and function of the 
protein.
181-183
 
 
p53 operates primarily as a transcription factor with both transactivation and repressor 
functions and is biologically active as a homotetramer that cooperatively binds to its target 
duplex DNA in a sequence-specific manner.
184
 The target binding sites were originally 
believed to only consist of two decameric half-site motifs formed of RRRCWWGYYY (R= 
adenine or guanine; W= adenine or thymine; Y= cytosine or thymine) separated by 0–13 base 
pairs and usually located 5’ to the gene or in the first or second intron of the gene regulated 
by p53.
185,186
 However, recent studies have also shown that many p53 response elements have 
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consecutive half-sites and that an increase in spacer length between half-sites for a given 
response element correlates with a decrease in p53 affinity and transactivation.
187,188
 
Furthermore, Wang et al. (2009) developed a set of predictive rules to distinguish between 
response elements accountable for activation or repression of target genes, the latter having 
characteristic deviations from the canonical response element sequence that are generally 
associated with weaker affinity.
189
 
 
In its role as a transcriptional regulator, p53 controls the expression of hundreds of genes  
involved in mediating cell growth, division and survival, apoptosis and DNA repair, 
angiogenesis, metabolic processes and even the immune response.
190,191
  Its activity is often 
transient and this is regulated mainly through changes in its protein stability.
181
 p53 is 
induced and activated by a range of stress stimuli including DNA damage, hypoxia, heat/cold 
shock, activated oncogenes (hyper-proliferation), nutritional deprivation,  ribosomal stress, 
nitric oxide and spindle damage.
17,18
 Each stress stimulus induces p53 by supressing its 
degradation and this leads to a coordinated cellular response that occurs in a context-
dependent manner, the outcome of which is reliant upon the balance between growth arrest, 
senescence and DNA repair and that of apoptosis or programmed cell death, and appears 
specific to the cell type and the manner, intensity and duration of the activating stress.
17,18
 To 
add further complexity to the process, p53 can also operate in a transcription-independent 
manner and regulate the onset of apoptosis through a direct interaction with the 
mitochondrion and its apoptotic machinery.
167
 The purpose of such a complex but 
coordinated p53-mediated cellular response to stress is to protect cells from damage induced 
by the stimulus and to allow them to repair or reverse the insult where possible or ‘hibernate’ 
until the stimulus diminishes, but also to allow the cell to undergo programmed cell death in 
the event of irreparable or prolonged damage. Perhaps one of the most important roles of p53 
is to coordinate tumour suppression mechanisms that block uncontrolled proliferation of 
transformed or damaged cells.
17,18
 
 
Levine et al. (2006)
17
 elegantly described the p53 pathway by dividing it conveniently into 
five parts: 
 
1. The input signals that induce the network (e.g. DNA damage) 
2. The upstream regulators that detect and interpret those signals and activate the 
functional pathway by relaying the inputs to the p53 protein or molecules that most 
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immediately regulate its concentration and activity (e.g. ataxia telangiectasia mutated; 
ATM). 
3. The core set of proteins, including the p53 itself, which regulates p53 activity and 
function (e.g. MDM2). 
4. The downstream events which are composed of sets of genes and their proteins that 
are regulated by p53, most commonly by transcriptional activation but in some cases 
by protein–protein interactions (e.g. CDKN1A) 
5. The cellular outputs of these downstream events (e.g. cell cycle arrest, cellular 
senescence or apoptosis). 
  
DNA damage is probably the best described ‘input signal’ in this context and most relevant to 
this thesis. DNA damage takes the form of single- or double-strand breaks and initiates the 
p53 response predominantly through the activation of the upstream regulators ataxia 
telangiectasia and Rad3 related (ATR) and ATM, respectively. These are protein kinases that 
coordinate and assimilate various signalling pathways leading to changes in the post-
translational status of p53 itself and several of its direct or indirect regulators such as MDM2 
and MDMX.
192-194
 MDM2 is the principal regulator of p53 protein levels and function. 
Through its role as a RING-finger type E3 ligase, MDM2 can mono- or poly-ubiquitylate 
lysine residues on p53 leading to nuclear export or proteosomal degradation of p53, 
respectively.
195,196
  MDMX, a functionally defective E3 ligase related to MDM2 also binds 
the MDM2/p53 complex and promotes MDM2-mediated ubiquitylation and supresses p53-
mediated transcription.
197,198
 Therefore, ATR/ATM-mediated post-translational 
phosphorylation of p53 leads to its almost universal uncoupling from MDM2-induced 
degradation and allows the subsequent recruitment of crucial transcription factors, leading to 
chromatin remodelling and transcriptional activation.
17
  
For example, following a double strand break, ATM (and later ATR) phosphorylate serine 
residues on the N-terminus of p53 (such as Serine 15 or Serine 20), and these 
phosphorylation events initiate a cascade of further post-translational modifications. The 
protein kinase, casein kinase 1 (CK1), uses the phosphorylation of Ser15 as a recognition 
determinant and sequentially phosphorylates Threonine (Thr) 18 which then inhibits 
p53/MDM2 association and promotes the uncoupling of p53 from degradation and nuclear 
export.
199,200
 Ser20 phosphorylation occurs through the activation of the CHK2 protein kinase 
by ATM, which further uncouples p53 from MDM2 mediated suppression. Phosphorylation 
44 
 
events do not only affect p53 signalling through the promotion of its uncoupling from 
regulatory partners such as MDM2, but they also do so through the regulation of transcription 
factor/co-activator recruitment. For example, Thr18 phosphorylation promotes the binding of 
the p300/CBP translational co-activators which stimulate p53 transcriptional activity. 
Furthermore, phosphorylation of Ser46 by various protein kinases, including ATM,
201
 
homeo-domain interacting protein kinase-2 (HIPK2)
202
 and protein kinase C-delta
203
 
following DNA damage, has been suggested  to be involved in promoting apoptosis through 
induction in the expression of genes such as PTEN.
204
 ATM and ATR also activate a number 
of other proteins following DNA damage that induce other post-translational modifications 
on p53 and its regulators. These include deubiquitinases such as HAUSP which 
deubiquitylates and activates p53,
205,206
  phosphatases such as pyrophosphatase 2 (PP2A) that 
remove phosphate groups from MDM2 and p53 thus suppressing p53 activtiy,
207
 neddylases 
such as NEDD8 which inhibit p53 transcriptional activity,
208
 and deacetylases such as histone 
deacetylase (HDAC) and situin-1 (SIRT-1) that provide crucial p53 deacetylation activity to 
shut off p53-dependent transcription.
209-211
 Interestingly, DNA damage has been show to 
induce the acetylation of p53 at various lysine residues on the C-terminus by 
acetyltransferases, and this promoted p53 stability and favoured survival over cell death by 
promoting p53-mediated activation of cell cycle arrest genes.
212
    
The downstream events mediated by p53 following a stress stimulus usually involves a large 
number of genes with the precise gene signature being specific to the nature and intensity of 
the stimulus and the cell type and surrounding environment. Some p53-regulated genes 
appear to be transcribed in response to many different types of stress signals and in all tissues 
responding to the stress (e.g. CDKN1A, cyclin G, Growth Arrest and DNA damage 
45(GADD45) and MDM-2) and others appear to be neither stimulus- nor tissue specific (e.g. 
PTEN). Following DNA damage, p53 can mediate cell cycle arrest by inducing a number of 
negative regulators of the cell cycle such as CDKN1A, 14-3-3 sigma and GADD-45, and can 
activate apoptosis through the upregulation of positive mediators of both the intrinsic and 
extrinsic apoptotic pathways. These include Fas,
213
 TRAIL,
214
 killer/DR5,
215,216
 p53-induced 
protein with death domain (PIDD),
217
 bax,
218
 noxa
219
 and puma
220
. p53 can also induce 
senescence through the transcriptional upregulation of CNKN1A, which activates the 
retinoblastoma protein (Rb) to shut down the transcription of E2F target genes.
221
 DNA repair 
can also be mediated by p53 through its regulation of the expression of proteins such as 
p48,
222-224
 the p53R2 subunit of ribonucleotide reductase,
225
 and the sestrins. 
226,227
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Interestingly, as well as regulating response pathways in a cell that has undergone DNA 
damage, p53 can also regulate the ability of that cell to communicate with other cells in its 
environment through the transcription of secreted proteins. In this way a cell can ‘inform’ 
neighbouring cells that it has DNA damage and coordinate an appropriate response in its 
surrounding environment. For example, p53-mediated upregulation and sectetion of Insulin-
like Growth Factor Binding Protein 3 (IGFBP3) prevents the activation of growth signalling 
pathways in neighbouring cells. Similarly the p53-regulated protein thrombospondin is 
secreted following DNA damage and can alter the cellular matrix and supress 
angiogenesis.
228,229
 Finally, as well as regulating the signaling pathways described above, 
many p53-responsive genes also initiate positive or negative feedback loops with the p53 
protein and the core gene products of the pathway.
230
 For example, in some cell types, PTEN, 
which is induced by p53, dephosphorylates Phosphatidylinositol (3,4,5)-triphosphate (PIP3) 
leading to a reduction in the activity of the AKT kinase. AKT kinase normally 
phosphorylates MDM2, resulting in the translocation of MDM2 into the nucleus where it 
inactivates p53, but this is inhibited by PTEN here. This is an example of a positive feedback 
loop whereby p53 activity is enhanced through the actions of the genes that it 
transcriptionally induces.
230,231
 Other genes involved in similar pathways include 
CDKN1A,
230
 cyclin G,
232
 WIP-1
233,234
 and MDM2.
235,236
 
 
1.3.2 The regulatory relationships between p53 and miRNAs 
 
 miRNAs have evolved to allow cells to effectively respond to stresses such as DNA 
damage, hypoxia and oncogene activation.
237
 Accordingly, they have been strongly 
associated with the p53 stress-response pathway, and in recent years, have been identified as 
key mediators of p53-associated tumor suppression. Interactions between p53 and miRNAs 
occur at various stages. At the transcriptional level, p53 can induce the expression of several 
miRNAs which mediate its role in apoptosis, epithelial-mesenchymal transition (EMT), 
stemness, angiogenesis, senescence and cell cycle arrest.
238-240
 Interestingly, p53 can also 
directly repress expression of oncogenic miRNAs, such as the miR-17-92 cluster.
241
 These 
p53-regulated miRNAs have the potential to be involved in complex feedback and 
feedforward loops and contribute collectively to control, amplify and fine-tune cellular 
signals in response to stress, although there a few examples of this in the literature. 
Furthermore, gene targets of p53-regulated miRNAs may also be transcriptionally regulated 
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by p53, creating even more complex coherent and incoherent feedforward loops.
242
  p53 is 
able to regulate miRNA expression transcriptionally, by a direct interaction with a subset of 
pri-miRNA promoters, and also post-transcriptionally. Post-transcriptionally, it regulates 
miRNA processing and maturation by interacting with the Drosha processing complex, 
associating with the DEAD-box RNA helicase p68.
243,244
 miRNAs can also negatively 
regulate p53 protein levels through direct binding to the p53 mRNA 3’-UTR,245,246 and can 
positively regulate p53 function through targeting several negative regulators of p53.
247,248
  
miRNAs could therefore potentially act as novel p53 target genes to facilitate p53-induced 
tumor suppression. Furthermore, they may be as important in regulating p53 activity as the 
previously identified phosphatases (e.g. Wip1), kinases (e.g. ATR, ATM) and ubiquitin 
ligases (Cop1, MDM2). Additionally, the effects of epigenetic and genetic variations in the 
p53-miRNA interactome further suggest the importance of these networks in 
tumorigenesis.
249,250
  
 
1.3.2.1 Transcriptional Regulation of miRNAs by p53 
 
 p53 is a transcription factor and mainly exerts its regulatory action by a direct 
interaction with protein-coding target gene promoters. However, studies over the last 5 years 
have shown that non-coding RNAs, such as miRNAs, are also under its direct transcriptional 
control. Furthermore, there appears to be variability in the p53-regulated miRNA expression 
signatures, and their gene targets, depending on the cell type, nature of the stress, and cause 
of DNA damage.  
 
In 2007, several groups using various screening methods reported miR-34a and miR34b/c as 
the first identified miRNA genes to be p53-regulated.
238,239,251-253
 These and subsequent 
studies demonstrated that miR-34a/b/c display multiple tumor suppressive activities and are 
summarized in Table 2. Bioinformatically predicted and experimentally validated miR-34 
targets comprise cell cycle-related factors, predominantly those involved in G1/S phase 
transition, including E2F3, cyclin E2, cyclin-dependent kinase 4/6 (CDK4/6) and MYC. 
Furthermore, miR-34 has been shown to target genes involved in EMT (e.g. SNAIL),
254
 DNA 
repair,
238
 angiogenesis,
238
 stemness (e.g. CD44, WNT1/3),
254
 cell survival (e.g. SIRT1),
247
 
metabolism (e.g. LDHA)
255
 and tumor immune surveillance.
256
 Accordingly, decreased 
expression of miR-34 has been observed in various tumors,
238,257
 suggesting that its loss 
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could promote tumorigenesis and further implying its potential importance in stabilizing p53-
signalling. 
  
Other miRNAs shown to be transcriptionally induced by p53 include miR-15a/16,
258
 miR-
107,
259
 miR-122, miR-143, miR-145, miR-182, the miR-192/194/215 and miR-200 family 
members,
260-262
 miR-205, miR-605 and miR-1204. Although all these miRNAs have been 
shown, in at least one study, to be induced by direct binding of p53 to the relevant miR-gene 
promoter, it is worth noting that not all of the studies demonstrating potential or validated 
gene targets of these miRNAs specifically show this in each case. Interestingly, miR-22 has 
been shown to be a direct transcriptional target of p53 following doxorubicin-induced DNA 
damage, and the resulting upregulation in the expression of this miRNA led to targeting of 
CDKN1A and stimulated cells to undergo apoptosis rather than cell cycle arrest.
263
 
 
Genes involved in p53-signalling pathways that are targeted by miR-15a/16 are shown in 
Table 3. These miRNAs are encoded by an intron of the DLEU2 gene and although they 
were initially thought to be only induced by p53 post-transcriptionally,
243
 Fabbri et al. (2011) 
subsequently demonstrated the direct transcriptional regulation of DLEU2 by p53.
258
 The 
majority of studies demonstrating that miR-15a/16 target genes involved in p53-signalling do 
not specifically demonstrate direct binding of p53 to the miRNA promoter. However, these 
miRNAs have been implicated in targeting genes involved in various p53-associated 
signaling pathways including G0/G1-S transition,
264-266
 cell proliferation,
267,268
 migration,
268
 
invasion
268
 and clonogenicity
267
  in various cancer cell lines. miR-15a/16-1 deletions have 
been detected in several tumor types including, CLL,
86
 non-small cell lung cancer
265
 and 
prostate cancer,
107
 suggesting that an impaired p53 response may drive them.  
The miR-200 family has been strongly associated with p53-regulated signaling pathways that 
also play a crucial role in suppressing the formation of metastases, including EMT, stemness, 
clonogenicity and angiogenesis, through direct targeting of genes including ZEB1/2, SOX2, 
Klf4 and VEGF.
260-262
 miR-107 contributes to the role of p53 in the regulation of 
angiogenesis and hypoxic signaling through the targeting of hypoxia inducible factor-1β 
(HIF-1β),259 which interacts with HIF-1α subunits to form a transcription factor complex that 
mediates the tumor response to hypoxia. miR-107 is also involved in the regulation of G1/S 
cell cycle arrest through its gene target CDK6.
269
 Its expression is inversely associated with 
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HIF-1β levels in human colon cancer, and ectopic expression of miR-107 suppresses both 
tumor growth and angiogenesis in murine colon cancer models.
259,269
 
p53 binds directly to a p53 response element in the miR-145 promoter to induce expression 
of this tumor suppressive miRNA. miR-145 targets and negatively regulates c-MYC, and 
other cell cycle regulators such as CDK4/6, which accounts in part for the miR-145-mediated 
inhibition of tumor cell proliferation in vitro and in vivo.
240,270
 miR-145 represses 
pluripotency in human embryonic stem cells (hESCs) through the targeting of OCT4, SOX2, 
and KLF4,
271
 and regulates MDM2 in squamous cell carcinoma (SCC) HN30 and SCC-25 
cells leading to increased p53-induced apoptosis and senescence.
272
 The tumor suppressive 
role of other p53-induced miRNAs is summarized in Table 4. 
Interestingly some miRNAs are transcriptionally down-regulated, rather than induced, by p53 
although relatively few have been identified or experimentally validated to date. These 
include miR-100, miR-125b, miR-99b, miR-221 and miR-501.
253
 Let-7a/b expression was 
down-regulated in a p53-dependent manner in colon cancer HCT116 cells exposed to DNA 
damage through UV radiation.
273
 Let-7a/b levels were inversely correlated with the 
expression of pro-apoptotic BAX and PUMA, although direct targeting of these genes was 
not shown in this study. Exogenous expression of let-7a/b increased radiation-induced 
cytotoxicity in a p53-dependent manner. These results were the first demonstration of a 
mechanistic connection between the radiation-induced stress response and the regulation of 
miRNAs and radiation-induced cytotoxicity.
273
 Furthermore, although most p53-regulated 
miRNAs function as tumor suppressors, some act as oncogenes. miR-194 is transcriptionally 
induced by p53 in colon cancer HCT116 cells and targets thrombospondin-1, leading to 
increased tumor angiogenesis.
274
 Furthermore, in melanoma cells, p53 directly up-regulates 
miR-149*, that in turn targets glycogen synthase kinase-3α, resulting in increased expression 
of Mcl-1 and resistance to apoptosis. This provides further evidence that miRNA*s 
(passenger strands) play important roles in regulating gene expression similar to their 
complementary mature miRNAs.
275
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miRNA Up or down 
reg
d
 by p53 
Related Gene targets Gene target 
validation 
method 
Cellular pathway Cell/organism  Ref 
miR-34a/b/c 
 
miR-34a 
 
miR-34a 
 
 
miR-34a/b/c 
 
 
 
 
miR-34a/b/c 
 
 
miR-34a/b/c 
 
 
miR-34a 
 
 
miR-34a 
 
 
 
miR-34b/c 
 
 
 
miR-34a/c 
 
 
miR-34a 
 
 
 
miR-34a 
Up 
 
Up 
 
Up 
 
 
Up 
 
 
 
 
Up 
 
 
Up 
 
 
Up 
 
 
Up 
 
 
 
Up 
 
 
 
Not shown 
 
 
Up 
 
 
 
Up 
 
CDK4/6, CCNE2, MET 
 
E2F3, NOTCH1, DLL1 
 
IMPDH 
 
 
SNAIL 
SLUG, ZEB1/2,BMI1, 
CD44, CD133, OLFM4, 
c-MYC 
 
SNAIL, β-catenin, LEF1, 
Axin2 
 
β-catenin, WNT1, 
WNT3, LRP6, LEF1 
 
FRA-1 
 
 
c-MYC, c-MET, c-Myc–
Skp2–Miz1 , c-Myc-
pTEFB  
 
Myc, CDK6, Delta-like1, 
NOTCH1, Met, Ezh2, 
E2f3, Bcl2, Cyclin D1  
 
ULBP2 
 
 
AXL, LEF1, MTA2, 
LDHA, YY1 
 
 
SIRT1 
WB corr, LRA 
 
PS 
 
WB/RTqPCR 
corr 
 
WB corr, LRA 
WB/RTqPCR 
corr 
 
 
WB Corr, 
LRA 
 
LRA, PS 
 
 
LRA, PS,  WB 
corr 
 
LRA, PS 
 
 
 
PS 
 
 
 
LRA, PS, WB 
corr 
 
LRA, genome 
wide pSILAC, 
microarray 
 
LRA, corr WB 
 
Cell cycle arrest 
 
Apoptosis, G1 arrest 
 
Nucleotide biosyn, GTP-
dependent Ras signalling 
 
Stemness, TGFβ 
signalling, MET/EMT, 
 
 
 
Invasion, EMT/MET 
 
 
WNT signalling, 
stemness, invasion 
 
Migration, invasion 
 
 
c-myc activated 
transcription, invasion 
 
 
Proliferation, adhesion-
independent growth  
 
 
Tumor immune 
surveillance 
 
Glycolysis, lipid 
metabolism, WNT-sign 
 
 
Apoptosis 
MEFs 
 
H1299, MCF7 
 
H1299, HCT116 
 
 
H1299, HCT116 
 
 
 
 
HCT116, MCF7, 
A549 
 
A549, MCF7, 
Xenopus 
 
HEK293, RKO, 
HCT116 
 
PC-3 
 
 
 
Primary mouse 
OSE cells 
 
 
Natural Killer 
Cells 
 
SW480 
 
 
 
HCT116 
239
  
 
253
  
 
276
  
 
 
254
  
 
 
 
 
277
 
 
 
278
  
 
 
279
  
 
 
280
  
 
 
 
251
 
 
 
 
256
  
 
 
255
  
 
 
 
247
 
Table 2: Studies demonstrating the gene targets of the miR-34 family following transcriptional induction by p53.  
CCNE2: cyclin E2; CDK4/6: cyclin dependent kinase 4/6; MET: hepatocyte growth factor receptor; MEFs: mouse embryonic fibroblasts; 
corr: Correlation; WB: western blot; LRA: luciferase reporter assay; PS: Prediction software;  RTqPCR: realtime quantitative PCR;  IMPDH: 
Inosine 50-monophosphate dehydrogenase;  EMT: epithelial-mesenchymal transition; MET: mesenchymal-epithelial transition; Fra-1: Fos-
related antigen 1; ZEB1/2: zinc finger E-box binding homeobox 1/2; BMI1:  polycomb ring finger oncogene; OLFM4: olfactomedin 4; c-
MYC: myelocytomatosis viral oncogene homolog; LEF1: Lef1 lymphoid enhancer binding factor 1; WNT1/3: wingless-related MMTV 
integration site 1/3; ULBP2: UL16 binding protein 2; SIRT1: sirtuin 1; MTA2: metastasis associated 1 family, member 2; LDHA: lactate 
dehydrogenase A; YY1: YY1 transcription factor; E2F3: E2F transcription factor; BCL2: B-cell CLL/lymphoma 2; EZH2: enhancer of zeste 
homolog 2 (Drosophila) 
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Table 3: Studies demonstrating the gene targets of the miR-15a/16 following transcriptional induction by 
p53 
CCNE2: cyclin E2; CDK4/6: cyclin dependent kinase 4/6; CCND1: cyclin D1; corr: Correlation; WB: western 
blot; LRA: luciferase reporter assay; PS: Prediction software;  RTqPCR: realtime quantitative PCR; FGF: 
fibroblast growth factor; FGFR: fibroblast growth factor receptor WNT1/3: wingless-related MMTV integration 
site 1/3; BCL2: B-cell CLL/lymphoma 2; Chk: checkpoint kinase 1 
 
 
 
 
 
 
 
 
miRNA Up or down 
reg
d
 by p53 
Related Gene targets Gene target 
validation 
method 
Cellular pathway Cell/organism Ref 
miR-15a/16 
 
 
miR-15a/16 
 
 
miR-15a/16 
 
 
miR-15a/16 
 
 
miR-15a/16 
 
miR-15a/16-1 
Not shown 
 
 
Up by 
p53/E2F1 
 
Not shown 
 
 
Not shown 
 
 
Not shown 
 
Not shown 
FGF2,FGFR1, 
WNT3A,CCND1,BCL-2 
 
CCNE 
 
 
BMI1 
 
 
CDK4/6, CCND1/3, 
CCNE1 
 
CCND2/3, Cdk4/6, Chk1 
 
CCND1, WNT3a 
 
PS, LRA 
Corr WB 
 
Corr WB 
 
 
PS, corr WB, 
LRA 
 
PS, corr WB 
 
 
PS, GEP 
 
LRA, corr 
WB 
Proliferation, migration, 
invasion 
 
G1/S transition, cell 
cycle progression 
 
Cell proliferation, 
clonogenicity 
 
G1/S transition 
 
 
G0/G1-S phase transition 
 
Survival, proliferation, 
invasion 
CAFs, PC3, 
CAHPV10, DU145 
 
H1299, U2OS 
 
 
Ovarian cancer, 
OVCAR-5, OV-202 
 
A549,H2009,H129,
H358 
 
B-cells/CLL 
 
LNCaP, RWPE-1 
268
 
 
 
264
 
 
 
265,267
 
 
 
266
 
 
 
107
 
 
107
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miRNA Up or 
down reg
d
 
by p53 
Related Gene 
targets 
Gene target 
validation 
method 
Cellular pathway Cell/organism  Ref 
Let7a/let7b Down Inverse correlation 
with BAX/PUMA  
Corr p53-dependent response to 
DNA damage UV radiation  
HCT116  
273
 
miR-107 
 
miR-107 
Up CDK6, ?p130 
 
HIF-1β 
LRA, PS 
 
LRA, PS, corr 
WB 
Regulation G1/S arrest 
 
Angiogenesis 
HCT116 
 
HCT116 
269
 
 
259
 
miR-122 Up Activates AKT Corr WB AKT/p53 apoptotic circuit Cutaneous T-cell 
lymphoma 
281
 
miR-
143/145 
 
 
miR-
143/145 
 
 
miR-145 
 
miR-145 
 
 
miR-145 
Up  
 
 
EGFR 
induc
d 
 
Up 
 
 Up 
 
 
Not shown 
 
 
MDM2 
 
 
K-Ras, MYC, 
CCND2, cdk6, 
E2F3 
 
- 
 
c-MYC 
 
 
OCT4, SOX2, and 
KLF4 
LRA, corr 
WB/RTqPCR 
 
LRA, corr 
WB/RTqPCR 
 
- 
 
LRA, corr 
WB/RTqPCR 
 
LRA, corr WB 
p53 activation, Apoptosis /cell 
cycle arrest 
 
G1-growth arrest  
 
 
Apoptosis 
 
Growth inhibition 
 
 
Repress pluripotency in 
hESCs 
HN30, SCC-25 
 
 
HCT116 
 
 
Prostate Ca e.g. PC3 
 
HCT116, MCF7 
 
 
hESCs 
 
272
  
 
 
270
 
 
 
282
 
 
240
  
 
 
271
 
miR-149
* 
(oncogenic) 
Up GSK3α (Mcl-1 
indirectly) 
LRA, corr WB Resistance to apoptosis 
(oncogenic) 
Melanoma, Mel-RM 
275
 
miR-182 
 
 
miR-182 
Up  
 
 
Not shown 
MITF, BCL2, 
CCND2 
CCNE2, CDK2/4/6  
 
MTSS1 
LRA, PS, corr 
WB 
Corr WB 
 
LRA, corr 
WB/RTqPCR 
 
Cell growth, invasion, 
migration 
 
Metastasis 
Uveal melanoma 
M23, SP6.5 
 
HCC, HLE, HLF, 
HepG2, Hep3B, 
HUH1 
283
  
 
 
284
 
miR-
192/215 
Up 
 
Multiple  Microarray, 
siRNAs, LRA 
Cell proliferation, G1/S & 
G1/M  transition  
A549, TOV21G, 
HCT116 
285
 
miR-
192,194,215 
Up 
 
IGF1 LRA, PS, corr 
WB 
Cell survival/migration Myeloma cell lines 
286
 
miR-192 
 
 
miR-192 
Up 
 
 
Up 
DHFR 
 
 
ZEB2 
LRA, corr 
WB/RTqPCR 
 
LRA 
Cell cycle control, cell 
proliferation 
 
EMT/migration/invasion 
HCT116 
 
 
HCC cell lines 
287
 
 
 
261
 
miR-194 
(oncogenic) 
Up TSP-1 
 
LRA, corr 
WB/RTqPCR 
Promotes angiogenesis 
 
HCT116 
 
274
 
miR-200 
family 
 
miR-200c 
 
 
 
Up 
 
 
Up 
 
 
 
ZEB1/ZEB2 
 
 
BMI1 
 
 
 
LRA 
 
 
PS, LRA 
 
 
 
EMT/migration/invasion 
 
 
Inh stemness, clonogenicity & 
tumor growth 
 
 
HCC, Breast cancer 
cell lines 
 
Human BCSCs,  
Human/murine 
MSPCs, ECCs 
 
261,262
 
 
 
288
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Table 4: Studies demonstrating the gene targets of miRNAs transcriptionally regulated by p53 
Corr: Correlation; WB: western blot; LRA: luciferase reporter assay; PS: Prediction software;  RTqPCR: 
realtime quantitative PCR; CCNE2: cyclin E2; CCND2: cyclin D2; CDK4/6: cyclin dependent kinase 4/6; 
BAX: BCL2-associated X protein; EMT: epithelial-mesenchymal transition; MET: mesenchymal-epithelial 
transition; ZEB1/2: zinc finger E-box binding homeobox 1/2;BMI1:  polycomb ring finger oncogene; OLFM4: 
olfactomedin 4; c-MYC: myelocytomatosis viral oncogene homolog; LEF1: Lef1 lymphoid enhancer binding 
factor 1; WNT1/3: wingless-related MMTV integration site 1/3; LRP6: low density lipoprotein receptor-related 
protein 6; HIF-1 β: hypoxia inducible factor β; hESC: human embryonic stem cells; Mcl-1: myeloid leukemia 
cell differentiation protein; MTSS1: metastasis suppressor 1; MITF: microphthalmia-associated transcription 
factor; HCC: hepatocellular carcinoma; IGF1: Insulin-like growth factor1; TSP-1: thrombospondin-1; BCSCs: 
breast cancer stem cells; MSPCs: mammary stem/progenitor cells; ECCs: embryonal carcinoma cells;  MDM2: 
murine double minute 2; CAFs: cancer-associated fibroblasts; FGF: fibroblast growth factor; FGFR: fibroblast 
growth factor receptor; GEP: gene expression profiling; VEGF(R): Vascular endothelial growth factor 
(receptor); Sox2: sex determining region Y-box 2; KLF4: Kruppel-like factor 4; LAMC1: laminin gamma 1 
 
1.3.2.2 Post-transcriptional regulation of miRNA expression and function by p53 
 
p53 controls miRNA expression post-transcriptionally through the regulation of miRNA 
processing and maturation. This was first demonstrated in a study by Suzuki et al. (2009), 
where the authors used quantitative polymerase chain reaction with reverse transcription (RT-
qPCR) to measure miRNA expression levels in p53
+/+
 HCT116 cells following DNA-damage 
with doxorubicin.
243
 They observed an increase in miR-15a, miR-16-1, miR-23a, miR-26a, 
miR-103, miR-143, miR-203 and miR-206, in addition to the previously published miR-
34a.
243
 However, although DNA damage induced the expression of the pri-miRNA, pre-
miRNA and mature miR-34a, several other miRNAs (including miR-15a, miR-16-1, miR-
143 and miR-145) increased only at the precursor and mature levels. Thus suggesting a role 
of p53 in enhancing the post-transcriptional maturation of these miRNAs, which all have 
miR-200c 
 
 
miR-200b 
 
miR-200 
 
Up 
 
 
Not shown 
 
Not shown 
ZEB1 
Sox2 and Klf4 
 
VEGF 
 
VEGF, VEFGR1 
PS, LRA 
PS, corr WB 
 
LRA 
 
LRA, PS, WB 
corr 
Inh stemness & tumor growth 
 
 
Angiogenesis 
 
Growth, invasion, metastasis 
PANC1, MiaPaCa2, 
 
 
A549 
 
Lung CAFs, lung 
cancer cell lines 
260
  
 
 
289
  
 
290
 
miR-205 
 
 
 
miR-205 
Up 
 
 
 
Not shown 
 
E2F1, LAMC1 
 
 
 
ZEB1/ZEB2 
 
PS, LRA, corr 
WB/RTqPCR 
 
 
LRA 
 
cell proliferation, cell cycle 
progression, clonogenicity, 
cell adhesion/migration 
 
EMT/migration 
MDA-MB-231, BT-
549, MCF7 
 
 
Breast cancer cell 
lines, MDCK cells 
291
 
 
 
 
262
 
miR-605 Up 
 
MDM2 LRA, corr WB Apoptosis A549, MCF-7, 
HCT116 
292
 
miR-1204 Up 
 
- - Apoptosis, proliferation, cell 
cycle arrest 
HCT116, RKO, SK-
HEP1 
293
 
53 
 
important roles in the regulation of cell cycle transition and cell proliferation.  The maturation 
of these miRNAs was induced by the association of p53 with DROSHA and its partner 
DGCR8 via the interaction with DEAD-box RNA helicase p68 (DDX5) that is part of this 
complex (microprocessor). This enhanced DDX5 interaction with the microprocessor and 
promoted the cleavage of pri-miRNAs to pre-miRNAs. Furthermore, a transcriptionally 
inactive mutant p53 impeded the binding of p68 to the complex leading to a reduction in 
miRNA processing which may have relevance to tumor biology.
243
 Interestingly, DNA 
mutations in the p53 gene that are repeatedly observed in tumors (e.g. R273H and R175H) 
are associated with decreased DROSHA-mediated processing of pri-miRNAs and reduced 
expression of their mature miRNAs.
294
 Furthermore other members of the p53 family, such as 
p63 and p73, appear to regulate components of miRNA processing (i.e. Drosha-DGCR8, 
Dicer-TRBP2, and Argonaute proteins).
295
 A recent study also found a link between DNA 
damage-induced activation of p53 and miRNA biogenesis.
296
 Here, the investigators 
demonstrated that following DNA damage, phosphorylation of Serine-46 on p53 led to 
transcriptional upregulation of amphiregulin (AREG) through binding to its promoter 
region.
296
 AREG was shown to interact with DDX5 and regulate processing of pre-miRs such 
as pre-miR-15a which led to a reduction in the expression of the anti-apoptotic protein, Bcl-
2.
296
  
In addition to promoting miRNA maturation through DROSHA processing, the p53 response 
also monitors miRNA maturation at the level of DICER1. Loss of DICER1 function can be 
tumorigenic,
297,298
 predominantly due to incomplete miRNA maturation. DICER1 deficiency 
and subsequent loss of mature miRNAs in embryonic fibroblasts, induced expression of p53 
and ARF, leading to reduced proliferation and premature senescence,
244
 which could be 
rescued by the deletion of p53 or Cdkn2a, which encodes ARF.
244
 This provides evidence 
that efficient miRNA processing is monitored by a p53-dependent checkpoint, and that loss 
of p53 function may significantly increase the tumorigenic potential of cancer cells with 
deficient DICER1 function or reduced mature miRNA levels. 
Finally, p53 can also influence miRNA target gene selection at the level of miRNA-target 
interaction, via the regulation of mRNA binding proteins, such as RNA-binding-motif protein 
38 (RBM38).
299
 This provides another level of complexity in the mediation of miRNA 
function by p53, and suggests another process by which p53 deletions or mutations in cancers 
can affect their tumor suppressive capabilities. 
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The importance of post-transcriptional miRNA regulation by p53 is not yet fully understood, 
however these studies suggest that this process is fundamentally involved in p53-mediated 
tumor suppression. Additionally, p53 mutations in tumors, target not only the transcriptional 
functions and protein-protein interactions mediated by its central DNA binding domain, but 
also the regulation of miRNA processing. This suggests a new mechanism by which p53 
gain-of-function mutations contribute to cancer, as the effects of p53 mutations on miRNA 
processing will almost certainly be different to complete loss of p53 expression and this 
requires further evaluation.  
1.3.2.3 The regulation of p53 expression by miRNAs 
 
On the other hand, miRNAs are able to regulate p53 itself. This occurs either directly, 
through interactions between miRNA seed regions and the 3ʹUTR of TP53 mRNA, or 
indirectly through the down-regulation of upstream p53 regulators. Those miRNAs that bind 
p53 directly, function in a p53-repressive manner and include miR-125b,
246,300
 miR-504,
245
 
miR-33,
301
 miR-380,
302
 miR-1285,
303
 miR-25 and miR-30d.
250
 These may be clinically rel-
evant oncogenes and their overexpression has been correlated with more advanced disease 
and poorer survival in various tumor types.
242
 An in silico approach identified that miR-504 
could bind to two sites on the p53 3’UTR and negatively regulate p53 expression.245 
Furthermore, miR-504 over-expression impaired p53-mediated G1 cell cycle arrest and 
apoptosis and promoted tumorigenesis in colon cancer in vivo models.
245
 
miR-125b negatively regulates p53 in humans and zebrafish during the stress response and 
development. Its knockdown increased p53 protein levels and induced apoptosis in zebrafish 
brain and human cells, whilst its overexpression repressed endogenous p53 levels and 
reduced apoptosis.
246,300
 In colorectal cancers, elevated miR-125b expression was associated 
with invasion and increased tumor size and correlated with decreased survival.
249
 
Interestingly, miR-125b has also been proposed to regulate many other genes in the p53 
signaling pathway and mediate both apoptosis and proliferation depending on the cellular 
context. Le et al. (2011) used a gain- and loss-of-function screen for miR-125b targets in 
humans, mice, and zebrafish. These were then validated with luciferase reporter assays and a 
novel miRNA pull-down assay to demonstrate that miR-125b directly controls at least 20 
targets in the p53 network.
300
 Amongst its targets were regulators of apoptosis such as Bak1, 
Igfbp3, PUMA and Prkra, and also cell-cycle regulators including cyclin C, Cdc25c and 
Cdkn2c.
300
 These results suggested that miR-125b shields and adjusts p53 network activity 
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by modifying the activity of both apoptotic and proliferative regulators, with implications for 
tumorigenesis and stem cell homeostasis.
300
 
 
A number of miRNAs indirectly control p53 activity through targeting of p53 regulators such 
as MDM2, SIRT1 and HDAC1, and this regulation often occurs as part of complex 
feedback/feedforward loops. miR-192, miR-194, miR-215 and miR-605 decrease MDM2 
activity by direct binding, but miR-122 achieves this indirectly via the down-regulation of 
cyclin G1 and subsequent inhibition of PP2A phosphatase recruitment to MDM2. Both 
pathways result in reduced p53 polyadenylation and hence increased activity of this tumor 
suppressor. miR-34a and miR-449 have similar seed sequences and have both been shown to 
target SIRT1, leading to increased p53 acetylation and p53 induced apoptosis.
242,247
   
1.3.2.4 Feedback loops involved in miRNA-regulated p53 signaling 
 
The expression and activity of p53 is under the control of miRNAs, and p53-regulated 
miRNAs mediate tumor suppression and stress responses by regulating p53-signaling 
pathways. They achieve this by directly targeting the stability and translation of central 
mRNA components of these processes, usually via their involvement in various types of 
feedforward and feedback loops that mediate the integrity, amplification, buffering and fine-
tuning of signals, and that jointly contribute to appropriate cellular reactions.
242
 This may 
occur via simple positive or negative feedback loops, whereby a miRNA can either amplify 
or suppress signaling respectively; or via more complex coherent or incoherent feedforward 
loops. These are demonstrated in Figure 2. 
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Figure 2: Examples of p53-regulated feedback/feed-forward loops involving miRNAs.  
(A) A positive feedback loop involving p53, miR-34a and SIRT-1. (B) A complex regulatory network involved 
in p53 and TGF-β signaling. (C) A coherent feed-forward loop involving the regulation of MYC by p53. (D) An 
incoherent feed-forward loop involving the regulation of TSP-1 by p53. EMT: epithelial-mesenchymal 
transition; MET: mesenchymal-epithelial transition. 
 
  
A signaling pathway involving p53, miR-34a and SIRT1 is an example of a positive feedback 
loop (Figure 2a).
304
 SIRT1 is an NAD(+)-dependent deacetylase able to inhibit p53 
activation. In response to stress, p53 induces miR-34a expression, which increases p53 
acetylation by targeting SIRT1. The resultant increase in p53 activity intensifies p53-
associated tumor suppressive signaling and further augments miR-34a expression, 
heightening the specific effects of this miRNA on apoptosis, cell growth arrest and 
senescence.
304
 Furthermore, miR-605 creates a positive feedback loop that enables p53 to 
escape the p53:MDM2 negative feedback loop. In response to cellular stress, miR-605 
expression is induced due to initial p53 activation and this then feeds back to increase the 
transactivation activity of p53 by repressing MDM2.
305
 
 
The miR-34 and miR-200 family members are involved in a complex p53-regulated negative 
feedback loop that mediates and fine-tunes p53 (and TGF-β) associated EMT/MET and 
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stemness (Figure 2b).
254
 Cellular stress activates p53, leading to the induction of miR-34 and 
miR-200. In addition to targeting other genes that promote stemness and EMT, miR-34 
directly targets SNAIL. This has a number of effects, including a reduction in TGF-β-
activated SNAIL signaling and EMT; and a decrease in SNAIL induced repression of miR-34 
and miR-200 transcription.
306
 
  
A coherent feedforward loop, describes a system whereby a transcription factor inhibits 
expression of a target gene, whilst also inducing expression of a miRNA that represses the 
mRNA encoded by that gene. This allows for a more reliable regulation of the target gene, as 
its mRNA will be repressed even if the transcription factor is intermittently dysfunctional. In 
an incoherent feedforward loop, expression of the target gene may be stronger as there is 
transcriptional co-induction of a miRNA and its mRNA target by the relevant transcription 
factor. Others have described a slightly different type of incoherent feedforward loop termed 
a ‘type-2 feedforward loop’.300 This is a regulatory pattern in which X represses a target Z 
and also represses Y, another repressor of Z; and functions to accelerate responses to specific 
stimuli and have a buffering effect to reduce the variance of network dosage (Figure 3).
300
 
Such incoherent feedforward loops have been found in the transcription factor networks of 
hematopoietic stem cells and hESCs, and have been shown to modulate p53-signalling and 
the Myc-E2F1pathway.
300,307
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Coherent and incoherent feed-forward loops 
 
 
Coherent FFLs                                     Incoherent FFLs
A feed-forward loop (FFL) is made of two cascaded molecules, that in the scope of the examples given in
this review, will generally involve a transcription factor (X) and a microRNA (Y) that jointly regulate a gene
(Z). More specifically, X directly regulates Z, but it also directly regulates Y that can regulate Z. Therefore, X
regulates Z via a direct interaction but also indirectly via Y. In a coherent FFL, the effect that X has on Z
expression by direct regulation is the same as the effect it has on Z indirectly through Y. Conversely, in an
incoherent FFL the effect that X has on Z expression by direct regulation is the opposite of the effect it has
on Z indirectly through Y. Since each of the three interactions of the FFL can be either activating or
repressing, there are eight types of FFLs, four coherent and four incoherent (see diagram below).
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The p53, miR-145 and MYC pathway exemplifies a coherent feedforward loop (Figure 2c). 
p53 directly represses the expression of MYC,
308
 but induces the transcription of miR-145 
which targets MYC mRNA,
240
 leading to cell cycle arrest. miR-194 is involved in an 
incoherent feedforward loop and its actions may in fact promote oncogenesis by increasing 
tumor angiogenesis. This miRNA is transcriptionally induced by p53 in HCT116 cells, and 
targets TSP-1, an endogenous inhibitor of angiogenesis. The promoter region of THBS1, the 
gene that encodes TSP-1, is directly activated by p53 and therefore there is transcriptional co-
induction of both miR-194 and its mRNA gene target TSP-1 by p53 (Figure 2d).
274
  miR-
125b seems to function in a ‘type-2 feedforward loop’ via its targeting of multiple genes 
involved in p53 signaling,
300
 although it may in fact be transcriptionally down-regulated 
rather than induced by p53.
253
 Several studies have implicated miR-125b as an oncogene in a 
various malignancies, due to its direct suppression of p53 and Bak1.
309-311
 However, others 
have described its function as a tumor suppressor.
312,313
 This can be explained by the fact that, 
depending on the cell type and environmental stresses, miR-125b can target genes in the p53 
network that promote both apoptosis and cell proliferation and in doing so can fine-tune and 
protect the p53 network dosage.
300
 miRNA-target pairs are relatively poorly conserved 
throughout evolution and between species, but miRNA-gene network relationships are 
strongly conserved.
314,315
 These findings are consistent with the idea that miRNAs function as 
buffers of gene expression. It is possible that this buffering feature of miR-125b represents a 
general principle of miRNA regulation of p53 and other gene networks. 
Rather than depending on one or a few mediators, p53 represents a central regulator which 
uses numerous coding and non-coding genes to achieve tumor suppression. Therefore the 
experimental deletion of single p53-induced protein-coding genes rarely recapitulates the loss 
of p53 in terms of suppressing tumor cell growth in vitro or in vivo.
316
 Furthermore, the 
frequent inactivation of p53-induced miRNAs in tumors suggests that their loss may promote 
tumorigenesis by destabilizing or disabling the p53 pathway. Accordingly, some studies have 
shown that replacement of single p53-induced miRNAs can prevent tumorigenesis and cancer 
cell proliferation in p53-knockout models,
317
 suggesting that their ability to target more than 
one coding gene may confer significant therapeutic potential. However, the evaluation of the 
effects of single p53-induced miRNAs is complicated, as several may co-target the same 
mRNA and this can lead to phenotypic compensations. Bandi and Vassella (2011) 
demonstrated that the synergistic effect of miR-15a/16 and miR-34a was required to control 
cell cycle arrest (but not apoptosis) in lung cancer cell lines, as their concerted action enabled 
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the down-regulation of more targets than each miRNA alone, suggesting a functional link 
between these miRNAs.
265
 Therefore the collective importance of p53-associated miRNAs 
and their gene targets in terms of mediation of tumor suppression requires further 
experimental validation and the combined deletion/up-regulation of several miRNAs may be 
crucial to testing and understanding their relevance to p53 function. In order to achieve this, a 
better appreciation of the p53-associated miRNA-mRNA interactome is required. However, 
in mammals it is often difficult to directly predict relevant downstream miRNA targets, as 
perfect complementarity between miRNAs and their gene targets rarely exists. Many 
algorithms have been developed that predict miRNA targets (e.g. TargetScan, PicTar and 
miRanda),
1,318,319
 but the number of targets predicted for each miRNA by these programs is 
usually in the tens or hundreds. The identification of global miRNA targets relevant for tumor 
suppression by p53 is therefore a complex task. Over the coming years, this can potentially 
be achieved by investigating global p53-associated changes in miRNA and mRNA levels and 
interactions on AGO2.  These data could be used to evaluate which p53-regulated miRNAs 
may be utilized as diagnostic, prognostic and therapeutic tools in the cancer clinic. miRNA-
replacement therapies could be used to augment the expression of p53-induced miRNAs and 
this approach would have the advantage of not relying on the presence of functional, wild-
type p53. Interestingly, the systemic delivery of miR-34a mimetics to mouse models of 
prostate and lung cancer have shown therapeutic benefit and pre-clinical trials involving other 
p53-induced miRNAs have produced encouraging results.
320,321
 Furthermore, the design of 
novel therapies to exploit p53–miRNA target networks may be possible and these could 
overcome difficulties such as resistance to DNA-damaging agents in tumors with aberrant 
p53 function.  The fact that miRNAs can target multiple mRNAs involved in the p53-
signaling pathways may provide further protection against the emergence of therapy-resistant 
tumors during systemic treatment. 
1.3.3 Identifying p53-associated miRNA Targets 
 
The mutation or dysregulation of miRNAs contributes to or causes a number of 
diseases including cancer, and this is predominantly due to the down-regulation or loss of 
repression of tumour suppressor and oncogenic mRNA targets respectively. Therefore 
accurate identification of miRNA targets or target networks is vital to our understating of 
miRNA function in specific cellular pathways. However, until recently web-tool based 
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approaches and experimental techniques were limited in their ability to provide this 
information.  
 
Initial techniques allowed the identification of one or a few mRNA targets of a single miRNA 
in a certain cell or tissue. They generally involved expression profiling of pre-specified 
miRNAs using RTq-PCR, followed by the use of computational prediction software to 
identify potential targets. Results were then validated using knockdown or over-expression of 
the specific miRNA followed by mRNA and protein correlations using RTq-PCR and 
Western blot, as well as validation of putative targets by luciferase assays and site directed 
mutagenesis.  This was limited to identifying only a few selected targets based on prior 
biological data, which is suboptimal due to the fact that many genes are synchronously 
regulated by many miRNAs, and that most miRNAs have hundreds of gene targets. 
Furthermore, it is difficult to accurately predict miRNA targets using computational methods, 
particularly transcriptome-wide, as the relatively small number of nucleotides in the seed 
sites involved in target recognition often leads to a high number of false-positive 
predictions.
322
 However, this problem has been partially overcome by assessing the 
evolutionary conservation of predicted target sites, as conserved binding sites are considered 
more likely to be functional.
323,324
 To elucidate such a complex system of miRNA-mediated 
regulation requires extensive target identification.
322
  To this end, substantial progress has 
been made through the successful development of techniques such as microarray expression 
analyses and next generation sequencing to measure global expression changes after miRNA 
transfection
325,326
  or knockdown,
153,327
 coupled with proteomics or seed-enrichment analyses. 
Since 2009 a number of studies have used AGO RIP-chip (a form of AGO 
immunoprecipitation followed by reverse transcription and a microarray) or RIP-seq (a form 
of AGO immunoprecipitation followed by next generation sequencing), to analyze changes in 
gene target expression and identify specific target features that may determine target 
binding.
328-331
 Such techniques provide an indirect measure of global miRNA regulation, but 
the advent of new CLIP techniques, particularly involving AGO, in conjunction with large-
scale sequencing has allowed more direct target identification in various species and cell 
lines.
332-337
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1.3.3.1 Cross-linking and immunoprecipitation (CLIP) 
 
CLIP involves the use of ultraviolet (UV)-induced crosslinking of the miRNA-target 
RNAs to an RNA binding protein such as AGO, followed by cell lysis and recovery of the 
protein of interest along with the crosslinked RNA via  immunoprecipitation. The next steps 
involve the use of ribonuclease (RNase) treatment to reduce the RNA targets to their protein 
binding sites, and subsequent co-purification of the miRNA and target genes using 
radioactive labeling, SDS-PAGE and electroelution. This is followed by identification of the 
precise miRNA target sites on the mRNA via adaptor ligation, reverse transcription, library 
generation and finally high-throughput sequencing and computational analysis. Various 
different CLIP methods have been described, including high-throughput sequencing of RNA 
isolated by crosslinking immunoprecipitation (HITS-CLIP),
335,338
 individual-nucleotide 
resolution UV crosslinking and immunoprecipitation (iCLIP)
339
 and photoactivatable-
ribonucloeaside-enhanced cross-linking and immunoprecipitation (PAR-CLIP),
332,334
 many of 
which used AGO2. In contrast to other RBPs used in CLIP protocols such as Pumlio2 and 
IGF2BP1,
332
 which contain a specific mRNA recognition site, miRNP (e.g AGO) targets’ are 
specified by the interaction of the miRNA on the RISC with partially complementary 
sequences in the target mRNAs.
333
 
 
Classical cross-linking uses a UV wavelength of 254nm in the absence of a modified 
nucleotide. The PAR-CLIP protocol (Figure 4) uses a UV wavelength of 365nm in the 
presence of a modified photoreactive nucleotide such as 4-thiouridine (4SU) or 6-
thioguanosine (6SG). These crosslinked modified nucleotides induce a greater crosslinking 
efficiency but more importantly result in the introduction of specific mutations (G-to-A for 
6SG and T-to-C for 4SU) during the reverse transcription step which is an accurate indicator 
for quality control and also provides a means to precisely identify the individual binding sites 
of the selected protein(s) on their targets.
332,334
 The T-to-C conversion generally occurs just 
outside the seed region, where AGO proteins are in close proximity to the single stranded 
target mRNA, which suggests that the miRNA-mRNA base pairing prevents crosslinking 
between AGO and 4SU in the mRNA seed region.
333
 Interestingly, contrary to initial opinion, 
classical cross-linking in the absence of a modified nucleotide can also lead to specific 
mutations that can be similarly used to pinpoint binding sites, although they occur less 
frequently than in PAR-CLIP. 
334,340
 Furthermore, Granneman et al (2008), using a classical 
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CLIP technique demonstrated that crosslinking using UV 254nm induced an increase in 
nucleotide deletions at U3 snoRNA RBP binding sites.
341
 
 
CLIP techniques have been used successfully to identify many miRNA target sites and to 
better understand miRNA interactions with RNA binding proteins. Although the 
computational analysis is complicated, and the technique itself is open to certain biases, CLIP 
does provide a more accurate method for miRNA target identification than target prediction 
programs. However, despite demonstrating binding of the miRNP complex to mRNA targets, 
CLIP does not allow accurate assessment of the effects of miRNA binding on the subsequent 
mRNA repression, as strength of binding does not necessarily correlate with the extent of 
down-regulation of the target gene. For example binding affinity can be affected by a number 
of factors, not least the tertiary structure of the binding protein. However this can be 
overcome by using CLIP in conjunction with techniques such as RIP-Chip or AGO 
immunoprecipitation with high-throughput sequencing, that provide quantitative estimates of 
miRNA function, to more accurately unravel miRNA-regulated gene networks at a 
transciptome level. Furthermore, Corcoran et al. (2011) describe a method of enrichment 
analysis of AGO PAR-CLIP data that can be used to identify those miRNAs with the 
strongest impact on mRNA targeting even in the absence of expression data.
333
   
 
Interestingly only around 40-60% of miRNA-target interaction sites identified by CLIP are 
matched to the miRNA seed region indicating that the miRNA-target interaction is more 
complex than previously thought. Seed pairing has previously been shown to correlate 
strongly with target gene expression changes and is considered to be a key factor in miRNA-
target interaction. 
326,329,342
 However, a number of other determinants of miRNA targeting 
have been demonstrated, and they are summarized in Table 5. Using a bioinformatics 
approach, Wen et al. (2011) found differences in target determinants between miRNA 
transfection/expression-based data and CLIP-seq data.
329
 Seed-related features such as seed 
type and target site number were found to be stronger determinants in expression based data 
than CLIP data but target flanking features such as flanking region conservation were more 
important in the latter than the former. Features that were highly ranked for both data types 
were target-site accessibility and flanking AU composition. These findings suggest that 
determinants of miRNA binding differ from those of mRNA degradation. Others have shown 
in RIP-chip experiments that U frequency in entire transcripts is associated with mRNA 
degradation,
330
 and that miRNAs have a target preference for short 3’-UTRs.328,330 This is 
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contrary to earlier studies that suggested miRNAs preferentially target genes with long 3’-
UTRs containing multiple miRNA binding sites,
343
 and that highly expressed transcripts are 
evolved to possess shorter 3’-UTRs to avoid miRNA targeting.323  Furthermore, Corcoran et 
al. (2011) found that nucleotides immediately adjacent to a seed match in a 3’-UTR were AU 
rich and that there was an under-representation of guanines (Gs) surrounding the interaction 
sites. This latter finding may be due to the use of RNase T1 in the PAR-CLIP protocol, as this 
enzyme cleaves next to G. This may result in some binding sites being missed if they are 
immediately surrounded by Gs as this would lead to the formation of reads that are too short 
to be included in the library step, which specifically collects reads of 30 nucleotides in 
length.
333
 Furthermore, CLIP methods has identified that although the majority of interaction 
sites on AGO are located in the 3’ UTR, there are also a number of interaction sites found in 
the intergenic, coding, intronic and 5’ UTR regions,333 although the functional significance of 
this is uncertain.    
 
The initial approach designed by Hafner et al. (2010), aligned reads on the genome, using a 
read length of at least 20 nucleotides and allowed for one T-to-C mismatch. They then used 
crosslink-centered regions (CCRs), 41-nucleotide regions re-centered on the read group 
location with the highest percentage of T-to-C conversion events, to identify AGO interaction 
sites.
332,333
 However, Corcoran et al. (2011) used more lenient alignment parameters, 
allowing read lengths as short as 13 nucleotides after adapter stripping, which could contain 
up to two T-to-C mismatches. They then used a kernel density estimate to calculate a ‘signal-
to-noise ratio’ in order determine interaction sites. The PARalyzer method was used to test 
miRNA binding sites across 3’ UTRs of genes known to be expressed in HEK293 cells. The 
signal-to-noise ratio was higher in the top expressed miRNAs but fell to below the 
background level for miRNAs with very low expression. However when the PARalyzer 
method was used to re-analyse the CCRs reported by Hafner et al. (2010), these regions were 
associated with a lower signal-to-noise ratio for highly expressed miRNAs, suggesting that 
the newer PARalyzer technique creates a higher resolution map of miRNA binding sites than 
the original method.
333
 It is probable that CLIP-seq protocols may preferentially select for the 
miRNP-target interactions with the highest binding affinities, and with the increased use of 
such protocols in the search to determine miRNA targets on a genome wide scale, it is 
important to understand the determinants of miRNA targeting to avoid selection biases in the 
data. It may be that predictive models need further integration into the computational analysis 
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of CLIP data in order to fully understand the relevance of certain miRNA binding interactions 
with their target mRNAs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Diagrammatic representation of an AGO PAR-CLIP experiment 
4-SU: 4-thiouridine; 
32
P: radioactive phosphate. 4-SU: 4-thiouridine; UV: ultraviolet; PCR: polymerase chain 
reaction; kda: kilodaltons. 
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Feature Region of interest Determinant 
 
3‘ UTR related 
 
3’UTR 
 
 
Length
329
 
Relative distance to 3’UTR ends329 
Minimum distance to 3’UTR ends329 
Number of target sites
329
 
 
Target Complementarity Seed  
 
Out-seed 
Target 
 
Seed mismatch
329
 
Seed type i.e. 6-mer, 7-mer etc
41
 
3’ out-seed pairing41 
Target sequence alignment
318
 
Conservation 70nt 
Seed 
Target 
Flanking region conservation
329
 
Seed conservation
329
 
Entire target sequence conservation
329
 
Target site flanking region 70nt 
30nt 
 
Mono/dinucleotide frequencies
329
 
AU content
41
 
Target free-energy Target 
 
Free-energy loss ΔΔG47 
ΔGduplex miRNA-target hybridization 
energy
329
 
Flanking Strand asymmetry 70nt Base asymmetry bias eg. G vs C
344
 
G+U content
344
 
Folding-energy difference ΔG between 
the two strands
344
 
 
Table 5: Determinants of miRNA-target interaction 
UTR: untranslated region; nt: nucleotides; AU: Adenylate-uridylate; G: guanine; A: Adenine; C: cytosine. 
 
 
 
1.4 Small nucleolar RNAs  
1.4.1 The structure, synthesis and function of small nucleolar RNAs 
 
snoRNAs are a well-characterized class of ubiquitously expressed, non-coding RNAs 
(ncRNAs) that are 60–300 nucleotides in length.345 Predominantly located in the nucleolus 
they classically function as guide RNAs for the post-transcriptional maturation and 
modification of ribosomal RNAs (rRNAs), and snRNAs involved in the spliceosome. 
snoRNA guide sequences hybridize specifically to their rRNA target sequence, and, via 
associations with proteins, form small nucleolar ribonucleoprotein complexes (snoRNPs) and 
execute specific rRNA modifications.
345
 Therefore, snoRNAs are crucial for ribosomal 
function and the effective regulation of translation and thus, unsurprisingly, are highly 
conserved throughout evolution.
346
 There are two major classes of snoRNAs, termed C/D box 
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snoRNAs and H/ACA box snoRNAs, respectively. They differ in terms of their sequence and 
structure, their binding partners and the nature of the post-transcriptional modifications that 
they induce.
346,347
  
 
C/D box snoRNAs are typically 60-200 nucleotides in length and are characterized by highly 
conserved Box C (UGAUGA) and Box D (CUGA) domains located near to their 5’- and 3’-
ends, respectively. Although the C and D boxes are located at different ends of the molecule, 
an interaction between the 5’- and 3’-termini causes it to fold, forming a hairpin-like structure 
containing a stem region in which the C and D Box elements are brought into close 
proximity. This region provides a binding site for core box C/D snoRNP proteins, including 
the methyltransferase, fibrillarin.
348
 Internal copies of the Box C and D elements, termed Box 
C’ and Box D’, display lower sequence conservation and are located nearer to the centre of 
the molecule.
348,349
 C/D box snoRNAs form snoRNPs containing a core of four proteins 
(fibrillarin, nucleolar protein 56 (NOP56), NOP58 and NHP2-like 1) and define the target 
sites for the 2’-O-ribose methylation of specific rRNA residues. The guide region, which 
ensures the specificity of this modification by base pairing to the target RNA, is a region of 
10-20 nucleotides found immediately upstream of the D and/or D’ boxes.348   
 
Measuring approximately 120-250 nucleotides in length, the H/ACA box snoRNAs are 
generally longer than C/D box snoRNAs and function as guides for the pseudouridylation of 
rRNA. They are folded structures consisting of two hairpins connected by a hinge region 
containing the H box domain, which is characterized by an ANANNA-motif (N can be any 
nucleotide). The ACA box, consisting of the trinucleotide, ACA, terminates the second 
hairpin and is located three residues upstream of the 3’ end of the molecule. H/ACA box 
snoRNAs form snoRNPs containing dyskerin (a pseudouridine transferase responsible for 
pseudouridylation of the rRNA), GAR1, NHP2 and NOP10, and the internal stem-loops of 
one or both of their hairpins serve as guides for the pseudouridylation of their 
substrates.
350,351
 In addition to their role in rRNA pseudouridylation, these snoRNAs are also 
involved in the nucleolytic processing of precursor rRNA (pre-rRNA) and in telomeric DNA 
synthesis.
352
 
 
Small Cajal body-specific RNAs (scaRNAs) represent a class of small RNA with similar 
functions to the two main types of snoRNA described above. They are clustered in the small 
membrane-less sub-compartments of the nucleus termed the Cajal bodies, where they have 
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been shown to be involved in the post-transcriptional modification of snRNAs. scaRNAs are 
larger than the classical snoRNAs but are structurally similar, displaying the characteristic 
boxes of both C/D and H/ACA snoRNAs in addition to CAB boxes (motif UGAG) which 
function as a Cajal body localization signal.
353
 
 
In eukaryotic genomes, snoRNAs have been shown to be predominantly encoded in the 
introns of protein-coding host genes but some are under the control of independent 
promoters.
354
 In humans, most snoRNAs are intronic and co-transcribed with their host gene 
transcripts, and then processed out of the excised introns.
355
 However, the transcription of a 
minority occurs through independent RNA polymerase II or III activity in a similar manner to 
many miRNAs.
353,355
 Closely related snoRNA family members are usually encoded in 
different introns of the same host gene, but some host genes encode numerous unrelated 
snoRNAs. Although some snoRNA host genes appear to be non-protein coding, the host 
genes of many intronic snoRNAs are involved in nucleolar function and protein synthesis, 
and as such there is often an element of co-functioning.
355,356
 The fact that in humans, most 
snoRNAs are encoded in the introns of protein-coding and non-protein-coding genes (the 
latter generally containing short, poorly conserved open reading frames) gives rise to the 
assumption that these host genes act solely as cellular housekeepers via their snoRNA-
encoding sequences.
357,358
 However, recent studies have challenged this concept and have 
implicated snoRNAs and their host genes in the control of oncogenesis and cell fate.
359,360
 
The existence of a number of ‘orphan’ snoRNAs with no known rRNA targets, and the 
demonstration of their presence in subcellular locations other than the nucleolus,
361
 supports 
the concept that this group of small non-coding RNAs may regulate other molecules and have 
additional cellular functions.
362
 Furthermore, a number of studies suggest an evolutionary 
relationship between miRNAs and snoRNAs,
363
 and others report that mature snoRNAs may 
undergo further cellular processing to form smaller snoRNA-derived RNAs (sdRNAs) with 
miRNA-like functions.
347,363-366
 Additionally, snoRNA expression has been shown to be as 
variable as miRNA expression in human tumour samples and normalising miRNA 
polymerase chain reaction (PCR) expression data to these snoRNAs introduced bias in 
associations between miRNA and outcome.
367
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1.4.2 ‘Non-housekeeping’ roles of snoRNAs 
 
Ender and colleagues (2008)
364
 were the first to identify a human snoRNA with a miRNA-
like function. They performed a RIP-seq analysis of small RNAs associated with human 
AGO1 and AGO2 in multiple cell lines and identified small RNAs originating from the 
snoRNA, ACA45, that were able to target mRNA (e.g. CDC2L6) on the RISC complex. 
Furthermore, they demonstrated that ACA45 processing was independent of the Drosha-
containing microprocessor complex but did require DICER; but the authors acknowledge that 
other transporters and nucleases may also be involved. Interestingly they also showed that 
ACA45 is more abundant in cells in its full-length form and that only a minor portion is 
processed to a small miRNA-like RNA, which is consistent with the finding that ACA45 
exists as a functional snoRNA that forms snoRNPs with the protein factor GAR-1.
361
 This 
suggests that ACA45 is transcribed and functions as a classical snoRNA in the nucleolus of 
human cells, but that a minor portion is also transported to the cytoplasm by an undiscovered 
export receptor and then, following further processing can regulate gene expression via an 
interaction with the RISC complex.
364
 Interestingly, recent proteomic and 
immunofluorescence analyses of AGO-containing RNA–protein complexes in animals have 
also suggested that a relationship exists between the snoRNA and RNA silencing pathways; 
368,369
 and mass spectrometry of AGO-associated proteins in HEK-293 cells demonstrated 
direct interactions between AGO1 and AGO2, and Nop56 and fibrillarin, respectively, both 
of which are key components of snoRNPs.
368,370
  
 
Kishore et al. (2010)
366
 provided further evidence supporting a functional role for sdRNAs by 
introducing the concept of a miRNA-like ‘orphan’ snoRNA. HBII-52 (SNORD 115), is a 
C/D box snoRNA expressed from the SNURF–SNRPN locus (the loss of which is associated 
with Prader-willi syndrome)
366
 that shows no clear sequence complementarity with rRNAs, 
tRNAs or snRNAs and is not involved in their methylation. Instead HBII-52 appears to target 
mRNA and exhibits sequence complementarity to an alternative exon of the human serotonin 
receptor 2C mRNA and regulates alternative splicing of this pre-mRNA. Furthermore, the 
mouse homolog of HBII-52 (MBII-52) was shown to regulate five other pre-mRNAs (DPM2, 
TAF1, RALGPS1, PBRM1 and CRHR1) and the authors demonstrated that MBII-52 is 
processed into shorter RNAs lacking the snoRNA stem that are responsible for its function.
366
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Taft et al. (2009) further demonstrated a relationship between the RNA processing/silencing 
machinery and sdRNAs in eukaryotes.
365
 They demonstrated the existence of sdRNAs with 
evolutionary conservation in size and position that were derived from the majority of 
snoRNA loci in animals, Arabidopsis, and fission yeast. They showed that in animals, 
sdRNAs derived from C/D snoRNAs had a bimodal size distribution of 17–19 nt and >27 nt 
and predominantly originated from the 5’ end; and that H/ACA snoRNA-derived sdRNAs 
were predominantly 20–24 nt in length and originated from the 3’ end. They also showed an 
association between sdRNAs and the RISC complex and suggested that, in some cases, 
DICER was required for the processing of snoRNAs to sdRNAs.
365
 Interestingly, it appears 
that loss of DICER1 and DGCR8 caused a more pronounced reduction in H/ACA-derived 
sdRNAs than C/D-derived snoRNAs, suggesting that the production of the later may occur 
predominantly via a different processing pathway which may account for their bimodal size 
distribution. 
 
Brameier et al. (2011)
347
 performed massive parallel pyrosequencing on small RNA fractions 
(up to 40nt) extracted from human CD4
+
 T-lymphocytes. Although over 60% of sequences 
corresponded to known human miRNAs, the authors identified over 9000 RNAs 
(approximately 2% of the total reads) of 18-28nt in length that originated from snoRNAs, 
which they termed sno-miRNAs.
347
 Although C/D box snoRNAs, were the primary source of 
sno-miRNAs in this study, many also derived from H/ACA box snoRNAs.
347
 For the C/D 
box derived sno-miRNAs the guide strand generally contained the box C element of the 
snoRNA, whilst the passenger strands were usually flanked by the box D element in their 3’-
end. Following testing in further cell lines the authors demonstrated that the processing of 
particular snoRNAs to functional sno-miRNAs occurred in a cell line specific manner (for 
example, U74 was processed to sno-miRNAs in Jurkat cells but not HeLa cells).
347
 
Furthermore, although luciferase assays demonstrated that many of the sno-miRNAs had 
gene silencing capabilities similar to those of miRNAs, this also appeared to be cell line 
specific. For example U27-derived sno-miRNAs had gene regulatory capabilities in HeLa 
and Jurkat cells but not RPMI8866 cells. Additionally, a significant number of sno-miRNAs 
had no significant gene silencing effects in any of the tested cell lines. For example, the 
majority of the sno-miRNAs derived from the GAS5 gene cluster of snoRNAs had little or no 
gene silencing effects (e.g. U44 and U48), although U78 did do in two of the three cell lines 
tested.
347
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Scott et al. (2009)
363
 compared the genomic locations of known miRNAs and H/ACA box 
snoRNAs to investigate the possibility of an evolutionary relationship between the two 
classes of ncRNA. They revealed an interesting overlap between specific members of these 
classes and suggested that some miRNAs might have evolved from snoRNA encoding 
genomic regions, which they confirmed by scanning reported miRNA-encoding regions for 
the presence of H/ACA box snoRNA features. In fact, they showed that 20 miRNA 
precursors exhibited significant similarity to H/ACA snoRNAs, which included molecules 
predicted to target known rRNA pseudouridylation sites in vivo for which no guide snoRNA 
had been reported.
363
 Furthermore, the predicted folded structures of these 20 H/ACA 
snoRNA-like miRNA precursors resembled known H/ACA box snoRNAs. The genomic 
regions surrounding the predicted snoRNA-like miRNAs contained transposable elements, 
target site duplications and poly (A) tails that correspond strongly to those regions around 
known snoRNA retroposons.
363
 Furthermore, the authors demonstrated that the precursors of 
five H/ACA snoRNA-like miRNAs could bind to dyskerin, suggesting that they had retained 
some H/ACA snoRNA functionality.
363
 The Brameier study
347
 also suggested an evolutionary 
relationship between snoRNAs and miRNAs by identifying a number of miRNAs on 
miRBase that were in fact C/D box-derived sdRNAs (HBII-99b and SNORD126) or H/ACA 
box-derived sdRNAs (ACA34, ACA36b and HBI-61).
347
 
  
These studies clearly suggest that, in addition to their roles as regulators of ribosomal 
function, snoRNAs have other important functions such as the control of gene expression at 
the post-transcriptional level by either directly targeting mRNA or through their conversion 
to smaller miRNA-like sdRNAs. In view of these various functions, it is not surprising that 
data are accumulating supporting an important role for snoRNAs in a host of cellular 
pathways including those involved in development, metabolism and carcinogenesis. An 
imbalance in the expression of specific snoRNAs could theoretically promote or prevent 
carcinogenesis as the effect that this could have on rRNA modification and maturation could 
affect the translation and hence expression of specific tumour suppressor genes or oncogenes. 
Furthermore, the ability of snoRNAs or sdRNAs to directly target tumour suppressor genes or 
oncogenes at the mRNA level suggests another mechanism by which they could promote or 
prevent carcinogenesis.   
 
A study in zebrafish showed that suppressing the expression of three snoRNAs (U26, U44 
and U78), either by disrupting host gene splicing or by inhibiting snoRNA precursor 
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processing, reduced snoRNA-mediated methylation of rRNA targets and caused severe 
morphological defects and embryonic lethality.
371
  Others showed that the loss of three C/D 
box snoRNAs (U32a, U33 & U35a) encoded in the ribosomal protein L13a locus conferred 
resistance to lipotoxic and oxidative stress in vitro and prevented the propagation of oxidative 
stress in vivo.
372
 
 
Liao et al (2010)
373
 profiled snoRNA signatures in 22 human non-small cell lung cancer 
(NSCLC) tissues and matched noncancerous lung tissues, as well as plasma expressions of 
any identified snoRNAs in 37 NSCLC patients, 26 patients with chronic obstructive 
pulmonary disease, and 22 healthy controls in order to develop a novel diagnostic biomarker 
panel for NSCLC, similar to previously described miRNA-based diagnostic platforms.
99
 
Using microarray technology with qRT-PCR validation, they identified six snoRNAs 
(SNORD33, SNORD66, SNORD73B, SNORD76, SNORD78, and SNORA42) as being 
statistically differentially expressed between the paired tumour and noncancerous samples 
and three of these snoRNAs (SNORD33, SNORD66 and SNORD76) were also differentially 
expressed in the plasma of NSCLC patients and healthy controls.
373
 The same group 
subsequently selected SNORA42 for further investigation into its potential role in 
tumorigenesis of NSCLC, as its host gene is located on chromosome 1q22 which is 
frequently amplified in this disease.
374
 They observed genomic amplification and associated 
high expression of SNORA42 in lung cancer cell lines but there was no overexpression of its 
host gene KIAA0907. Furthermore SNORA42 knockdown in NSCLC cells inhibited 
tumorigenicity in vitro and in vivo, whereas SNORA42 overexpression increased cell growth 
and colony formation.
374
 
 
Dong et al. (2009)
360
 identified the snoRNA, U50, as a candidate tumour suppressor gene in 
human breast, suggesting that it plays a role in the development and/or progression in this 
malignancy. U50 is located on chromosome 6q14.3-15 which is within the 6q14-16 region 
frequently deleted in breast cancer.
360
  U50 underwent frequent somatic and germline 
deletions and transcriptional down-regulation in breast cancer cell lines as well as primary 
breast tumours, and functionally, re-expression of U50 inhibited colony formation in breast 
cancer cell lines.
360
 The same group also identified that U50 is mutated and transcriptionally 
down-regulated in prostate cancer and that its overexpression prevented colony formation is 
prostate cancer cell lines.
375
 These two studies suggest the U50 has a malfunctioning role in 
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the development and progression of breast and prostate cancer. Another study has also shown 
that down-regulation of the H/ACA box snoRNA, h5sn2, is associated with meningioma.
376
  
 
1.4.3 SnoRNAs encoded for by the growth arrest-specific transcript 5 gene  
 
The growth arrest-specific transcript 5 gene (GAS5), located at 1q25, is a non-protein-coding 
multiple snoRNA host gene comprising of 12 exons, 
377,378
 initially discovered during 
screening for potential tumor suppressor genes expressed at high levels during growth 
arrest.
12,13
 In humans, it encodes ten intronic C/D box snoRNAs and two mature long non-
coding RNAs (lncRNAs) that originate from alternative 5′-splice donor sites in exon 7.378 The 
open reading frame encoded within GAS5 exons is short and is not thought to encode a 
functional protein. Mapping of its 5* end demonstrates that it possesses an oligopyrimidine 
tract characteristic of the 5*-terminal oligopyrimidine (5*TOP) class of genes that 
accumulate during cell cycle arrest but are rapidly degraded by nonsense-mediated decay 
during cell growth. The classification of GAS5 as a 5*TOP gene offers an explanation as to 
why it is a growth arrest specific transcript as while the spliced GAS5 RNA is normally 
associated with ribosomes and rapidly degraded, during arrested cell growth it accumulates in 
mRNP particles. Interestingly, the only regions of conservation between mouse and human 
GAS5 genes are their snoRNAs and 5*-end sequences,
378
 suggesting that these are the most 
important functional components.  Although GAS5 plays a role in post-transcriptional 
modification of ribosomal RNA through its snoRNAs, a number of recent studies have 
implicated this gene in other important cellular processes.
359,367,379,380
 The GAS5 lncRNA was 
shown to interact with the DNA-binding domain of the glucocorticoid receptor where it acts 
as a riborepressor, influencing cell survival and metabolic activities during starvation by 
modulating the transcriptional activity of this receptor.
359
 Furthermore, the same group 
showed in prostate cell lines, that GAS5 mRNA sequesters the androgen/androgen receptor 
complex and prevents its binding to target DNA sequences,
359
 which is likely to play an 
important role in modulating the effects of androgens in the prostate. GAS5 transcripts have 
also been shown to be important regulators of cell survival and apoptosis in human T-cells 
and breast and prostate cancer cell lines,
379-381
 and their overexpression sensitized mammalian 
cancer cell lines to inducers of apoptosis.
379
 Furthermore, reduced expression of GAS5 and/or 
its snoRNAs has been demonstrated in  head and neck squamous cell carcinoma,
367
 breast 
cancer
367,379
 and glioblastoma multiforme,
382
 whilst over-expression of U44, U76 and U78 
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has been shown in NSCLC.
373
 The aberrant GAS5 expression demonstrated in breast and 
head and neck cancer was associated with poor prognosis.
367
 Despite these data, little is 
known as to the precise role of specific GAS5 snoRNAs in the pathways in which they have 
been implicated, and even less is accepted about the mechanisms underlying them.  
 
Aims and objectives 
 
It is known that p53 co-ordinates cell signalling pathways through regulating the expression 
of gene targets. This is achieved mainly through transcriptional regulation of mRNA 
expression but also through the ability of p53 to regulate miRNA abundance and hence fine 
tune target gene expression post-transcriptionally through AGO2 mediated mRNA 
translational repression and/or mRNA degradation. To understand this process in more detail, 
we aimed to comprehensively illustrate the network of miRNA-mRNA interactions that 
occurs in response to DNA damage using RNA-seq, AGO2 RIP-seq and PAR-CLIP-seq to 
determine sets of genes (RNA seq) and miRNAs (small RNA-seq) whose expression levels 
change in response to DNA damage and use AGO2 IP approaches to investigate the 
differential loading of miRNAs and mRNAs onto AGO2. Furthermore, we wished to 
combine the AGO2 RIP and PAR-CLIP approaches with deep sequencing to determine the 
exact interaction sites between the AGO2-bound miRNAs and their mRNA targets in 
response to double-strand break DNA damage. In addition, we wished to investigate the p53-
associated miRNA/mRNA interactome at a genome wide level, and to establish the 
functional effects of miRNA/mRNA binding in terms of p53-regulated signaling networks. 
We also aimed to find previously unidentified p53-dependent post-transcriptional processes 
that could affect mRNA or miRNA expression or function, and in particular, whether p53 
might regulate the loading of miRNAs onto AGO2 and hence control gene expression 
through an unexplored mechanism of miRNA regulation in response to stimuli. Furthermore, 
we planned to identify differential AGO2 binding sites in response to DOX treatment that 
might occur independently of the miRNAs regulated by the DNA damage. Combining these 
findings with a motif discovery analysis, we wanted to see if any particular RNA motif 
present on the UTR of the mRNA targets was necessary for this regulation to occur. Finally, 
given the previously described role of GAS5 in the regulation of apoptosis and the well 
documented role for p53 in the same process, we aimed to further investigate the relationship 
between p53 and the GAS5 snoRNAs to gain further insight into their potential role in cell 
survival and oncogenesis in colorectal cancer both in vivo and in vitro. 
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2.1 Materials  
2.1.1 Mammalian cell culture 
 
Table 6: List of mammalian cell lines 
Cell Type        Tissue Morphology Tumourigenicity 
 
HCT116 wild-type 
HTC116 p53-knockout  
 
Colon 
Colon 
 
Epithelial 
Epithelial 
 
Human colorectal carcinoma cell line 
Human colorectal carcinoma cell line  
DLD-1 
 
DLD-1 Dicer knock-down 
 
RKO 
 
RKO Dicer knock-down 
Colon 
 
Colon 
 
Colon 
 
Colon 
Epithelial 
 
Epithelial 
 
Epithelial 
 
Epithelial 
Human colorectal carcinoma cell line 
 
Human colorectal carcinoma cell line 
 
Human colorectal carcinoma cell line  
 
Human colorectal carcinoma cell line 
 
 
 
Table 7: Normal growth media 
Cell Type Media Additives Storage 
 
HCT116 
 
McCoy’s 5A medium 
(modified) (Gibco
®
) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% fetal calf serum (FCS) 
 
4°C, used within one 
month 
 
DLD-1 
DLD-1 Dicer knock-down 
 
RPMI (Roswell Park 
Memorial Institute) 
1640 )(Sigma-
Aldrich
®
) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% fetal calf serum (FCS) 
 
4°C, used within one 
month 
 
RKO 
RKO Dicer knock-down 
 
DMEM (Dulbecco’s 
Modified Eagle’s 
Medium)(Sigma-
 
2mM Glutamine 
50 units/ml Penicillin 
 
4°C, used within one 
month 
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 Aldrich
®
) 50μg/ml Streptomycin 
10% FCS 
 
2.1.2 Buffers and Solutions 
 
Table 8: List of buffers and reagents 
Reagent Recipe Storage 
 
1M DTT (Dithiothreitol) 
 
 
1M Tris-HCl 
 
 
Laemmli’s buffer 
 
 
 
SDS (Sodium Dodecyl 
Sulphate) loading 
buffer (2x) 
 
10x SDS PAGE  
Running buffer 
 
10x Transfer buffer 
 
 
TBS 10x 
(Tris-Buffered Saline) 
 
 
TBST buffer 
(TBS/ Tween
®
 20) 
 
Blocking solution  
 
RIP Washing buffer 
 
 
 
 
 
RIP Lysis buffer 
 
 
 
 
 
 
 
1.54g of DTT in total of 10ml ddH20 (double 
distilled MilliQ water) 
 
60.5g Tris in total of 500ml ddH20 and adjusted to 
desired pH with pure HCl 
 
50mM Tris-HCl pH 6.8, 15% glycerol, 
0.1% (w/v) bromophenol blue,  
4% SDS (BioRad) 
 
125mM Tris-HCl pH 6.8, 20% glycerol,  
4% SDS, 100mM DTT,  
0.04% (w/v) bromophenol blue 
 
10g SDS, 30.3g Tris, 144.1g glycine dissolved in  
1l of ddH20 
 
30.3g Tris, 144,1g glycine dissolved  
in 1l of ddH20 
 
24.23g Trizma HCl, 80.06 g 
NaCl dissolved in 1l of ddH20 and 
adjusted pH to 7.6 with pure HCl 
 
100ml of TBS 10x, 900ml ddH20,  
1ml Tween
®
 20 (BDH) 
 
5% dried skimmed milk powder in TBST 
 
50mM Tris-HCL pH7.5 (2.5ml of 1M) 
300mM NaCl (3ml of 5M) 
5mM MgCl2 (2.5ml of 100mM) 
NP40 0.05% (25ul) 
Make up to 50ml with ddH20 
 
20mM Tris-HCL pH7.5 (1ml of 1M) 
150mM KCL (7.5ml of 1M) 
0.5% NP40 (250ul) 
2mM EDTA (200ul of 500mm) 
1mM NaF (500ul of 100mM) 
Make up to 50ml with ddH20 
Just before use add to this the following for a 20 ml 
 
100μl aliquots at -20°C 
 
 
Room temperature 
 
 
Room temperature 
 
 
 
500μl aliquots at 4°C 
 
 
 
Room temperature 
 
 
Room temperature 
 
 
Room temperature 
 
 
 
Room temperature 
 
 
Prepared as required 
 
Prepared as required 
 
 
 
 
 
Prepared as required 
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4-Thiorudine stock 
 
 
 
PAR-CLIP NP40 lysis buffer 
 
 
 
 
 
 
 
 
 
PAR-CLIP Citrate-
phosphate buffer 
 
 
 
PAR-CLIP wash buffer  
 
 
 
 
 
 
 
PAR-CLIP High salt wash 
buffer 
 
 
 
 
 
 
PAR-CLIP 
Dephosphorylation buffer 
 
 
 
 
 
 
PAR-CLIP Phosphatase 
wash buffer 
 
 
 
 
PAR-CLIP PNK buffer 
 
 
 
 
 
batch of lysis buffer: 160u/ml of RNAsin (80ul), 
0.5mM DTT (100ul), Protease inh 50x (1 tab in 1ml 
ddh20) (400ul), Phosphotase inh 1x (2 tab in 2ml is 
10x stock) (2ml) 
 
Made to a final conc of 50mM by adding 100mg to 
7.69ml of ddh20 
 
 
50mM HEPES pH7.5 ( 2.5ml of 1M) 
150mM KCL (7.5ml of 1M) 
0.5% NP40 (250ul) 
2mM EDTA (200ul of 500mM) 
1mM NaF (500ul of 100mM) 
Make up to 50ml with ddH20 
Just before use add to this the following for a 20 ml 
batch of lysis buffer: 0.5mM DTT(10ul of 1M), 
Protease inh 50x (1 tab in 1ml ddh20) (400ul) 
 
94mg citric acid and 184 mg Na2HPO4 in 50ml 
made to pH 5.0 (4.7g/l citric acid and 9.2g/l  
Na2HPO4 gives pH 5.0) 
 
 
50mM HEPES-KOH pH7.5= 2.5ml of 1M  
300mM KCL= 15ml of 1M 
0.05% NP40= 25ul  
Make up to 50ml with ddH20 
Just before use add to this the following for a 20 ml 
batch of IP wash buffer: 0.5mM DTT (10ul of 1M), 
protease inh 50x (1 tab in 1ml ddh20) (400ul) 
 
50mM HEPES-KOH pH7.5 (2.5ml of 1M) 
500mM KCL (25ml of 1M) 
 0.05% NP40 (25ul)  
Make up to 50ml with ddH20 
Just before use add to this the following for a 20 ml 
batch of high salt wash buffer: 0.5mM DTT (10ul of 
1M), Protease inh 50x (1 tab in 1ml ddh20) (400ul) 
 
50mM Tris-HCL pH7.9 (2.5ml of 1M) 
100mM NaCl (1ml of 5M) 
10mM MgCl2 (5ml of 100mM) 
Make up to 50ml with ddH20 
Just before use add to this the following for a 20 ml 
batch of Dephosphorylation buffer: 1mM DTT (20ul 
of 1M) 
 
50mM Tris-HCL pH7.5  (2.5ml of 1M) 
50mM NaCl (0.5ml of 5M) 
20mM EGTA (10ml)  
0.5% NP40 (250ul) 
Make up to 50ml with ddH20 
 
50mM Tris-HCL pH7.5  (2.5ml of 1M) 
50mM NaCl (0.5ml of 5M) 
10mM MgCl2 (5ml of 100mM) 
Make up to 50ml with ddH20 
 
 
 
 
 
 
 
Prepared as required 
 
 
 
Prepared as required 
 
 
 
 
 
 
 
 
 
Prepared as required 
 
 
 
 
Prepared as required 
 
 
 
 
 
 
 
Prepared as required 
 
 
 
 
 
 
 
Prepared as required 
 
 
 
 
 
 
 
Prepared as required 
 
 
 
 
 
Prepared as required 
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PAR-CLIP SDS-PAGE 
loading buffer 
 
 
 
 
 
 
PAR-CLIP 2x protease 
buffer 
 
 
10% Glycerol (v/v)  
50mM Tris-HCL, pH6.8 
2mM EDTA 
2% SDS 
100mM DTT 
0.1% bromophenol blue 
 
 
100mM Tris-HCL pH7.5 (1.5ml of 1M) 
150mM NaCl (450ul of 5M) 
12.5 mM EDTA (350ul of 0.5M) 
2% SDS (300ul of 10%) 
Make to up to 15ml with ddH20   
Prepared as required 
 
 
 
 
 
 
 
Prepared as required 
 
 
 
 
 
 
2.1.3 Antibodies/probes for western blots & immunoprecitiation 
 
Table 9: Primary antibodies 
Antibody Dilutions 
for 
western 
blots 
Company Dilution buffer 
 
Monoclonal mouse p53 (DO-1) 
 
Monoclonal rat AGO-2 
 
Monoclonal mouse Dicer  
 
Monoclonal mouse β-actin 
 
Monoclonal mouse E-cadherin 
(HECD-1) 
 
Monoclonal mouse GAPDH 
 
1/5000 
 
1/5000 
 
1/2500 
 
1/100000 
 
1/1000 
 
 
1/1000 
 
 
Santa Cruz, California, USA 
 
Sigma-Aldrich, Dorset, UK 
 
Santa Cruz, California, USA 
 
abcam
®
, Cambridge, UK 
 
Takara Bio Inc., Shiga, Japan 
 
 
abcam
®
, Cambridge, UK 
 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
 
Blocking buffer  
  
 
 
 
Table 10: Secondary antibodies 
Antibody Dilution Company Dilution buffer 
 
Polyclonal rabbit anti-rat 
IgG/HRP 
 
Polyclonal goat anti-mouse 
IgG/HRP 
 
Polyclonal goat anti-rat IgG/HRP 
 
 
 
1/2500 
 
 
1/2500 
 
 
1/1000 
 
 
 
Dako, Cambridge, UK 
 
 
Dako, Cambridge, UK 
 
 
EMD Millipore Corporation, 
Billerica, MA, USA, 
 
 
Blocking buffer 
 
 
Blocking buffer 
 
 
Blocking Buffer 
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2.1.4 Reagents used in the luciferase assays 
 
Table 11: List of luciferase 3’UTRs 
Gene 3’-UTR Product ID Company 
 
Cyclin D1 (CCND1) 
 
Pogo transposable element with ZNF domain 
(POGZ) 
 
 
S813994 
 
S810968 
 
SwitchGear Genomics, Menlo Park, CA 
 
SwitchGear Genomics, Menlo Park, CA 
 
 
 
Table 12: Transfection media and reagents 
Transfection Media Additives Transfection reagent   Storage 
 
Opti-MEM
® 
I Reduced Serum 
Medium(Gibco
®
) 
 
 
No 
 
 
 
Lipofectamine
®
 2000 Reagent (Invitrogen, Life 
Technologies Ltd, Paisley, UK) 
 
 
4°C 
 
 
 
2.1.5 Primers used for reverse transcription  
All the primers were designed by myself and synthesized by Sigma-Aldrich (Dorset, UK) 
 
Table 13: Primers used for reverse transcription and their sequences 
Gene Primer sequence (5’ to 3’) Gene Primer sequence (5’ to 3’) 
 
GAPDH 
forward AGGGCTGCTTTTAACTCTG 
reverse CCCCACTTGATTTTGGAGG 
 
p21 
forward GGAGACTCTCAGGGTCGAAA 
reverse GGATTAGGGCTTCCTCTTGG 
 
U44 
forward TGATAGCAAATGCTGACTGA 
reverse CAGTTAGAGCTAATTAAGAC 
 
U47 
forward GGAGACTCTCTTCCTCTTGG 
reverse CAAATGCTGACTGATGATAG 
 
2.2 Methods  
2.2.1 Mammalian cell culture 
2.2.1a Growing and passaging cells 
  
 Cells were cultured in 150 cm
2
 flasks or 100-mm dishes or 6-well plates unless 
otherwise specified and maintained at 37°C in a humidified 5% CO2 incubator. They were 
routinely passaged when a confluence of ~90% was reached. During cell passage, medium 
was aspirated, cells were washed once with PBS solution and then trypsinised with EDTA-
trypsin at 37°C for 3 minutes to allow detachment. FCS was added to inactivate the trypsin 
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(1:1 ratio) and cell clumps were disrupted by gentle pipetting. The cell suspension was 
pipetted out of the flask, transferred to a 15 mL sterile centrifuge tube and centrifuged for 4 
min at 1300 rpm. After centrifugation, the supernatant was aspirated and the cell pellet was 
re-suspended in the appropriate volume of medium. The resulting suspension was split to the 
desired dilution into new flasks and fresh media was added. In all experiments cells had 
undergone between 4 and 20 passages. 
2.2.1b Cell treatments with doxorubicin 
  
 Cells were plated in 150 mm dishes at a 50% confluence and incubated under 
normal growth conditions to adhere. They were then treated with doxorubicin at a 
concentration of 0.2ug/ml or equivalent volume of vehicle (ddh20). After each treatment time 
point, dishes were placed on ice and medium was aspirated. Cells were washed twice with 
cold PBS, scraped and centrifuged for 5 minutes at 1300 rpm. The supernatant was removed 
and the cell pellet was processed for RNA and/or protein extraction. 
2.2.2 Quantitative real-time Reverse Transcription-PCR 
2.2.2a RNA preparation 
 
 Working under hood cells were lysed using 1ml of Trizol reagent (Invitrogen) 
andvigorous pipetting. Lysates were collected in eppendorf tubes and 200µl of chloroform 
per 1ml of Trizol reagent were added. Samples were vortexed vigorously for 15 seconds, 
incubated at RT for 2 to 3 minutes, and then centrifuged at 12,000 x g for 15 minutes at 2 to 
8°C. Following centrifugation, each mixture separates into a lower red, phenol-chloroform 
phase, an interphase, and a colourless upper aqueous phase, with RNA remaining exclusively 
in the aqueous phase which was transferred carefully into fresh eppendorf tubes. Total RNA 
was precipitated from the aqueous phases by mixing with 500µl of isopropyl alcohol and 
incubating for 10 minutes at RT. The mixtures were stored overnight at -80 °C to allow small 
RNA precipitation and the RNA precipitates were then centrifuged at 12,000 x g for 10 
minutes at 2 to 4°C to form a pellet on the side and bottom of the tube. The supernatants were 
discarded, and the RNA pellets were washed in 1ml of 75% ethanol and vortexed. Samples 
were centrifuged at 7,500 x g for 5 minutes at 2 to 8°C. The supernatants were removed and 
pellets were air-dried to remove residual ethanol. Finally the RNA pellets were re-suspended 
in an appropriate volume of RNAse-free water. Subsequently, RNA concentration was 
measured at 260nm and 280nm wavelengths, using a NanoDrop ND-100-Spectrophotometer 
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(NanoDrop Technologies). The RNA quality was determined on non-denaturing agarose gel 
electrophoresis: for each RNA sample isolated, two intensive bands at approximately 4.5 and 
1.9 kb were observed at the transilluminator. These bands represent 28S and 18S rRNA and 
indicate successful RNA preparation. RNA extraction from 5 to 8 10µm FFPE sections of 
each tumour tissue sample was performed using the RNeasy FFPE kit (Qiagen), in 
accordance to manufacturer’s instructions. 
2.2.2b cDNA synthesis 
 
 Reverse transcription of mature miRNAs and selected pri-miRNAs and was 
performed using 10ng of total RNA and the TaqMan MicroRNA Reverse Trascription Kit 
(Applied Biosystems). For measurement of gene or selected pri-miRNAs expression, cDNA 
was synthetized from 1 µg of purified Dnase-treated RNA by the Superscript III First Strand 
cDNA synthesis system (Invitrogen). Reverse transcription reaction were performed by 
incubating the samples in a 7900Ht Thermal Cycler (Applied Biosystems). After RT cycles, 
the cDNAs samples were placed in ice and then prepared for quantitative real-time PCR. 
2.2.2c Quantitative real-time PCR 
 
 To amplify mature miRNAs and selected pri-miRNAs, for a single reaction, 1 ng 
of relative cDNA template was distributed in a Fast Optical 96-well reaction plate (Applied 
Biosystems), followed by the appropriate volume of TaqMan
®
 Universal PCR Master Mix, 
No Amperase
®
 UNG and the relative 20x Real Time TaqMan probe (both Applied 
Biosystems). For both gene-specific expression and selected pri-miRNAs, 10 ng of cDNA per 
reaction were amplified using the Power SYBR green PCR master mix (Applied 
Biosystems). Quantitative real-time PCR (qPCR) was performed with an ABI Prism 7900HT 
sequence detection system (Applied Biosystems). Data were analysed using qBasePlus 
software (biogazelle).  
2.2.3 SDS-polyacrylamide gel electrophoresis and western blot 
 
2.2.3a Protein extraction 
  
 Cell pellets or fresh frozen tissue samples were lysed in 30 to 60 μl of NP-40 lysis 
buffer + protease inhibitors cocktail solution (Roche). eppendorf tubes containing cell lysates 
were rotated for 15 minutes at 4°C. and then microcentrifuged at maximum speed (13,000 
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rpm) for 15 minutes at 4°C to allow separation of proteins from insoluble elements. The 
supernatants containing proteins were transferred into new eppendorf tubes and subjected to 
protein quantification. 
2.2.3b Protein quantification  
 
 Protein concentration was calculated using the Bradford Reagent Kit (BioRad). 
Absorbance readings were measured at 595nm using a Beckman DU® 530 Life Science 
UV/Visible spectrophotometer. After data collection, the concentration of the unknown 
samples was determined based on standard absorbance value. The protein samples were then 
prepared for the SDS-polyacrilamide gel electrophoresis: 3µg/µl of protein samples were 
mixed with SDS Loading Buffer (5x) and boiled at 95°C for 5 minutes. 
2.2.3c SDS-polyacrylamide gel electrophoresis 
 
 Both acrilamide (8-20%) resolving and 4% stacking gels were prepared manually 
as required. Rainbow markers (Fermentas, Life science) and the protein samples (10µl) were 
loaded and electrophoresis was carried out for 2 to 3 hours at 80V. Proteins were separated 
by SDS-polyacrilamide gel electrophoresis (SDS-PAGE) and run in a running buffer.  
2.2.3d   Western blots 
 Proteins were transferred to a Hybond C super nitrocellulose membrane (GE 
Healthcare) for 3 hours at 100V in transfer buffer using a Mini-PROTEAN® Tetra Cell 
(BioRad). The membrane was stained with Ponceau S solution (Fluka) to check if the transfer 
was successful. The membrane was washed once for 10 minutes with blocking buffer in order 
to remove the staining and then blocked with blocking buffer at RT for 1 hour. The 
membrane was transferred to the primary antibody solution and left at 4°C overnight. 
Membranes were washed three times for 15 minutes each in TBST. An IgG/HRP secondary 
antibody diluted in blocking solution was then added, and the membrane was incubated at 
room temperature for 1 hour. Membranes were washed 3 times with TBST and Enhanced 
Chemiluminescence (ECL) detection system (GE Healthcare) was used for visualization. The 
emitted fluorescence was detected using Hyperfilm ECL (GE Healthcare) on SRX-101A x-
ray developer.  
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2.2.4 Immunoprecipitation 
 
2.2.4a Preparation and washing of the sepharose beads 
 
Lysis and washing buffers were prepared as per Table 8. Forty microliters of 
sepharose beads were uses for each immunoprecipitation sample and for pre-clearing of each 
lysate. Beads were spun down in the centrifuge by pulsing and the supernatant was removed. 
They were then washed 3 times in 1ml of washing buffer and the supernatants were removed. 
Beads were resuspended in 1ml lysis buffer with additives and alliquoted out in equal 
volumes into the required number of eppendorf tubes (1 per sample). 
2.2.4b Preparation of the cell lysate 
 
Cells (e.g. HCT116 p53WT, HCT116 p53
-/-
, RKO or DLD-1) were plated in 150 mm 
dishes at a 50% confluence and incubated under normal growth conditions to adhere. They 
were then treated with doxorubicin at a concentration of 0.2ug/ml or equivalent volume of 
vehicle (ddh20) for 24 hours. The cell plates were then removed from the incubator and the 
medium was completely removed. The cells were then washed twice in cold PBS, scraped in 
1ml of PBS, collected into falcons (1 for each point) and centrifuged at 1300 rpm for 3min. 
The PBS supernatant was removed and cells were re-suspended in lysis buffer with additives 
and passed 3 times through a syringe connected to a 25G needle and once through a 27G 
needle. Lysates were incubated on ice for 15mins  and then centrifuged at 16000xg at 4
o
C for 
10 minutes. Lysates were transfered into a clean falcon and pre-cleared by the addition of 
sepharose beads followed by rotation at 4
0
c for 2 hours. The lysates/bead mixtures were then 
spun down and the supernatants transferred to new falcons for each point and the beads 
discarded. The lystates were then filtered using using a 0.45um syringe. 10% of total lystate 
was removed and kept as the input samples and the remainder used for the 
immunoprecipitation steps.  
 
2.2.4c Conjugation of antibodies to the beads, and the immunoprecipitation steps 
 
10ug of anti-AGO (anti-p53 or anti–Dicer) or anti-IgG antibodies were added to the 
appropriate bead samples in addition to 1mg/ml of heparin and were then rotated for 2 hours 
at 4
0
c. Eppendorfs containing the antibody/bead mix were spun down, the supernatant was 
removed and the beads were washed 3 times in washing buffer and then re-suspended in lysis 
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buffer. The lysates prepared previously were then divided evenly and added to the 
appropriate antibody/bead mixtures. The samples were rotated for 4 hours at 4
0
C and then 
spun down. 10% of the supernatants were removed and kept in eppendorfs as the flow 
through and the remaining supernatants were discarded.  The beads then underwent a 
prolonged washing step using lysis and washing buffers. 
 
2.2.4d Extraction of RNA from the immunoprecipitated samples using phenol 
chloroform 
 
Samples were spun down and the supernatants were removed. Beads containing the 
samples, and the input and flow-through samples were reconstituted with 30ul of DNAse 
buffer and 1ul of DNase I and left at RT for 15min . 300ul of 2x protease buffer was added 
followed by 3ul of protease K (20mg/ml) and the samples were incubated at RT for 20min on 
a thermomixer. 300ul of phenol-chloroform was then added to each samples followed by 
vortexing and then centrifugation at 13,000xg for 5min at 4
o
c. The supernatants containing 
the RNA were transferred to new eppendorfs and 1/10 volume of 3M NaAC was added 
followed by vortexing. 2ul of glycogen carrier was added to each sample followed by 2.5 
volume of 100% ethanol. Samples were left at -20
0
c overnight and then centrifuged at 
13,000xg speed for 20min at 4
o
c the following day. The supernatants were discarded and the 
remaining pellets were washed in 1ml of 70% ethanol and centrifuged at 13,000xg for 10 
minutes at 4
o
c. The ethanol was completely removed and the pellets were air-dried and 
dissolved in ddH20. RNA concentrations were determined using the Nanodrop machine and 
and the input and flow through samples were then run on a 1% agarose gel to check the RNA 
quality. 
 
2.2.5 PARCLIP 
 
Buffers were prepared as per Table 8. The 150mm plates containing doxorubicin or 
vehicle treated HCT116 p53WT and HCT116 p53
-/-
 cells were removed from the incubator. 
A total of 400million cells were used for each experiment.  Each plate was treated with 4-
thiouridine at a final concentration of 100uM, fourteen hours prior to UV-crosslinking.  
 
Cells were washed once in 10ml of ice PBS and the PBS was removed completely. Plates 
were places uncovered on ice and the cells were Irradiated with 0.15 J/cm
2
 (of 365nm UV 
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light in a Stratalinker 2400. Cells were then scraped cells with a scraper in 1ml of PBS per 
plate, transferred to 50 ml falcon and centrifuged at 500 x g for 5mins at 4
0
C. The supernatant 
was then discarded to leave a wet cell pellet. Cell lysis and the first RNaseT1 digest were 
then performed as follows. Three volumes of 1x NP40 lysis buffer with additives was added 
to the cell pellet which was then incubated on ice for 10 minutes and centrifuged at 13000 x g 
for 15mins at 4
0
c to clear the cell lysate. Lysates were then filtered by passing through a 
0.2um membrane syringe filter and collecedt into a 15ml falcon. Lysates were then treated 
with RNase T1 (Fermentas 1,000U/u) to a final concentration of 1U, incubated for 15 mins at 
22
0
c on a heat block and then cooled on ice for 5 mins. 
 
AGO immunoprecipitation and radiolabelling of the crosslinked RNA was then performed as 
follows. 10ul of Dynabeads Protein G magnetic particles (Invitrogen) per ml of cell lysate 
were transfered to a 1.5ml eppendorf. The eppendorf was placed on a magnetic stand for two 
minutes and the supernatant was then removed. While the eppendorf was still on the 
magnetic stand, the beads were washed twice in 1ml of citrate-phosphate buffer and then 
resuspended in citrate-phosphate buffer at twice the original volume of bead suspension. 
AGO antibody was added to the tube containing the beads at a final concentration of 
0.05ug/ul and the tube was rotated at room temperature for 40 minutes to allow conjugation 
of the antibody to the beads. The beads were then washed twice in 1ml of citrate-phosphate 
buffer to remove any unbound antibody, and resuspended in citrate-phosphate buffer at twice 
the original volume of beads suspension. The freshly prepared antibody-conjugated magnetic 
beads were then added to each falcon containing the RNase T1 treated lysate at a volume of 
20ul per ml of lystate. Falcon tubes were placed on a magnetic particle collector for five 
minutes to allow the beads to collect at the bottom and sides and the supernatant was 
removed and discarded. The beads in each falcon were resuspended in 1ml of IP wash buffer, 
transferred to clean eppendorf tubes and washed twice in 1 ml of IP wash buffer using the 
magnetic stand for eppendorfs. After the final wash and with the eppendorfs still on the stand 
the original bead volume of IP wash buffer was added to the eppendorfs and the beads were 
resuspended by flicking. A second RNase T1 treatment was then performed using a final 
concentration of 10U/ul (not 100U/ul to avoid too much digestion of the RNA. The samples 
were then incubated at 22
0
c for 15mins on a heatblock, cooled on ice for 5 minutes and 
washed three times in high salt wash buffer. The supernatant was removed supernatant after 
the final wash and the beads were resuspended in one times the original bead volume of 
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dephosphorylation buffer. The beads were then treated with calf intestinal alkaline 
phosphatase at a final concentration of 0.5 U/ul and incubated on a thermocycler at 37
0
c for 
10 mins. The beads were then washed twice in 1ml of phosphatase wash buffer, placed back 
on the magnetic stand and then the supernatant was removed, leaving the beads stuck to the 
side. The beads were then washed twice in polynucleotide kinase buffer (PNK) without DTT, 
the supernatant was then removed and the beads were resuspended 1x the original bead 
volume of PNK buffer. The RNA segments were then radiolabelled using Y-
32
P-ATP to a 
final concentration of 0.5uCi/ul and T4 PNK to a final concentration of 1U/ul, followed by 
incubation for 30min at 37
o
c on a thermocycler. Non-radioactive ATP was then added to at a 
final concentration of 100uM and the samples were incubated for another 5 minutes at 37
0
C 
on a thermocylcer and then washed five times in 800ul of PNK buffer without DTT. The 
samples were placed back on the magnetic stand, the supernatants were removed and the 
beads were then resuspended in 70ul of SDS-PAGE loading buffer.  
SDS-PAGE and electroelution of the crosslinked RNA-protein complexes was then 
performed as follows. The radiolabeled samples were incubated at for 5min at 95
o
c on a heat 
block to denature and release immunoprecipitated RBP and crosslinked RNA. Samples were 
vortexed, placed on the magnetic stand and supernatants were then transferred to a clean 
1.5cm eppendorf. The 70ul of supernatant for each sample was split in half and loaded  into 
two wells of a Novex Bis-Tris 4-12% 1mm think precast polyacrylamide gel (invitrogen)  and 
run at 80v until the sample had run through the well and then 100v for a further two hours. 
The gel chamber was then dissasembled and the gel was mounted on one plate to facilitate 
alignment of the gel following exposure on photographic film. The gel was then wrapped in 
Saran wrap to avoid contamination, placed in a cassette and transferred to a dark room where 
a film was placed in the cassette and left at room temperature for 15-20 minutes to allow 
exposure. D-tube dialyzers (Dialyzer Midi Tubes) were then prepared by adding 800ul of 
sterile water, leaving them upright for five minutes and then removing the water. The gel 
bands corresponding to the expected size of AGO (approx. 100kda.) were cut for each sample 
and transferred to the D-tube Dialyzer Midi Tube and 800ul of 1x SDS running buffer was 
added to the tube. The crosslinked RNA-RBP complex was electroeluted in 1x SDS running 
buffer for 2h at 100V. The electric current was then reversed for two minutes to release the 
protein from the tube membrane. The D-tube dialyzers were then opened and the eluate was 
pipetted up and down five times on the inner side of membrane taking care to avoid the gel 
slice and not to puncture the membrane. Eluates were then transferred to a clean eppendorf 
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tube and centrifuged for 1min at 14000 x g to pellet the gel residues and the supernatants 
were transferred to clean eppendorfs. A proteinase K digestion was then performed by adding 
2x proteinase K buffer at an equal volume to the electroeluate followed by proteinase K to a 
final concentration of 1.2mg/ml. Samples were then incubated for 30min at 55
0
c on the 
thermocycler.  
Recovery of cross-linked target RNA fragments was then performed as follows. 300ul of 
phenol-chloroform was added to each sample which were then vortexed and centrifuged at 
13,000 xg for 5min at 4
o
c. The supernatant phase was transferred to a new eppendorf and 
1/10
th
 of the volume of 3M NaAC was added. Samples were vortexed immediately and 1ul of 
glcyoblue was added followed by 3 volumes of 100% ethanol. Samples were then mixed and 
left at -20
o
c overnight. Following this samples were defrosted and centrifuged at maximum 
speed for 20 minutes at 4
o
c to form a pellet at the bottom of the eppendorf. The supernatants 
were removed and discarded and the pellets were washed in 1ml of 70% ethanol. The 
samples were centrifuged at maximum speed for 10min at 4
o
c, the ethanol was removed and 
the pellets were air dried for 5 minutes and then dissolved in 6ul of sterile water. cDNA 
libraries were then prepared from these small RNA fragments. 
2.2.6 Preparation of the RNA and small RNA libraries 
RNA and small RNA libraries were produced using the Illumina TruSeq DNA 
Sample Prep Kit ® and Small RNA Sample Prep Kit ® respectively (Illumina, San Diego, 
USA), as per the manufacturer’s protocols. For both procedures, 200ng of RNA were used 
from the immunoprecipitation samples and 4ug from the input samples. For the RNA 
sequencing (RNA-seq), paired-end sequences (reads) of 100 nt in length were then generated 
using a HiSeq 2000 instrument (Illumina). For the small RNA-seq ), single-end reads of 50 nt 
in length were generated using a HiSeq 2000 instrument (Illumina). 
2.2.7 3’-UTR luciferase reported assays 
 
 The 3′UTRs of gene targets identified in the PAR-CLIP were cloned into 
pLightSwitch_3UTR GoClone vectors (SwitchGear Genomics, Menlo Park, CA) that were 
then used to confirm direct target binding. The day before transfections were performed, 
HCT-116 cells were seeded onto 24-well plates (10 × 10
5
 cells per well) in antibiotic-free 
media in triplicate per construct. Cells were then allowed to adhere and were grown at 37°C 
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with 5% CO2 for 24 h.  Cells (80% confluent) were then co-transfected with 
pLightSwitch_3UTR luciferase reporters (50 ng/well) and the relevant pre-miR (100 nmol/L) 
or a nontargeting negative control using Lipofectamine
®
 2000 (Invitrogen, Carlsbad, CA). 
Each transfection was performed in triplicate in three independent experiments. Luciferase 
assays were performed using the LightSwitch Luciferase assay reagent system (SwitchGear 
Genomics, Menlo Park, CA). Twenty-four hours after transfection, HCT116 cells were lysed 
with 50µl per well of the Cell Culture Passive Lysis Buffer (5x) (Promega, Madison, WI, 
USA) diluted fivefold in ddH2O and placed on an agitator for 30 minutes at a constant speed. 
These lysates were then transferred to an Opti-plate 96-well plate and mixed with 50µl of 1X 
LightSwitch assay reagent per well (SwitchGear Genomics, Menlo Park, CA). The plate was 
then covered to protect the reagents from the light, and left to stand for 30 minutes. Following 
this, the 96-well plate was sealed and the firefly luciferase activity was measured using a 
luminometer. Luminescence measurements were then calculated, and averages of triplicates 
were determined.  
 
2.2.8 Collection, handling and RNA extraction from laser captured micro-
dissected (LCM) tumour samples 
 
With the approval of our institutional review board, tissue specimens representing 
normal colonic tissue and colonic adenocarcinoma were obtained immediately after surgery, 
cut into blocks, and then formalin fixed and embedded in paraffin.   Prior to microdissection, 
eight 8-µm serial sections were cut (−25°C) from the same tissue block and placed onto 
slides (1mm) covered with polyethylene naphthalate membrane that had been heated to 180 
degrees for 4 hours prior to use to remove RNAses. After mounting, the slides were allowed 
to dry overnight in an oven at 56
o
C. Deparaffinization was performed using xylene and 
ethanol. 
Immediately after sectioning and mounting, slides were stained with Hematoxylin and Eosin 
(H & E) in the following way. Slides were dipped 5 times in RNase-free distilled water and 
were stained for 1-2 minutes in Mayer’s Hematoxylin solution (SIGMA, #MHS-32).  They 
were then rinsed for 1 minute in diethylpyrocarbonate (DEPC)-treated tap water and stained 
for 10 seconds in Eosin Y  (SIGMA, #HT110-2-32), followed by a quick increasing ethanol 
series (70%, 96%, 100%). They were then microdissected using the PALM Laser MicroBeam 
system (P.A.L.M. Microlaser Technologies GmbH, Bernried, Germany). This system 
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employs a high-energy laser beam to microdissect along a precise, predefined line and to 
catapult the tissue areas-of-interest from the slide into a collection cap of an eppendorf tube 
containing 6 µm solution [20 µL 0.5 M EDTA, pH 8.0, 2000 µL 1 M Tris, pH 8.0, 50 µL 
Igepal® Ca 630 (Sigma-Aldrich, St. Louis, MO, USA), and diethylpyrocarbonate (DEPC)-
treated double-distilled water]. A total area of 200,000 µm
2
 was micro-dissected from each 
slide. Figure 5 shows images of various stages of the microdissection process. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5: Photographs of tissue blocks on microdissection slides at various stages of the procedure. 
N= normal colon, T= tumour, A= adenoma.1: Hematoxylin and eosin staining; 2: areas to be microdissected 
have been marked; 3: slide following microdissection of marked areas; 4: microdissected tissue following 
catapulting onto the inside of the eppedorf caps.  
 
N1 N4 N3 N2 
T1 T4 T3 T2 
A1 A4 A3 A2 
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RNA was then extracted from the micro-dissected samples in the following way.  A volume 
of 150μl of Buffer PKD (Qiagen) was added to the eppendorf tubes containing the LCM 
elements in the adhesive cap. 10μl of Proteinase K was then added and the tubes were 
inverted to allow contact between the reagents and the samples on the adhesive surface. The 
samples were then digested by placing the tubes upside down in an incubator at 56°C 
overnight, after which they were vortexed and heated at 80°C for 15 minutes in a heat block 
and then incubated on ice for 3 minutes. Following this, 16 μl of DNase Booster Buffer 
(Qiagen) and 10 μl of DNase I stock solution (Qiagen) were added and the samples were 
mixed gently by inverting the tubes which were  then centrifuged briefly to collect any 
residual liquid from the sides of the tubes. The samples were then incubated at room 
temperature for 15 minutes, and the lysates were transferred to a new 1.5 ml microcentrifuge 
tube. 320μl of RBC (Qiagen) were added to adjust the binding conditions and the lysates 
were mixed thoroughly, prior to the addition of 720μl of 100% ethanol to the samples which 
were then mixed well by pipetting. 700μl of the sample were transferred to an RNeasy 
MinElute spin column (Qiagen) placed in a 2 ml collection tube and centrifuged for 15 
seconds at ≥10000 rpm. The flow-throughs were discarded and this step was repeated until 
the entire sample had passed through the RNeasy MinElute spin column. Following this, 
500μl of Buffer RPE (Qiagen) were added to the RNeasy MinElute spin column which was 
then centrifuged for 15 seconds at ≥10000 rpm to wash the spin column membranes. The 
flow-throughs were then discarded and the RNeasy MinElute spin columns were then placed 
in a new 2 ml collection tube. The spin columns were then centrifuged at full speed for 5 
minutes with their lids opened and the flow-throughs in the collections tubes were discarded. 
The RNeasy MinElute spin columns were placed into new 1.5 ml collection tubes and 30μl of 
RNase-free water were added directly to the spin column membranes. The lids of the 
collection tubes were closed gently and the tubes were centrifuged for 1 minute at full speed 
to elute the RNA. The RNA solution was then stored at -20°C or used directly for reverse 
transcription. 
 
Prior to use, the quality and quantity of isolated total RNA were assessed using the RNA 
6000 Pico LabChip kit and the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). 550ul of RNA 6000 Pico gel matrix were placed on a spin filter, centrifuged at 
maximum speed for 10 s, and divided in 65-µL aliquots. 1 µl of RNA 6000 Pico dye was 
added to each aliquot, and the mixture was mixed by vortexing and centrifuged for ten 
minutes at maximum speed. Using the priming solution, each aliquot was filled with gel-dye 
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mix, conditioning solution, marker, 1 µL RNA 6000 ladder, and RNA samples, and was then 
vortex mixed for 1 min before being run on the Bioanalyzer. Both the 28s/18s rRNA subunit 
ratio and the RNA integrity number (RIN) were used to evaluate RNA integrity. 
 
2.2.9 Collection, handling and RNA extraction from macro-dissected 
colorectal tissue 
 
Specimens of normal, adenomatous and malignant colorectal tissue were obtained 
from individuals undergoing colorectal surgery or colonoscopy between 2011 and 2013 at St 
Mary’s Hospital, London, UK. These were immediately macrodissected at the time of 
surgery, placed directly in RNALater stabilization solution (Qiagen, Hilden, Germany), 
stored at room temperature for 2−3 hours, and then frozen at −80°C. This was done to 
prevent any degradation and to ensure high-quality RNA for the subsequent molecular 
profiling. H&E staining was used for histological confirmation of cancer and to determine the 
cellularity of representative sections. A specialist colorectal pathologist reviewed the slides, 
and tissue for RNA isolation was verified to contain ≥60% neoplastic cells. Written informed 
consent was obtained from all patients, and ethical approval was provided by the hospital's 
research ethics committee. 
Fresh tissue stored in RNALater (Qiagen) was crushed in liquid nitrogen and the subsequent 
powder lysed in Trizol (Invitrogen, Paisley, UK) reagent. RNA isolation was carried out 
according to manufacturer's instructions, as described above in section 2.2.2 (‘RNA 
preparation’). The quality of isolated RNA was analyzed on the Agilent 2001 Bioanalyzer 
(Agilent Technologies Inc., Santa Clara, CA). 
 
2.2.10 Next generation sequencing and bioinformatic analysis of results 
 
2.2.10a Description of samples and experimental design 
 
          RNA-sequencing
383
 and PAR-CLIP
332
 methods were used to profile the abundance of 
small RNAs (3 biological replicates), poly-adenylated RNAs (2 biological replicates) and 
AGO-bound RNAs (3 biological replicates, with 3 technical replicates each) in total RNA or 
IPed RNA samples from human colon cancer HCT116 cell lines from human colon cancer 
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HCT116 cells with either wild-type or knockout TP53. Table 14 describes the different 
samples assayed. 
 
 
 
 
 
 
 
 
 
 
Table 14: Summary of Samples.  
Cell line: HCT116 colorectal carcinoma human cell line Abbreviations: -/-: p53 knockout cell lines; +/+: p53 
wilt-type cell lines. I: input or total RNA; A: AGO-IPed RNA; G: IgG-IPed RNA; n: p53 knockout; w: p53 wild 
type; D: doxorubicin treated; V: vehicle treated. 
 
2.2.10b Processing of small RNA sequencing data 
 
          Read preprocessing. Raw sequences were cleaned from any sequence derived from the 
sequencing library adapters using cutadapt version 1.2.1. Read mapping. Clipped reads were 
mapped to the human genome (hg19) by using bowtie
384
 (version 1.0.0). Read annotation to 
human miRNAs. Mirdeep2
385
 and miRNA sequence annotations from miRBase
386
 (release 20) 
were used to identify and quantify known and novel mature miRNAs. Figure 6 summarizes 
the aforementioned steps. 
 
The miRDeep analysis quantified the abundance of 2578 mature human miRNA sequences 
annotated in miRBase
386
- release 20. The analysis was then focused on identifying miRNAs 
expressed in at least one sample condition (i.e. any combination of p53+/+ or p53-/- cells; 
doxorubicin or control treatment; Total RNA or AGO-IPed sample), The dataset was first 
restricted to miRNAs having at least six raw read counts in at least two samples [N=1322 
mature miRNAs, including redundant identifiers owed to multiple stem-loops yielding the 
same mature sequence; N=1185 unique mature miRNAs]. The DESeq Bioconductor 
package
387
 was used to estimate library size factors and normalize read counts across samples 
Doxorubicin treatment - 
 
+ - + 
p53 status -/- -/- +/+ +/+ 
 
Total RNA InV 
 
InD IwV IwD 
AGO-IPed RNA AnV AnD AwV AwD 
 
IgG-IPed RNA GnV GnD GwV GwD 
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accordingly. Figure 7 shows the unsupervised clustering of samples in the miRNA dataset 
based on normalized read counts for 1322 selected miRNAs. 
 
 
 
 
 
 
 
 
Figure 6: Outline of small RNA sequencing data processing.  
Cutadapt was used to clip adapter sequences from the raw small RNA sequencing data. Different modules from 
miRDeep together with Bowtie were then applied to collapse clipped reads from the different samples, map 
them to the human genome (hg19) and quantify both known and novel human mature miRNAs. Known human 
miRNA sequence annotations were taken from miRBase. 
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Figure 7: Unsupervised clustering of miRNA samples based on normalized read counts. 
The 1322 miRNAs included in the count dataset used to cluster the samples were selected by setting an 
abundance threshold of at least six raw read counts in at least 2 samples. Normalization of read counts across 
samples was performed by using the DESeq Bioconductor package based on estimated library sizes. 
Abbreviations. Clustering of samples is based on euclidean distance of log2-transformed read counts. A tri-letter 
code specifiees the sample type: 1
st
 letter: Total (T) or AGO-IPed (A) RNA; 2
nd
 letter: p53+/+ (w) or p53-/- (n) 
cells; 3rd letter: doxorubicin (D) or vehicle (V) treatment. The subsequent part of each sample name indicates 
the biological replicate (r2,r3,r4 for the 1
st
,2
nd 
and 3
rd
 replicates, respectively) 
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2.2.10c Analysis of miRNA modulation following DNA-damage  
 
          To find miRNAs showing differential expression following induction of DNA-damage 
following doxorubicin treatment, mean log-fold changes (mean of 3 biological replicates) 
were computed for all miRNAs [N=1322] for the following four comparisons of doxorubicin-
treated vs. vehicle-treated cells: [i.] Total RNA samples from p53+/+ cells (TwD.vs.TwV); 
[ii.] Total RNA samples from p53-/- cells (TnD.vs.TnV); [iii.] AGO-IPed RNA samples from 
p53+/+ cells (AwD.vs.AwV); [iv.] AGO-IPed RNA samples from p53-/- cells 
(AnD.vs.AnV). Figure 8 reports histograms for all of the above contrasts. 
 
A moderated t-test for paired samples was used to evaluate significance of the observed 
modulation. To reduce the number of tests, we restricted the statistical significance analysis 
to top-abundant and modulated miRNAs in each given comparison by setting arbitrary 
thresholds for minimum average abundance (log2-scale) and absolute log-fold change to 5 
and 0.35, respectively. For comparisons involving AGO-IPed samples, we also required 
miRNAs to match the above abundance threshold in the total RNA samples. The outlined 
selection yielded 227, 209, 175 and 135 tests for significant modulation for miRNAs in the 
TwD.vs.TwV, TnD.vs.TnV, AwD.vs.AwV and AnD.vs.AnV groups, respectively (Figures 9 
& 10). A Benjamini-Hochberg adjusted p-value of the moderated t-test < 0.05 was regarded 
as significant.
388
 
 
Lists of regulated miRNAs were further grouped based on the dependancy of their 
modulation on TP53-status and they were defined as follows: 
 
miRNAs regulated in a TP53-dependent manner: [i] a significant modulation (i.e.: adjusted p-
value< 0.05) in TP53+/+ doxorubicin-treated samples compared to untreated controls, but not 
in TP53-/- background; [ii] a mean log fold-change in TP53+/+ doxorubicin-treated vs 
untreated samples exceeding that of TP53-/- background; [iii] either an absolute mean log 
fold-change in TP53-/- cells below the minimum change threshold (0.35) or a significantly 
different extent of modulation in TP53+/+ compared to TP53-/- cells (i.e.: t-test p-value < 
0.05 when comparing log fold-change values of doxorubicin-treated vs untreated samples 
between TP53 wild-type and TP53 knockout HCT116 cells). 
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miRNAs regulated in a TP53-independent manner: [i] a significant modulation (i.e.: adjusted 
p-value < 0.05) in TP53+/+ doxorubicin-treated samples compared to untreated controls; [ii] 
same as before, but for TP53-/- cells; [iii] comparable degree of modulation in TP53+/+ and 
TP53-/- cells (i.e.: no significant difference when comparing log fold-change values of 
doxorubicin-treated vs untreated samples between TP53 wild-type and TP53 knockout 
HCT116 cells). 
 
Subsets of differentially expressed miRNAs falling in each of the above-listed subcategories 
(i.e.: TP53-dependent and TP53-independent) were individually evaluated for the Total RNA 
and AGO-IPed samples, as well as for the upregulated and down-regulated miRNAs. 
 
2.2.10d Processing of long RNA sequencing data  
 
Read preprocessing. The quality of processed reads was assayed using FastQC - version 
0.10.1. Raw sequences from paired-end Illumina sequencing were processed by using TopHat 
and Cufflinks and according to the published protocol.389 Briefly, paired-end reads were 
mapped to the human genome (hg19) by using TopHat
390
 - version 2.0.9. Individual 
transcripts obtained from mapped reads were assembled into a reference transcriptome and 
quantified by using Cufflinks
391
 - version 2.1.1. Figure 11 summarizes the above procedure. 
. 
Analysis of gene modulation following DNA-damage. Gene expression levels were compared 
between doxorubicin-treated and control samples (two biological replicates for each 
experiment) by using Cuffdiff, a separate program included in the Cufflinks suite of software. 
The differential expression analysis was repeated for the same comparison groups between 
doxorubicin-treated and vehicle-treated cells as those listed for the miRNA analysis (see 
Analysis of miRNA modulation following DNA-damage). Genes included in the Cufflinks 
transcriptome assembly (N=29888 Cufflinks identifiers) were filtered to remove those with 
very low abundance. In particular, we required genes to have a Cufflinks status flag of ”OK” 
and an FPKM value above zero for Cufflinks identifiers to be considered in the next analyses. 
The above yielded filtered datasets of size 13165, 12528, 13090 and 13039 for the 
TwD.vs.TwV, TnD.vs.TnV, AwD.vs.AwV and AnD.vs.AnV groups, respectively. Figure 12 
reports histograms for all of the above comparator groups based on the log fold change values 
of Cufflinks identifiers retained in the filtered datasets. We next focused the analysis on 
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Cufflinks identifiers annotated to a gene symbol and made these datasets unique based on 
gene annotations (i.e. for each gene symbol, we retained only its first occurrence in the 
dataset sorted by decreasing absolute value of mean log fold change). For each comparison, 
we identified lists of modulated genes based on an absolute z-score-transformed log fold 
change value equal to or exceeding 1.5 (Figure 13). 
 
 
 
Figure 8: Histograms demonstrating miRNA mean fold changes in doxorubicin-treated vs. untreated 
samples.  
Mean fold changes were computed for all miRNAs (N=1322) across 3 biological replicates in the indicated 
compared groups of doxorubicin-treated vs. vehicle-treated samples. Abbreviations. TwD.vs.TwV: doxorubicin-
treated vs. untreated total RNA samples from p53+/+ cells; TnD.vs.TnV: as described above, but for p53-/- 
cells. AwD.vs.AwV: doxorubicin-treated vs. untreated AGO-IPed RNA samples from p53+/+ cells; 
AnD.vs.AnV: as described above, but for p53-/- cells. 
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Figure 9: Scatterplots of Log Fold-Change vs Average Expression for TP53+/+ cells 
Mean log fold-changes for doxorubicin-treated vs untreated samples are depicted as a function of their mean 
expression (mean of 3 biological replicates) for all miRNAs (top and bottome left panels) or selected miRNAs 
based on minimum abundance and change thresholds (top and bottom right panels). Upper panels: Total-RNA 
samples; Bottom panels: AGO-IPed samples. Applied filltering thresholds: average expression at least equal to 5 
(log2-scale) for samples included in the indicated contrast and - for AGO-IPed samples - also in Total RNA 
samples; absolute log fold-change in doxorubicin-treated vs untreated samples at least equal to 0.35. 
Differentially expressed miRNAs: Benjamini-Hochberg adjusted p-value < 0.05.Abbreviations. TwD.vs.TwV: 
doxorubicin- treated vs. untreated total RNA samples from TP53+/+ cells; AwD.vs.AwV: doxorubicin-treated 
vs. untreated AGO-IPed RNA samples from TP53+/+ cells. 
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Figure 10: Scatterplots of Log Fold-Change vs Average Expression for TP53-/- cells 
Mean log fold-changes for doxorubicin-treated vs untreated samples are depicted as a function of their mean 
expression (mean of 3 biological replicates) for all miRNAs (top and bottom left panels) or selected miRNAs 
based on minimum abundance and change thresholds (top and bottom right panels). Upper panels: Total-RNA 
samples; Bottom panels: AGO-IPed samples. Applied _ltering thresholds: average expression at least equal to 5 
(log2-scale) for samples included in the indicated contrast and - for AGO-IPed samples - also in Total RNA 
samples; absolute log fold-change in doxorubicin-treated vs untreated samples at least equal to 0.35. 
Di_erentially expressed miRNAs: Benjamini-Hochberg adjusted pvalue < 0.05. Abbreviations. TnD.vs.TnV: 
doxorubicin-treated vs. untreated total RNA samples from TP53-/- cells; AnD.vs.AnV: doxorubicin-treated vs. 
untreated AGO- IPed RNA samples from TP53+/+ cells. 
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Figure 11: Outline of long RNA sequencing data processing.  
FastQC
387
 was used to check quality of the RNA sequencing data. Mapping of the reads to the human genome 
(hg19), trascriptome assembly and gene quantification were performed by using TopHat and Cuffinks according 
to a published protocol
389
 Analysis of differentially expressed genes following the induction of DNA-damage 
through doxorubicin treatment was assayed by using CuffDiff_ for the following contrasts: [i.] Total RNA 
samples from TP53+/+ cells; [ii.] Total RNA samples from TP53-/- cells; [iii.] AGO-IPed RNA samples from 
TP53+/+ cells; [iv.] AGO-IPed RNA samples from TP53-/- cells. 
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Figure 12: Histograms of genes mean fold changes in doxorubicin-treated vs. untreated samples.  
Mean fold changes for Cufflinks gene identifiers retained in the filtered datasets across 2 biological replicates in 
the indicated contrasts (and gene dataset size) of doxorubicin-treated vs. vehicle-treated samples. Abbreviations. 
TwD.vs.TwV: doxorubicin-treated vs. untreated total RNA samples from TP53+/+ cells; TnD.vs.TnV: same as 
before, but for TP53-/- cells. AwD.vs.AwV: doxorubicin-treated vs. untreated AGO-IPed RNA samples from 
TP53+/+ cells; AnD.vs.AnV: same as before, but for TP53-/- cells. 
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Figure 13: Scatterplots of genes mean fold changes in doxorubicin-treated vs. untreated samples as a 
function of mean gene abundance. 
Scaled mean fold changes (z-scores) for Cufflinks gene identifiers retained in the filtered datasets across 2 
biological replicates in the indicated contrasts (and gene dataset size) of doxorubicin-treated vs. vehicle-treated 
samples. Abbreviations. TwD.vs.TwV: doxorubicin-treated vs. untreated total RNA samples from TP53+/+ 
cells; TnD.vs.TnV: same as before, but for TP53-/- cells. AwD.vs.AwV: doxorubicin-treated vs. untreated 
AGO-IPed RNA samples from TP53+/+ cells; AnD.vs.AnV: same as before, but for TP53 -/- 
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2.2.10e Seed enrichment analysis 
 
A miRNA is functional when loaded on the RNA-induced silencing complex (RISC), which 
it directs to target mRNAs via sequence-specific patterns of base pairing with partially 
complementary sites in their 3’UTR. RISC targets are largely dictated by complementarity 
between the seed region (nucleotides 2-8 at the 5´-end of the mature miRNA sequence) of the 
loaded miRNA and one or more sites in the mRNA 3’UTR. This principle of seed primacy is 
utilised by the most popular target prediction algorithms.
1,318,324
  To evaluate whether the 
observed remodelling of AGO2-bound mRNAs following induction of DNA damage could 
have been attributed to an association with the modulated miRNAs, we used human target 
predictions from the Targetscan algorithm
1
 and tested each AGO2-enriched (and AGO2-
depleted) miRNA for enriched proportion of their predicted targets among AGO2-enriched 
(and AGO-depleted) transcripts. We limited the database of miRNA target predictions 
downloaded from the targetscan website (http://www.targetscan.org/) - release 6.1 - to the 
union set of gene symbols included in our filtered gene datasets (background set, N=11375). 
Gene redundancy in the prediction database was removed by retaining only the first 
occurrence of each gene symbol after sorting the database by decreasing 3’UTR length. 
 
2.2.10f Processing of AGO2 PAR-CLIP data 
 
Read preprocessing. We used cutadapt- version 1.2.1 -to remove adapter sequences from  
raw PAR-CLIP data. In addition to adapter trimming, we also used cutadapt to remove low-
quality ends of reads and discard trimmed reads shorter than 13 nucleotides. FastQC- version 
0.10.1 - was used to check read quality before and after trimming. Trimmed reads were 
mapped against the human genome (hg19) allowing up to 2 mismatches by using Bowtie
384
 
and requiring mapped locations to be reported only for reads with, at most, 10 different 
genomic hits and limited to the optimal mismatch-stratum for each read. Mapped reads were 
checked for the distribution of mismatches to verify the expected primacy of T>C (and its 
reverse A>G) mutations (Figure 14), which are introduced by the PAR-CLIP method at sites 
of crosslinking.
332
 Bowtie output was purged of reads mapping in repetitive sequence regions 
identified by RepeatMasker (http://www.repeatmasker.org/) and whose specific locations 
were downloaded from the UCSC genome browser.
392
 PARalyzer
333
 was used to group 
mapped reads and identify ”clusters” (i.e.: AGO2 binding sites) based on T-to-C conversion 
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locations and read density. According to PARalyzer algorithm guidelines, input mapped reads 
obtained from Bowtie were further refined to retain only reads mapping uniquely to the 
genome and containing 0, 1 or 2 T>C (or A>G) mismatches. Figure 15 summarizes the above 
procedure. PARalyzer clusters were annotated to RefSeq
393
 transcripts whose genomic 
coordinates were downloaded from the UCSC genome browser.
392
 If a cluster mapped to a 
genomic location that could be annotated to multiple transcripts, it was assigned based on the 
following order of preference: 3’UTR, miRNA precursor, coding sequence, 5’UTR, intron, 
intergenic. 
 
 
 
 
Figure 14: Distribution of mismatches to the human genome for PAR-CLIP mapped reads 
PAR-CLIP method favor T-to-C transitions at sites of crosslinking.
387
 Mapped reads were checked for the 
distribution of mismatches with respect to the human genome to verify the expected primacy of T>C (and its 
reverse A>G) before refinement of the dataset of mapped reads to be retained for further analyses (i.e. removal 
of reads containing mismatches to the genome other than T>C and A>G). Abbreviations. AwD,AwV: 
doxorubicin-treated (AwD) and untreated (AwV) AGO-IPed RNA samples from TP53+/+ cells; AnD,AnV : 
same as before, but from TP53-/- cells; br[1-3]: biological replicate 1, 2 or 3. 
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Figure 15: Outline of PAR-CLIP data processing 
Cutadapt
383
 was used to clip the adapter sequence from PAR-CLIP sequencing data. Cutadapt was also used to 
remove low-quality ends of reads and discard trimmed reads shorter than 13 nucleotides. FastQC was used to 
check read quality before and after trimming. Reads were mapped to the human genome (hg19) by using 
Bowtie.
384
 AGO binding sites were identified based on a combination of T-to-C conversions and read density 
by using PARalyzer.
333
 
 
 
Analysis of AGO2 remodelling based on PAR-CLIP data. AGO2 binding sites across 
different samples and replicates, as identified by the PARalyzer run, located in 3’UTRs were 
merged using scripts from the bedtools
394
 suite to obtain a reference set of sites amenable to 
differential abundance analysis between DOX-treated and untreated AGO-IPed samples. 
Merged AGO2 binding sites were then normalized across samples based on library size using 
DESeq
387
 and tested based on the negative binomial distribution as implemented in the same 
package (function nbinomTest) to infer differential signals. Test p-values were adjusted for 
multiple comparisons based on the Benjamini and Hochber method
395
 and adjusted p-values 
< 0.05 used to select significant features. Post-transcriptional regulation of miRNAs is largely 
(if not completely) mediated by sequence complementarity between the mature miRNA seed 
(i.e.: 6-8 nucleotides at the 5’-end of the mature miRNA sequence, starting at position 1 or 2) 
and short sites in the mRNA 3’UTR.396 The dataset of 3’UTR AGO2 binding sites, as 
identified by the PARalyzer run were mapped to miRNA seeds. We limited the mapping to 
highly and/or differentially expressed miRNAs identified in our small RNA-sequencing 
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experiment. If an AGO2 binding site (i.e.: PARalyzer cluster) mapped to multiple miRNA 
seeds in our cohort, we assigned the cluster to the miRNA whose seed-complementary site 
occured closest to the maximum T-to-C conversion position in the cluster. This selection was 
based on previous reports that suggested that the highest enrichment of miRNA 
complementary regions occured at positions immediately downstream from the predominant 
site of CLIP-induced transition within clusters of sequence reads.
332,334
 All possible 6-, 7- and 
8-mers substrings spanning positions 1-8 of the mature miRNA sequence (seed sequences) 
for miRNAs were collected based on sequence annotations from miRBase.
386
 So obtained 
miRNA-mRNA interaction networks involved in the response to DNA damage were then 
visualized by using the Cytoscape software.
397
 
 
Mapping of PAR-CLIP raw data to sample type, individual biological replicate (N=3) and 
technical replicate (N=3 for each biological replicate) was retrieved based on the samples 
barcode included in the sequencing read header and according to the following mapping 
scheme: 
 
1. file:JK 2 1 ATCACG L002 R1 001.fastq; des:AwD biorep1 tecrep1; barcode:ATCACG 
2. file:JK 2 2 CGATGT L002 R1 001.fastq; des:AwV biorep1 tecrep1; barcode:CGATGT 
3. file:JK 2 3 TTAGGC L002 R1 001.fastq; des:AnD biorep1 tecrep1; barcode:TTAGGC 
4. file:JK 2 4 TGACCA L002 R1 001.fastq; des:AnV biorep1 tecrep1; barcode:TGACCA 
5. file:JK 2 5 ACAGTG L002 R1 001.fastq; des:AwD biorep2 tecrep1; barcode:ACAGTG 
6. file:JK 2 6 GCCAAT L002 R1 001.fastq; des:AwV biorep2 tecrep1; barcode:GCCAAT 
7. file:JK 2 7 CAGATC L002 R1 001.fastq; des:AnD biorep2 tecrep1; barcode:CAGATC 
8. file:JK 2 8 ACTTGA L002 R1 001.fastq; des:AnV biorep2 tecrep1; barcode:ACTTGA 
9. file:JK 2 9 ACTGAT L002 R1 001.fastq; des:AwD biorep3 tecrep1; barcode:ACTGAT 
10. file:JK 2 10 CACCGG L002 R1 001.fastq; des:AwV biorep3 tecrep1; barcode:CACCGG 
11. file:JK 2 11 CACGAT L002 R1 001.fastq; des:AnD biorep3 tecrep1; barcode:CACGAT 
12. file:JK 2 12 CACTCA L002 R1 001.fastq; des:AnV biorep3 tecrep1; barcode:CACTCA 
13. file:JK 3 1 ATCACG L003 R1 001.fastq; des:AwD biorep1 tecrep2; barcode:ATCACG 
14. file:JK 3 2 CGATGT L003 R1 001.fastq; des:AwV biorep1 tecrep2; barcode:CGATGT 
15. file:JK 3 3 TTAGGC L003 R1 001.fastq; des:AnD biorep1 tecrep2; barcode:TTAGGC 
16. file:JK 3 4 TGACCA L003 R1 001.fastq; des:AnV biorep1 tecrep2; barcode:TGACCA 
17. file:JK 3 5 ACAGTG L003 R1 001.fastq; des:AwD biorep2 tecrep2; barcode:ACAGTG 
18. file:JK 3 6 GCCAAT L003 R1 001.fastq; des:AwV biorep2 tecrep2; barcode:GCCAAT 
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19. file:JK 3 7 CAGATC L003 R1 001.fastq; des:AnD biorep2 tecrep2; barcode:CAGATC 
20. file:JK 3 8 ACTTGA L003 R1 001.fastq; des:AnV biorep2 tecrep2; barcode:ACTTGA 
21. file:JK 3 9 ACTGAT L003 R1 001.fastq; des:AwD biorep3 tecrep2; barcode:ACTGAT 
22. file:JK 3 10 CACCGG L003 R1 001.fastq; des:AwV biorep3 tecrep2; barcode:CACCGG 
23. file:JK 3 11 CACGAT L003 R1 001.fastq; des:AnD biorep3 tecrep2; barcode:CACGAT 
24. file:JK 3 12 CACTCA L003 R1 001.fastq; des:AnV biorep3 tecrep2; barcode:CACTCA 
25. file:JK 4 1 ATCACG L004 R1 001.fastq; des:AwD biorep1 tecrep3; barcode:ATCACG 
26. file:JK 4 2 CGATGT L004 R1 001.fastq; des:AwV biorep1 tecrep3; barcode:CGATGT 
27. file:JK 4 3 TTAGGC L004 R1 001.fastq; des:AnD biorep1 tecrep3; barcode:TTAGGC 
28. file:JK 4 4 TGACCA L004 R1 001.fastq; des:AnV biorep1 tecrep3; barcode:TGACCA 
29. file:JK 4 5 ACAGTG L004 R1 001.fastq; des:AwD biorep2 tecrep3; barcode:ACAGTG 
30. file:JK 4 6 GCCAAT L004 R1 001.fastq; des:AwV biorep2 tecrep3; barcode:GCCAAT 
31. file:JK 4 7 CAGATC L004 R1 001.fastq; des:AnD biorep2 tecrep3; barcode:CAGATC 
32. file:JK 4 8 ACTTGA L004 R1 001.fastq; des:AnV biorep2 tecrep3; barcode:ACTTGA 
33. file:JK 4 9 ACTGAT L004 R1 001.fastq; des:AwD biorep3 tecrep3; barcode:ACTGAT 
34. file:JK 4 10 CACCGG L004 R1 001.fastq; des:AwV biorep3 tecrep3; barcode:CACCGG 
35. file:JK 4 11 CACGAT L004 R1 001.fastq; des:AnD biorep3 tecrep3; barcode:CACGAT 
36. file:JK 4 12 CACTCA L004 R1 001.fastq; des:AnV biorep3 tecrep3; barcode:CACTCA 
 
Chronology of scripts used for parclip data analysis: 
 
1. parclip pipeline.sh 
2. filtra repeatmasker reads.sh 
3. filtra reads MM e gHITS.sh 
4. run paralyzer.sh 
5. annotate clusters to genome.sh 
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3.1 The post-transcriptional regulation of gene expression by p53 
is mediated by its ability to regulate miRNA abundance, control 
miRNA loading onto AGO2 and remodel the miRNA-mRNA 
interaction network through novel mechanisms 
 
p53 is one of the most frequently mutated tumor suppressors and regulates gene 
expression predominantly through its function as a transcription factor, but also to a lesser 
extent, through non-transcriptional processes.
166
 It regulates the expression of protein-coding 
genes and non-coding RNAs involved in numerous cellular signaling pathways
168
 and is  
fundamental in coordinating the cellular response to stresses, such as oncogene activation and 
DNA damage. Mutations or inactivation in p53 are the most frequent abnormalities observed 
in cancer cells.
169
 Such mutations have significant implications in terms of tumor growth and 
response to current treatment modalities. Many chemotherapeutic agents, in particular 
anthracyclines and platinum-containing compounds, as well as radiotherapy, induce cancer 
cell death or senescence via DNA damage and the subsequent activation of p53-mediated 
signalling pathways. Resistance to such treatments can occur due to mutations in components 
of these networks. A better understanding of the role of the various elements within these 
pathways and their interactions with each other may allow improvements to current anti-
cancer treatments and the design of novel therapies. Refining our knowledge of the role of 
miRNAs in p53-signalling networks and a better understanding of the genes they target is 
crucial to achieving this.  
To date, most studies designed to identify p53-regulated mRNAs or miRNAs have utilized 
techniques such as RT-qPCR or microarray platforms which, although informative, do not 
allow the most detailed analysis at the transcriptome wide level. Notably, microarrays suffer 
from a fundamental ‘design bias’, in that they only return results from those regions for 
which probes have been constructed and consequently are only as good as the databases from 
which they are devised. The list of known miRNAs on the database, miRBase, is continually 
updated and therefore even the most up-to-date array platform will not be able to detect every 
known miRNA.  Conversely, RNA-seq provides a tool by which the whole transcriptome can 
be studied without any prior knowledge of it and therefore enables the detection and analysis 
of novel transcripts. The global identification of the targets modulated by the p53-regulated 
miRNAs is lacking and needs further evaluation to enable a better understanding of the p53 
regulatory network. Furthermore, there are no data indicating a possible regulatory 
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mechanism that controls the interaction between miRNAs and AGO proteins in response to 
treatments (such as DNA damaging agents), or any mechanism that could either induce 
(through an increase in AGO loading) or reduce (through a decrease in AGO loading) their 
activity. Studies have shown that p53 can enhance the post-transcriptional maturation of 
specific miRNAs via its interaction with DDX5, a component of the DROSHA/DGCR8 
complex,
243
 and can also influence miRNA target gene selection at the level of the miRNA-
target interaction, via the regulation of RBM38 RNA binding protein,
299
 however further 
understanding of how p53 may regulate miRNA function post-transcriptionally is also 
lacking.  
It is known that p53 co-ordinates cell signalling pathways through regulating the expression 
of gene targets. This is achieved mainly through transcriptional regulation of mRNA 
expression but also through the ability of p53 to regulate miRNA abundance and hence fine 
tune target gene expression post-transcriptionally through AGO2 mediated mRNA 
translational repression and/or mRNA degradation. To understand this process in more detail, 
we aimed to comprehensively illustrate the network of miRNA-mRNA interactions that 
occurs in response to DNA damage using RNA-seq, AGO2 RIP-seq and PAR-CLIP-seq to 
determine sets of genes (RNA seq) and miRNAs (small RNA-seq) whose expression levels 
change in response to DNA damage and use AGO2 IP approaches to investigate the 
differential loading of miRNAs and mRNAs onto AGO2. Furthermore, we wished to 
combine the AGO2 RIP and PAR-CLIP approaches with deep sequencing to determine the 
exact interaction sites between the AGO2-bound miRNAs and their mRNA targets in 
response to double-strand break DNA damage.  
We induced double-strand break DNA damage in p53-wild type and -null cells using the 
chemotherapeutic agent doxorubicin (DOX) and performed an RNA-seq and AGO2 RIP-seq 
(Figure 16) to identify novel miRNAs and mRNAs regulated by the p53-dependent and p53-
independent responses to DNA damage and which miRNA (if any) and mRNA transcripts 
were differentially loaded onto AGO2. This sequencing approach gave us the potential ability 
to identify previously unidentified p53-dependent post-transcriptional processes that could 
affect mRNA or miRNA expression or function, and in particular, whether p53 might 
regulate the loading of miRNAs onto AGO2 and hence control gene expression through an 
unexplored mechanism of miRNA regulation in response to stimuli. In addition, we used an 
AGO2 PAR-CLIP experiment to investigate the p53-associated miRNA/mRNA interactome 
at a genome wide level, and to establish the functional effects of miRNA/mRNA binding in 
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terms of p53-regulated signaling networks. We hoped that this approach would enable us to 
identify which coding genes were regulated by the miRNAs that our RIP-seq had identified 
as being induced or repressed following DNA damage, and to characterize the sites to which 
miRNAs guide the RISC complex to bind to its target transcripts. Furthermore, we planned to 
identify differential AGO2 binding sites in response to DOX treatment in wild type and p53-
null cell lines that occured independently of the miRNAs regulated by the DNA damage. 
Combining these findings with a motif discovery analysis, we wanted to see if any particular 
RNA motif present on the UTR of the mRNA targets was necessary for this regulation to 
occur. In this way we wished to determine whether p53 might also affect AGO2 binding on 
the mRNA targets, hence remodeling the AGO2-mRNA interaction network following DNA 
damage.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Summary of the cell treatments, sample processing and sequencing of samples used 
 
 
Treated HCT116 p53
WT
 or
 
HCT116 p53
null
 cells with doxorubicin or vehicle for 24h 
Total RNA  
mRNA-seq Small RNA-seq 
AGO2 IP 
mRNA-seq Small RNA-seq 
RNA-seq RIP-seq 
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3.1.1 A small RNA-seq approach identifies novel miRNAs that are 
transcriptionally regulated following DNA damage in a p53-dependent and 
–independent manner 
 
Using the total RNA samples produced from treating HCT116 p53
WT 
and p53
null
 cells 
with DOX or vehicle control, we performed a small RNA-seq analysis to identify miRNAs 
whose relative abundance changed following DOX-induced double-strand DNA damage. 
Fold changes were calculated by directly comparing miRNA levels between the vehicle-
treated and DOX-treated cell lysates. Furthermore, by comparing changes in miRNA 
abundance between p53
WT
 and p53
null
 cells we were able to determine whether such 
differential expression occurred in a p53-dependent or p53-independent manner. We 
considered any positive or negative fold change with a threshold of 0.35 (log2) or greater and 
a p-value < 0.05 corrected for multiple testing (Benjamini correction), as significant. Of the 
1322 miRNAs expressed in our samples, we identified 34 miRNAs that were significantly 
upregulated and 26 miRNAs that were down-regulated in a p53-dependent manner (Figure 
17A). Conversely, we found 21 miRNAs that were significantly upregulated and 26 that were 
down-regulated in a p53-independent manner (Figure 17B).  
Firstly, we aimed to validate our approach by confirming that our results were consistent with 
previous studies focusing on p53-regulated miRNAs. We detected a significant upregulation 
in the relative expression levels of miR-34a, miR-23a, miR-143, miR-107, miR-149 and the 
miR-200 family (Figure 17A), and down-regulation in miR-100 (Figure 17B), which 
validated our assays because the expression of all of these miRNAs has been shown 
previously to change in response to DNA damage in various cell lines. However, we also 
found that the relative abundance of previously undescribed miRNAs also changed and thus 
identified a novel group of miRNAs involved in the DNA damage response.  For example 
miR-1247-5p, miR-486-5p and miR-22 were upregulated in a p53-dependent manner and 
miR-7974, the miR-548 family and miR-1255a were down-regulated in a p53-dependent 
manner (Figure 17A). Furthermore, we found that the abundance of a number of miRNAs 
changed in a p53-independent manner which suggested that the expression of these miRNAs 
was under the control of alternative transcription factors following DNA damage. The p53 
homologues, p63 and p73 may be the transcription factors responsible for the changes in 
miRNA abundance induced by DNA damage in the absence of p53 but this requires further 
validation. Interestingly, for the first time we show that miR-3065-5p was the most induced 
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miRNA, increasing by nearly 3-fold (log2) in both p53
WT 
and p53
null 
cells suggesting that it is 
particularly important in the p53-independent response to DNA damage. This indicates that 
RNA-seq approaches can be used to identify new important miRNAs that were not yet 
discovered and annotated when previous similar studies were performed.  
As a further validation of our results, we performed an RT-qPCR analysis to measure the 
differential expression of a group of identified miRNAs in RNA extracted from HCT116 
cells treated with DOX or vehicle. The RT-qPCR results were consistent with our small 
RNA-seq analysis. In particular, we validated that miR-3065-5p increased significantly with 
identical fold change in response to DNA damage in both p53
WT 
and p53
null
 HCT116 cells 
(Figure 19A).   
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Figure 17: A combined RNA-seq and RIP-seq approach identifies miRNAs showing differential expression and/or 
AGO2 loading following DOX-induced DNA damage. 
A & B, A small RNA-seq approach identifies a subset of known and novel miRNAs that are significantly up- or down-
regulated in a (A) p53-dependent or (B) p53-independent manner. C & D, A combined RNA-seq and AGO2 RIP-seq 
identifies a group of miRNAs that demonstrate differential loading onto AGO2 in a p53-dependent manner. E, Venn diagrams 
showing those miRNAs that demonstrate consistent expressional fold-changes in both the RNA-seq and RIP-seq analyses. 
Top left: miRNAs up-regulated in a p53-dependent manner; top right: miRNAs up-regulated in a p53-indepenent manner; 
bottom left: miRNAs down-regulated in a p53-dependent manner; miRNAs down-regulated in a p53-independent manner. 
miRNAs demonstrating a positive or negative fold change with a threshold of 0.35 (log2) or greater and a p-value < 0.05 
corrected for multiple testing (Benjamini correction), were considered as significant. Abbreviations A: AGO-IPed RNA; T: 
input or total RNA; G: IgG-IPed RNA; w: p53 wild type;  n: p53 knockout; D: doxorubicin treated; V: vehicle treated. 
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Figure 18: A combined small RNA-seq and AGO2-RIP seq approach confirms that the loading of members of the 
let-7 family onto AGO2 is regulated in a p53-dependent manner following DOX-induced DNA damage  
Abbreviations A: AGO-IPed RNA; T: input or total RNA; G: IgG-IPed RNA; w: p53 wild type; n: p53 knockout; D: 
doxorubicin treated; V: vehicle treated. 
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Figure 19: RT-qPCR and Western blotting validate our small RNA-seq 
and RIP-seq analyses and demonstrate that the AGO2 loading affect is 
dependent on the presence of wild-type p53 and is not the result of 
changes in AGO2 abundance. 
A, An RT-qPCR analysis comparing fold-changes in miR-3065-5p 
expression in total RNA or IP samples following an AGO2 IP in DOX or 
vehicle treated HCT116 p53
WT
 and p53
null 
cell lines.  B, An RT-qPCR 
analysis comparing fold-changes in miR-148-5p expression in total RNA or 
IP samples following an AGO2 IP in DOX or vehicle treated HCT116 p53
WT
 
and p53
null 
cell lines.  C & D, An RT-qPCR analysis demonstrating that the 
loading of let-7 family members onto AGO2 is significantly increased in 
p53
WT 
(C) but not p53
null
 (D) cells following DOX treatment. E, An RT-
qPCR analysis comparing fold changes in let-7 and miR-34a (control) 
expression following an AGO2 IP in DLD1 and RKO cell lines treated with 
DOX which suggests that the increased loading of let-7 onto AGO2 requires 
the presence wild-type p53. F, An RT-qPCR analysis demonstrating the fold 
changes in miR-34a (control) and let-7 family members at 1h, 3h, 12h and 
24h following DOX treatment in HCT116 p53
WT
 cells. G, A Western blot 
analysis showing the relative expression levels of AGO2 protein in HCT 116 
p53
WT
 and p53
null
 cells following DOX or vehicle treatment. Dotted lines in 
RT-qPCR analyses signify a positive or negative fold change of 0.35 (log2). 
Abbreviations A: AGO-IPed RNA; T: input or total RNA; G: IgG-IPed 
RNA; w: p53 wild type; n: p53 knockout; D: doxorubicin treated; V: vehicle 
treated. 
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3.1.2 A small RIP-seq approach demonstrates that DNA damage induces a 
previously undescribed mechanism that controls miRNA function post-
transcriptionally by regulating the loading of a subset of miRNAs onto 
AGO2 in a p53-dependent manner 
 
Next we focused on identifying novel mechanisms involved in the post-transcriptional 
regulation of miRNA function and gene targeting in response to DNA damage. We 
performed an AGO2 small RIP-seq analysis using lysates from HCT116 p53
WT 
and p53
null 
cells following treatment with DOX or vehicle, to determine whether DNA damage affected 
miRNA loading onto AGO2 in either a p53-dependent or p53-independent manner. 
Subsequently, we compared differences in the DNA-damage induced modulation of miRNA 
expression between the total RNA samples used in our small RNA-seq analysis and the 
AGO2-IP samples used in our RIP-seq analysis. This allowed us to differentiate those 
miRNAs whose differential expression in the RIP-seq analysis was due to transcriptional or 
processing effects and those whose differential expression was related to an increase or 
decrease in their loading onto AGO2.  
Following DNA damage, the expression of certain miRNAs changed in a similar manner in 
both the total RNA and AGO2-IP samples. These miRNAs are represented in orange in 
Figure 17C and are located in the top right or lower left sections of the graph. They 
predominantly consist of those miRNAs shown by ourselves and others to be 
transcriptionally induced by p53 following DNA damage (e.g. miR-34a, the miR-200 family 
and miR-143). Strikingly, we also found differences in miRNA expression changes between 
the total RNA and AGO2-IP samples (Figure 17C). We demonstrated an increased 
expression of certain miRNAs (e.g. let-7 family, miR-30a and miR-96) in the AGO2-IP 
samples that was not detectable in the total RNA samples indicating increased loading of 
these miRNAs onto AGO2 in response to DOX (Figure 17C, top central portion coloured 
red). Furthermore, we found a reduction in the expression of other miRNAs (e.g. miR-26b, 
miR-142 and miR-548e) in the AGO2-IP samples that was not demonstrable in the total RNA 
samples indicating decreased loading of this subset of miRNAs onto AGO2 in response to 
DOX  (Figure 17C, lower central portion coloured green). To our knowledge this represents 
the first finding that indicates that the loading of miRNAs onto the RISC complex can be 
affected by a particular stimulus. Interestingly, these differences were only detected in the 
p53
WT 
cells and not the p53
null
 cells (Figure 17D) and taken together these results suggest 
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that DNA damage can induce a p53-dependent mechanism capable of regulating the loading 
of specific miRNAs onto AGO2 making them more or less active in regulating their gene 
targets. This demonstrates that p53 can control the abundance of miRNAs on AGO2 via 
changes in cellular miRNA levels through the regulation of miRNA transcription and 
processing, but also by a previously undescribed mechanism that controls the loading of 
certain miRNAs onto AGO2. 
3.1.3 AGO2 loading of certain miRNAs, including the let-7 family, is 
regulated in a p53-dependent manner following DNA damage and this 
process is selective to those cell lines expressing wild-type rather than 
mutated p53 
 
Having identified by RNA-seq that DNA damage induced a p53-dependent effect on 
the loading of specific miRNAs onto AGO2 in HCT116 cell lines, we aimed to validate our 
findings using RT-qPCR to measure miRNAs derived from AGO2  in lysates resulting from 
these and additional cell lines. We were particularly interested in the let-7 miRNAs because 
AGO2 loading of various members of this family (let-7c-5p, let-7i-5p, let-7b-5p) increased in 
response to DNA damage in our RIP-seq analysis (Figure 17C and Figure 18).  We treated 3 
different colorectal cancer cell lines (HCT116 p53
WT
, RKO and DLD1) with DOX or vehicle 
and performed an AGO2-IP from the lysates, followed by RT-qPCR to measure miRNA 
expression. We selected these cell lines to enable us to detect whether the differential loading 
on AGO2 was specific to cells containing wild-type p53 (HCT 116, RKO cells) rather than 
mutant p53 (DLD1). Again, we considered any positive or negative fold changes with a 
threshold of 0.35 (log2) or greater as significant 
Firstly, we used RT-qPCR to measure the expression levels of the let-7 family members in 
total RNA or AGO-IP samples derived from HCT116 p53
WT
 or p53
null
 cells treated with 
DOX or vehicle. In the AGO-IP samples, we found a significant increase in the levels of let-
7c-5p, let-7i-5p, let-7e-5p, let-7f-5p, let-7b-5p, let-7g-5p and miR-98-5p but not let-7a-5p or 
let-7d-5p (Figure 19C). However, we did not detect any significant increases in the 
expression of these miRNAs in the total RNA samples (Figure 19C). Furthermore, there was 
no significant difference in the expression levels of these let-7 family members in the AGO-
IP or total RNA samples derived from the HCT116 p53
null
 cells treated with DOX (Figure 
19D). These results further validated our hypothesis that DNA damage induced a p53-
dependent regulation on the loading of specific miRNAs, including the let-7 family, onto 
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AGO2. The fact that, when compared to our small RIP-seq analysis, RT-qPCR identified 
additional let-7 family members that were loaded more onto AGO2 following DNA damage 
is likely to be due to subtle differences between the two techniques.  
We further validated our results using RT-qPCR to measure miRNAs whose loading onto 
AGO2 decreased in a p53-dependent manner following DNA damage. We found that miR-
148-5p (Figure 19B) and miR-142-5p (data not shown) expression levels were significantly 
reduced in AGO-IP samples from HCT116 p53
WT
 cells treated with DOX but there were no 
significant changes in the levels of these miRNAs in the AGO-IP samples obtained from 
p53
null
 cells or the total RNA samples derived from either cell line. Again, these results are 
consistent with our RIP-seq data and confirm that a p53-dependent reduction in loading of 
certain miRNAs onto AGO2 occurs after DNA damage.        
Interestingly, our RT-qPCR analysis also demonstrated that the p53-dependent regulation of 
miRNA loading onto AGO2 was specific to cells that expressed wild-type p53 and was not 
detectable in cell lines that expressed mutant p53 (Figure 19E). RKO are poorly 
differentiated cell lines derived from colorectal cancer and, like HCT116 p53
WT
 cells, they 
contain wild-type p53. Conversely, DLD1 cells are derived from a Duke’s stage C colorectal 
cancer and express p53 that has a missense C > T mutation at position 241 that results in a 
Ser > Phe substitution. We compared miRNA expression changes between AGO2-IP samples 
and total RNA samples derived from DOX or vehicle treated p53 wild-type RKO and p53 
mutated DLD1 cells. We found that DNA damage induced miRNA fold changes in samples 
derived from RKO cells that were suggestive of an AGO2 loading effect and which were 
consistent with our results in HCT116 p53
WT
 cells described above (Figure 19E). However, 
there was no evidence of differential loading of the identified miRNAs onto AGO2 in 
samples derived from DLD1 cells indicating that differential AGO2 loading requires p53 to 
be active (Figure 19E). More specifically, although DOX treatment did not affect let-7c-5p 
or let-7i-5p levels in total RNA samples derived from DLD1 or RKO cell lines, it did induce 
an increase in the expression of both miRNAs in AGO-IP samples derived from RKO cells 
but not DLD1 cells (Figure 19E). miR-34a was used here as a control and interestingly, 
DOX treatment increased the levels of this miRNA in the AGO-IP and total RNA samples 
derived from both cell lines (Figure 19E). This is consistent with our previous results that 
demonstrated that p53 regulated miR-34a transcriptionally but did not affect its loading onto 
AGO2.  
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3.1.4 Increased loading of the let-7 family onto AGO2 following DOX-
induced DNA damage is not related to an early transcriptional effect 
 
Our results outlined above derived from experiments in which DNA damage was 
induced by exposing cells to DOX treatment for 24 hours. At this time-point, let-7 expression 
levels in p53
WT
 cells were increased in the AGO-IP samples obtained from DOX treated cells 
when compared to vehicle controls, but no significant expression changes were seen in the 
total RNA samples. This led to the conclusion that DNA damage induced a p53-dependent 
increase in let-7 loading onto AGO2 and that these changes were not simply related to an 
increase in let-7 transcription. However it is possible that the differences demonstrated in let-
7 expression levels in the AGO-IP samples compared to the total RNA samples were due to a 
delayed effect caused by an earlier and transient increase in let-7 transcription and/or 
maturation. For example, if an increase in let-7 transcription occurred after 3 hours of DOX 
treatment, this increase may not be detectable in the total RNA samples by 24h but may still 
be seen in the AGO-IP samples due to the time taken for the miRNA to be processed and then 
loaded onto AGO2, which would lead to a false interpretation of the results.  
We therefore performed a timecourse experiment to detect whether DOX treatment did in 
fact induce let-7 transcription in cells exposed for less than 24 hours. We subjected HCT116 
p53
WT
 cells to DOX or vehicle treatment for 3, 6, 12 and 24 hours and used RT-qPCR to 
measure let-7 expressions levels in total RNA extracted from the cell lysates. We did not 
detect any significant induction in the expression of the relevant let-7 family members at any 
time-point (Figure 19F) but there was an increase in miR-34a (used as a positive control) at 
24 hours. These results provided further support to the hypothesis that AGO2 loading of 
specific members of the let-7 family is increased in a p53-dependent manner following DNA 
damage.   
3.1.5 The differential loading of identified miRNAs onto AGO2 following 
DOX-induced DNA damage is not due to changes in AGO2 expression 
  
We wished to confirm that the changes demonstrated in the loading of miRNAs onto 
AGO2 following DNA damage could not simply be explained by changes in AGO2 
expression. We performed a Western blot analysis using protein extracted from HCT116 
p53
WT
 and p53
null
 cells treated with DOX or vehicle. We found that DNA damage did not 
cause a significant p53-dependent or -independent change in AGO2 expression (Figure 
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19G), which suggests that a variation in the abundance of this protein was not responsible for 
the changes seen in miRNA loading. 
3.1.6 Combining our small RIP-seq and small RNA-seq analyses validates a 
group of miRNAs that are regulated in a p53-dependent or p53-
independent manner following DNA damage 
 
We wished to further investigate the role of the miRNAs that we had identified as 
being regulated in response to DNA damage, and to identify their gene targets. To ensure that 
we selected these miRNAs as accurately as possible we combined data from our small RNA-
seq analysis and small RIP-seq analysis and constructed venn diagrams to identify those 
miRNAs that demonstrated consistent expressional fold-changes between both experiments 
(Figure 17E). For example, to select miRNAs upregulated in a p53-dependent manner, we 
identified those shown to be upregulated in Figure 17A that were also upregulated in both 
the total RNA (TwD/TwV) and AGO-IP (AwD/AwV) samples illustrated in Figure 17C 
(coloured orange in the top right section of the graph). To select miRNAs upregulated in a 
p53-independent manner, we identified those shown to be upregulated in Figure 17B that 
were also upregulated in the total RNA (TwD/TwV) and AGO-IP (AwD/AwV) samples 
shown in Figure 17D (coloured orange in top right section of the graph). In doing so, we 
were able to use two different assays to confirm which miRNAs were regulated in a p53-
dependent or –independent manner following DNA damage.  
Of the 34 miRNAs that were significantly upregulated in a p53-depenedent manner in our 
small RNA-seq analysis (Figure 17A), 10 were also significantly upregulated in our small 
RIP-seq analysis (Figure 17E) and were selected for further investigation. Of the 26 miRNAs 
that were down-regulated in a p53-dependent manner in our small RNA-seq analysis, only 2 
were significantly down-regulated in our small RIP-seq analysis (Figure 17E). Of the 
miRNAs regulated in a p53-independent manner, 6 of the 21 that were significantly 
upregulated and 3 of the 26 that were down-regulated in the small RNA-seq analysis showed 
consistent fold changes in the small RIP-seq analysis and were selected for further 
investigation (Figure 17E).  
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3.1.7 An RNA-seq approach followed by an extensive bioinformatic 
analysis identifies genes whose abundance is regulated in a p53-dependent 
manner following DNA damage and illustrates their function within 
cellular signaling networks 
 
Having used an RNA-seq approach to better understand DNA damage-induced 
modulation of miRNA expression, we wished to use the same method to gain further insight 
into changes in mRNA expression. Firstly, we aimed to determine p53-dependent genome 
wide changes in mRNA expression that occurred following DNA damage.  We assessed 
changes in mRNA expression using total RNA samples obtained from HCT116 p53
WT 
and 
p53
null
 cells treated with DOX for 24 hours, and performed the experiment in duplicate to 
achieve better accuracy. We identified over 12,000 genes in the total RNA samples from 
HCT116 p53
WT
 cell lines, and Figures 12 and 13 (in the methods section) show the mean fold 
changes of these genes between DOX-treated and vehicle treated samples.   Furthermore, the 
heat map in Figure 20 illustrates genes relevant to the DNA damage response that were 
found to be up- or downregulated in p53-dependent manner following DOX treatment. Next, 
we produced a Pearson’s plot that showed a good correlation between biological replicates in 
terms of p53-dependent up- & down-regulated genes (Figure 21, Pearsons Correlation= 
0.71). We analysed the cellular functions of the identified genes using the DAVID online 
database for gene ontology (GO) annotation and pathway enrichment analysis, and performed 
KEGG pathways analyses to demonstrate the validity of our methods.
398,399
 Web-based 
bioinformatics databases such as DAVID
399
 and GO
398
 are able to process large lists of genes 
giving outputs with biological meaning, such as the cellular pathways enriched for a subset of 
genes. Both GO-term and KEGG analyses apply the Fischer’s exact test for enrichment but 
GO-term categorises genes by function or biological role, whereas KEGG gives information 
about the cellular pathways in which genes are involved. Notably, this analysis specifically 
implicated DNA damage-induced p53-dependent upregulated genes in the positive regulation 
of apoptosis, cell death, cellular proliferation and the DNA damage response (Figure 22A), 
as well as the co-ordination of pathways involved in p53-signalling, apoptosis and cancer 
(Figure 22B). Conversely, the analysis specifically implicated DNA damage-induced p53-
dependent down-regulated genes in controlling the cell cycle, mitosis and cell division 
(Figure 23A), as well as the regulation of pathways involved the cell cycle and DNA 
replication (Figure 23B).  
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Figure 20: Heat map illustrating 
the differential expression of a 
number of genes relevant to the 
DNA damage response that were 
found to be differentially 
expressed between DOX and 
vehicle treated p53
WT
 and p53
null
 
HCT116 cells in either the total 
RNA or AGO IP samples.  
 
Green: up-regulated; Red: down-
regulated. TwD: DOX treated total 
RNA samples from p53
WT
 cells; 
TwV: vehicle treated total RNA 
samples from p53
WT
 cells; TnD 
and TnV: same as before, but for 
p53
null
 cells; AwD: DOX treated 
AGO IP samples from p53
WT
 
cells; AwV: vehicle treated AGO 
IP samples from p53
null
 cells; AnD 
and AnV: same as before, but for 
p53
null
 cells. 
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3.1.8 An RNA-seq approach followed by an in depth bioinformatic analysis 
identifies genes whose abundance is regulated in a p53-independent 
manner following DNA damage and illustrates their function within 
cellular signaling networks 
 
We used the same RNA-seq approach to determine p53-independent changes in 
mRNA expression that occurred following DNA damage on a genome wide scale.  We 
identified over 12,000 in the total RNA samples derived from HCT116 p53
null
 cell lines and a 
number of important p53-independently up- and down-regulated genes are illustrated on the 
heat map in Figure 20. Again, a Pearson’s plot that showed a good correlation between the 
biological replicates in terms of p53-dependently up- & down-regulated genes (Figure 21, 
Pearson Correlation= 0.9). A DAVID analysis specifically implicated DNA damage-induced 
p53-independent upregulated genes in the co-ordination of angiogenesis, cell adhesion and 
cell motility (Figure 24). Conversely, the analysis implicated DNA damage-induced p53-
independent down-regulated genes in controlling the cell cycle, cell division and transcription 
(Figure 25). 
 
 
Pearson’s correlation= 0.9 Pearson’s correlation= 0.71 
A B 
Figure 21: Pearsons correlation plots demonstrate consistency between replicates in terms of gene expression 
changes in the RNA-seq experiments. 
A & B, Gene expression (mRNA) levels, as determined by RNA-seq, were measured in RNA derived from experimental 
replicates of HCT116 p53
WT
 (A) or p53
null
 (B) cells treated with DOX or vehicle and correlations between replicates were 
calculated using the Pearsons correlation formula. 
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Figure 22: Top GO-term and 
KEGG analyses of genes identified 
as being up-regulated in a p53-
dependent manner following DOX 
treatment in the RNA-seq. 
 A) GO term analysis showing the 
function of genes identified as being 
up-regulated in a p53-dependent 
manner in the RNA-seq. B) KEGG 
pathway analysis illustrating the 
cellular signalling pathways in which 
p53-dependently up-regulated genes 
identified in the RNA-seq are 
involved 
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Figure 23: Top GO-term and KEGG analyses of genes identified as being down-regulated in a p53-dependent 
manner following DOX treatment in the RNA-seq.   
A) GO term analysis showing the function of genes identified as being down-regulated in a p53-dependent manner in 
the RNA-seq. B) KEGG pathway analysis illustrating the cellular signalling pathways in which p53-dependently down-
regulated genes identified in the RNA-seq are involved. 
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Figure 24: Top GO-term and KEGG analyses of genes identified as being up-regulated in a p53-independent 
manner following DOX treatment in the RNA-seq  
A) GO term analysis showing the function of genes identified as being up-regulated in a p53-independent manner in the 
RNA-seq. B) KEGG pathway analysis illustrating the cellular signalling pathways in which p53-independently up-
regulated genes identified in the RNA-seq are involved. 
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3.1.9 p53 post-transcriptionally modulates the activity of a subgroup of 
genes involved in the DNA damage response through differential targeting 
by AGO2 and this process involves p53-regulated miRNAs 
 
Having used an RNA-seq approach to identify genes that showed differential 
expression at the mRNA level following DNA damage, we wished to assess whether any of 
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Figure 25: Top GO-term and 
KEGG analyses of genes 
identified as being down-
regulated in a p53-
independent manner following 
DOX treatment in the RNA-
seq. 
A) GO term analysis showing 
the function of genes identified 
as being down-regulated in a 
p53-independent manner in the 
RNA-seq. B) KEGG pathway 
analysis illustrating the cellular 
signalling pathways in which 
p53-independently down-
regulated genes identified in the 
RNA-seq are involved. 
 
A 
B 
129 
 
these mRNAs were specifically targeted post-transcriptionally by miRNAs regulated by DNA 
damage. Firstly, we made lists of genes that were differentially loaded onto AGO2 in the 
RIP-seq, By assessing p53-dependent AGO2 enriched genes we aimed to determine those 
whose expression at the protein level might be supressed by increased miRNA-mediated 
post-transcriptional regulation of the corresponding mRNA following DNA damage. 
Furthermore, by assessing p53-dependent AGO2 depleted genes we aimed to determine those 
whose activity might be increased through a reduction in miRNA-mediated post-
transcriptional regulation of the corresponding mRNA following DNA damage. We 
identified 1366 of such AGO2-enriched genes (i.e. log fold change >= log2(1.5) in DOX-
treated AGO2-IP samples compared to vehicle-treated AGO2-IP samples) which included 
genes such as RET, cyclin-dependent kinase 6 (CDK6) and fibroblast growth factor 18 
(FGF18). Furthermore, we found 1543 AGO2-depleted genes (i.e. log fold change <= 
log2(1.5) in DOX-treated AGO2-IP samples compared to vehicle-treated AGO2-IP samples). 
Interestingly, a number of the AGO2-enriched genes and AGO2-depleted genes were down-
regulated and upregulated respectively in the RNA-seq or their expression did not change.  
These findings suggested that the activity of this subset of genes that were enriched or 
depleted on AGO2 following DNA damage were specifically controlled by miRNAs that 
were regulated in a p53-dependent manner. Even more strikingly, these results indicated that 
some of these genes might be targeted specifically by those miRNAs that demonstrated 
differential loading onto AGO2 following DNA damage. To provide further evidence for this, 
we performed a Targetscan analysis
1,40
 (Figure 26A) and established that many of these 
genes were in fact predicted targets of p53-activated miRNAs (such as miR-34a, miR-27 and 
miR-23a/b) and in some cases were targets of miRNAs shown to be more loaded onto AGO2 
following DNA damage (such as let-7). For example, RET is a predicted target for miR-34a, 
CDK6 is a predicted target of miR-34a-c and the let-7 family and FGF18 is predicted target 
of miR-103a and the mir-200 family (Figure 26A). Furthermore, we performed a seed 
enrichment analysis to determine whether any AGO2-enriched genes were targeted by p53-
regulated miRNAs. Remarkably, the miRNAs to which the AGO2-enriched genes 
demonstrated the strongest seed-complementary matches were in fact the p53-regulated 
miRNAs, including miR-34a, let-7, miR-143 and miR-23a which further suggested that these 
AGO2-enriched genes were potentially targeted by p53-regulated miRNAs (Figure 27). 
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Figure 26: Many AGO2-enriched genes, including RET, CDK6 and FGF18 are targets of the p53-regulated 
miRNAs, including in some cases those miRNAs that were more loaded onto AGO2 following DOX treatment and 
these genes are involved in many cellular signalling pathways that p53 would seek to inhibit after DNA damage 
A, Representation of human RET, CDK6 and FGF18 3’UTRs presenting conserved sites for the p53-regulated miRNA 
families which are highlighted by a rectangular box (adapted from TargetScan). B, A pathways analyses determines that 
many AGO2-enriched genes (highlighted with red boxes) are predicted to play vital roles in p53-regulated signalling 
pathways such as those involved in cell proliferation, negative regulation of apoptosis, positive regulation of the cell 
cycle, tumour cell invasion and metastasis, angiogenesis and resistance to chemotherapy.    
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Finally, when we analysed the signalling networks that the AGO2-enriched genes were 
involved in we found that they were vital components in pathways that p53 would seek to 
inhibit in response to DNA damage, particularly those that promoted tumorigenesis such as 
proliferation, invasion, metastasis, angiogenesis and resistance to chemotherapy (Figure 
26B). Furthermore, a DAVID analysis determined that the group of genes that were more 
abundant in the RIP-seq samples following DOX treatment were involved in signalling 
pathways that promoted cell proliferation and cell cycling and supressed apoptosis, whereas 
the converse was the case for those genes found to be less abundant on AGO2 following 
DNA damage (Figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: A seed enrichment analysis strongly predicts that AGO2-enriched genes are targets of p53-regulated 
miRNAs 
To evaluate whether the observed remodelling of AGO2-bound mRNAs following induction of DNA damage could have 
been attributed to an association with the modulated miRNAs, we used human target predictions from the Targetscan 
algorithm
1
 and tested each AGO2-enriched (and AGO2-depleted) miRNA for enriched proportion of their predicted 
targets among AGO2-enriched (and AGO-depleted) transcripts. We limited the database of miRNA target predictions 
downloaded from the targetscan website (http://www.targetscan.org/) - release 6.1 - to the union set of gene symbols 
included in our filtered gene datasets (background set, N=11375). Gene redundancy in the prediction database was 
removed by retaining only the first occurrence of each gene symbol after sorting the database by decreasing ’UTR 
length. 
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In aggregate, these results demonstrated that in its capacity as a guardian against the effects 
of DNA damage, p53 could fine-tune the activity of a subgroup of genes not through 
transcriptional means but post-transcriptionally by modulating their targeting by AGO2 
through p53-regulated miRNAs. Many genes that were targeted more by the RISC through 
p53-regulated miRNAs following DNA damage appeared to be crucial components in 
pathways that promoted cell growth and prevented apoptosis. 
 
3.1.10 An AGO2 PARCLIP analysis illustrates the p53-associated 
miRNA/mRNA interactome at a genome wide level and establishes the 
functional effects of miRNA/mRNA binding in terms of p53-regulated 
signaling networks 
 
The analyses outlined above used RNA-seq and RIP-seq approaches to identify a 
novel panel of DNA damage-induced miRNAs that were regulated in a p53-dependent and 
p53–independent manner and the fraction of mRNAs that were regulated at the post-
transcriptional level by AGO2 and miRNAs. Furthermore, they enabled a genome wide 
analysis of the variations in gene expression levels that occurred during the cellular response 
A B 
Figure 28:A DAVID analysis of the RIP-seq genes 
A & B, A DAVID analysis demonstrates that (A) the group of genes that were more abundant in the RIP-seq samples 
following DOX treatment were involved in signalling pathways that promoted cell proliferation and cell cycling and 
supressed apoptosis, whereas the converse was the case for (B) those genes found to be less abundant on AGO2 following 
DNA damage. 
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to DNA damage. Additionally, they allowed us to identify a subset of miRNAs and genes that 
were differentially loaded onto AGO2, and with the aid of Targetscan and seed-enrichment 
analyses we were able to predict that many of the regulated genes were targeted by the 
modulated miRNAs. However, there were limitations to this approach which only enabled an 
indirect or predictive measure of global miRNA/mRNA targeting. Therefore, we wished to 
provide a more robust analysis of the DNA damage-associated miRNA/mRNA interactome at 
a genome wide level using an AGO2 PAR-CLIP approach. We hoped that this approach 
would enable us to confirm which coding genes were regulated by the miRNAs that our RIP-
seq analysis had identified as being induced or repressed following DNA damage, and to 
characterize the sites to which these miRNAs guided the RISC complex to bind to these 
target transcripts. We also wished to further establish the potential functional effects of any 
miRNA/mRNA binding on the signaling networks involved in the DNA damage response. 
Furthermore, we planned to evaluate whether DNA damage modulated the binding of AGO2 
on the 3’UTR of mRNAs, independently of the miRNAs modulated by DNA damage. It is 
feasible that RNA binding proteins modulated by DNA damage might interact with the UTR 
of specific transcripts and antagonize or aid the interaction of AGO2 with those mRNAs 
mediating a post-transcriptional regulation. To evaluate this we proceeded to identify whether 
differential changes in AGO2 loading following DOX treatment was associated with 
statistically significant differences in the amount of sequence overlapping clusters that 
constitute the PAR-CLIP signal on discrete regions of the UTRs. This was done in 
combination with a motif discovery analysis to determine whether particular RNA motifs are 
associated with these changes in either a p53 dependent or independent manner.  
We performed the PAR-CLIP experiment as outlined in the methods section and following 
deep sequencing we analysed the data using a bioinformatic approach. Briefly, we treated 
HCT116 p53
WT 
or p53
KO
 cells with DOX or vehicle and performed an AGO-IP after UV-
crosslinking in the presence of 4-thiorudine. Following de-crosslinking and RNA extraction, 
we produced small RNA libraries for each sample and performed a deep sequencing analysis.  
We produced 3 biological replicates for each experiment and sequenced each in triplicate to 
produce 9 experimental replicates per sample, in total. In our analysis, we selected for read 
lengths as short as 13 nucleotides after adapter stripping that contained at least 5 T-to-C 
mismatches. We defined a cluster as having greater than 5 over-lapping reads and each 
corresponded to an individual AGO2::mRNA interaction site. We used a kernel density 
estimate to calculate a ‘signal-to-noise ratio’ in order to determine interaction sites and 
134 
 
matched clusters to the genome to determine the identity of the corresponding gene. The deep 
sequencing revealed 290,011,684 reads, of which 38% mapped to the genome. We identified 
232,964 AGO2-binding sites (clusters) in all PAR-CLIP libraries, 63,385 (27%) of which 
corresponded to 3’UTRs. These mapped to 5,058 unique genes (4,470 of which were also 
found in the RNA-Seq) and corresponded with 2,031 human miRNA seeds (nucleotides 2-8). 
We only considered the AGO2 binding sites that mapped on the 3UTR for further analysis as 
it has been demonstrated that this interaction co-ordinates post-transcriptional regulation of 
gene expression but there is conflicting evidence  about the possible regulation of gene 
expression by miRNAs and AGO2 interacting with the coding and 5’UTR regions of the 
transcripts.  
We then performed analyses of selected miRNAs whose seeds matched with each cluster to 
determine which miRNAs may target these genes. We particularly focused on two subgroups 
of miRNAs. Firstly, we concentrated on those miRNAs identified in both the small RNA-seq 
and small RIP-seq analyses as being differentially modulated in a p53-dependent or p53-
independent manner in response to DNA damage (illustrated in the venn diagrams in Figure 
1E-F) in order to choose the miRNAs regulated most confidently. Secondly, we focused on 
those miRNAs that were differentially loaded onto AGO2 in a p53-dependent manner 
following DNA damage. As miRNAs typically target multiple genes within a specific 
regulatory pathway,
400
 we used Cytoscape software
401
 to illustrate the network of genes 
identified as being high confidence candidates for targeting by each selected miRNA. 
Cytoscape is a free program developed for the analysis, integration and visualisation of 
molecular and genetic interaction networks. It processes large amounts of data derived from 
gene expression profiling, and other functional genomic and proteomic analyses, and 
integrates them according to an interaction network retrieved for the analysed genes. Data are 
then visualised in a network graph where biological entities, such as miRNAs, genes or 
proteins, are represented by nodes, connected with links or edges, which define 
intermolecular interactions. In our Cytoscape illustrations (Figure 29), miRNAs are 
represented as triangles that are connected by links to the genes (coloured squares) which our 
PAR-CLIP analysis identified as being targets of the represented miRNA. Genes shaded in 
red represent those found to be transcriptionally upregulated in our RNA-seq analysis 
following DNA damage and those shaded in green depict genes that were transcriptionally 
down-regulated. Genes shaded in white represent those that showed no differential expression 
between treatment groups in the RNA-seq analysis but that were identified as targets of the 
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illustrated miRNA by the PAR-CLIP analysis. It is likely that these genes were insufficiently 
expressed to be detected in our RNA-seq analysis, rather than them not being actual targets of 
the illustrated miRNA. Interestingly, this PAR-CLIP analysis showed that in some cases the 
interaction network for certain miRNAs contained a combination of genes shown to be 
upregulated and down-regulated in the RNA-seq, whilst in other cases the miRNA in 
question only targeted genes shown to be down-regulated. For example, let-7 targeted genes 
such as cyclin D1, polymerase lambda (Poll) and Phorbol-12-Myristate-13-Acetate-Induced 
Protein 1 (PMAIP1) whose abundance in the RNA-seq analysis was shown to be increased 
following DOX treatment, but that it also targeted genes such as POGZ, HMGA and PDP2 
whose expression decreased. Conversely, miR-3065-5p whose expression was so strongly 
induced following DNA damage in the RIP-seq was shown only to target genes that were 
down-regulated in the RNA-seq.   
 
Finally, having identified the gene networks targeted by each selected miRNA, we used 
DAVID to analyse the cellular signaling pathways in which the genes in each interaction 
network were involved. Figure 30 illustrates the top GO-term and KEGG analyses of genes 
identified by PAR-CLIP to be targeted by miRNAs that were upregulated in a p53-dependent 
manner in the RNA-seq.  Interestingly, this analysis demonstrated that amongst these miRNA 
targets, there was a clear enrichment of genes involved in cell signaling, cell cycling, the 
DNA damage response and in promoting tumorigenesis. Specifically, our GO-term analysis 
demonstrated that genes targeted by miR-143-3p (Figure 30C), such as cyclin D1 (CCND1) 
and the protein regulator of cytokinesis 1 (PRC1), and those targeted by miR-200a-3p 
(Figure 30D), including Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A or p21), Protein 
Tyrosine Phosphatase Type IVA Member 1 (PTP4A1 or PRL1), cyclin-dependent kinase 6 
(CDK6) and Cell Division Cycle 25B (CDC25B) were important components of such 
signalling networks. CCND1 encodes a protein belonging to the highly conserved cyclin 
family that function as regulators of cyclin dependent kinase (CDKs) and whose members are 
characterized by a dramatic periodicity in protein abundance throughout the cell cycle.
402,403
 
Amplification, overexpression or mutation of this gene can alter cell cycle progression and 
are observed frequently in a variety of malignancies.
404-406
 PRC1 encodes a protein that is 
involved in cytokinesis and that is highly abundant during the S and G2/M phases of mitosis 
but not during the G1 phase.
407
 It is has been shown to be a substrate of several CDKs and is 
necessary for polarizing parallel microtubules.
408,409
 CDKN1A regulates cell cycle 
progression at G1 and is a potent cyclin-dependent kinase inhibitor that binds to and prevents 
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the activity of cyclin-CDK2 or -CDK4 complexes.
410,411
 It mediates the p53-dependent cell 
cycle G1 phase arrest in response to stress and plays a regulatory role in S phase DNA 
replication and DNA damage repair.
412
 CDC25 is a dual specificity phosphatase with three 
isoforms (A, B and C) that inhibit mitosis under stress conditions through the activation of 
CDK complexes that regulate cell cycle progression and DNA damage checkpoints.
413,414
  
 
 
 
Figure 29: Cytoscape illustrations depicting miRNA:mRNA 
interaction networks involved in the DNA damage response 
as identified by a PAR-CLIP analysis 
A) A complete illustration of the miRNA:mRNA interactions 
activated by DNA damage in p53
WT 
cells. B) A complete 
illustration of the miRNA:mRNA interactions activated by DNA 
damage in p53
null 
cells. C) An interaction wheel depicting those 
genes targeted by let-7f-5p following DNA damage as 
determined by PAR-CLIP. miRNAs represented by triangles and 
genes respresented by coloured squares (A and B) or circles (C). 
Red= transcriptionally upregulated by DOX in RNA-seq; 
Green= transcriptionally down-regulated by DOX in RNA-seq; 
White= no differential expression between treatment groups in 
the RNA-seq analysis but that were identified as targets of the 
illustrated miRNA by the PAR-CLIP analysis. Yellow circle 
highlights CCND1 as a specific target of let-7f-5p.    
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Figure 30: Top GO-term and KEGG analyses of genes identified by PAR-CLIP to be targeted by miRNAs that were 
upregulated in a p53-dependent manner in the RNA-seq  
A) GO term analysis showing the function of genes identified by PAR-CLIP to be targeted by any of the miRNAs 
upregulated in a53-dependent manner in the RNA-seq. B) KEGG pathway analysis illustrating the cellular signalling 
pathways that genes targeted by any of the upregulated miRNAs are involved in. C) GO term analysis showing the function 
of genes identified by PAR-CLIP to be targeted by miR-143-3p D) GO term analysis showing the function of genes 
identified by PAR-CLIP to be targeted by miR-200a-3p. 
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Similarly, genes identified by PAR-CLIP to be targeted by miRNAs that were loaded more 
onto AGO2, were generally implicated in the promotion of cell division, proliferation and 
survival and the regulation of cell death in response to DNA damage (Figure 31). 
Specifically, the let-7 family targeted networks of genes involved in mitosis and cell cycling 
that included Activin A Receptor Type IB (ACVR1B), CCND1, Type IB Class I Beta-Tubulin 
(TUBB), Extra Spindle Poles-Like 1 Protein (ESPL1), High Mobility Group AT-Hook 2 
(HMGA2), Tumor Suppressor Candidate 2 (TUSC2), Pogo Transposable Element With ZNF 
Domain (POGZ) and  Structural Maintenance Of Chromosomes 1A (SMC1A). Furthermore, 
let-7 targeted genes involved in the DNA damage response such as Polymerase Lambda 
(POLL), Proliferating Cell Nuclear Antigen (PCNA), RAD18, and SMC1A. miR-24-3p 
predominantly targeted genes involved in suppressing or promoting apoptosis such as the 
NUAK Family SNF1-Like Kinase, 2 (NUAK2) and BCL2-Like 11 (BCL2L11), respectively. 
However we also showed that it targeted genes that repress or stimulate cell proliferation 
such as Sestrin 1 (SESN1) and epiregulin (EREG), respectively. Interestingly, the miRNAs 
loaded more onto AGO2 following DNA damage, in particular miR-185-5p and miR-24-3p, 
appeared to also target mRNAs corresponding to genes that regulate protein phosphorylation, 
which is relevant for a number of reasons. Firstly, DNA damage pathways engender a large 
number of phosphorylation events that activate or suppress cell signalling pathways. 
Secondly, these phosphorylation events also involve p53 and its regulatory partners, 
including Mdm2 and Mdm4, and such modifications can mediate the induction of p53 and 
stimulation of its activity.
415-417
 mRNAs targeted by these miRNAs included Protein Kinase 
Membrane Associated Tyrosine/Threonine 1 (PKMYT1), that encodes a membrane-
associated kinase that negatively regulates the cell cycle at the G2/M transition by 
phosphorylating and inactivating CDK1, and KIT ligand (KITLG) that encodes a protein 
critical to the regulation of cell survival, proliferation and migration through its ability to 
promote phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, 
and subsequent activation of the kinase AKT1.  
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Figure 31: Top GO-term analyses of genes identified by PAR-CLIP to be targeted by miRNAs that were identified as 
being loaded more onto AGO2 in the combined RIP-seq/RNA-seq analysis. 
A) GO term analysis showing the function of genes identified by PAR-CLIP to be targeted by the let-7 family B) GO term 
analysis illustrating the cellular signalling pathways that genes targeted by miR-185-5p C) GO term analysis showing the 
function of genes identified by PAR-CLIP to be targeted by miR-24-3p. 
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Figure 32 illustrates the top GO-term and KEGG analyses of genes identified by PAR-CLIP 
to be targeted by miRNAs that were upregulated in a p53-independent manner in the RNA-
seq. Importantly, these genes are intricately involved in pathways implicated in the DNA 
damage response in a similar manner to those targeted by miRNAs that were upregulated in a 
p53-dependent manner, however the target gene sets generally differ. These miRNAs, in 
particular miR-3065-5p, target mRNAs corresponding to Phosphatase And Tensin Homolog 
(PTEN), Nucleus Accumbens Associated 1 (NACC1) and PIM1, as well as those mRNAs 
targeted by p53-dependently upregulated miRNAs such as BBC3 and BCL2L11. NACC1 
represses the transcription of the tumour suppressor, Growth Arrest And DNA-Damage-
Inducible Gamma Interacting Protein 1 (Gadd45GIP1), and thus promotes cell proliferation 
and survival as well as oncogenesis.
418,419
 PTEN acts as a dual-specificity protein 
phosphatase that can function as a tumor suppressor by antagonizing the PI3K-AKT/PKB 
signalling pathway thereby modulating cell cycle progression and cell survival. Furthermore, 
PTEN can increase p53 stability and activity through negative regulation of PI3K-AKT/PKB 
signalling thereby restricting the phosphorylation and movement of Mdm2 into the 
nucleus.
420,421
 Interestingly, p53 can also directly induce PTEN transcription by interacting 
with a p53-binding element directly upstream of the PTEN locus.
204
 PIM1 is a 
serine/threonine kinase that promotes cell proliferation and survival through the positive 
regulation of MYC transcriptional activity and cell cycle progression, and by phosphorylating 
and inhibiting pro-apoptotic proteins such as BAD and FOXO3.
422-426
 Furthermore, at 
physiological levels PIM1 can phosphorylate and activate Mdm2, thereby suppressing p53 
activity, but surprisingly, at high levels of expression, PIM1 expression blocks the 
degradation of both p53 and Mdm2 in a manner that is independent of Mdm2 
phosphorylation, leading to increased p53 levels.
427
 Remarkably, the p53-independently 
upregulated or AGO2 loaded miRNAs, including miR-3065-5p, also targeted mRNA 
corresponding to the von Hippel-Lindau (VHL) protein. Under normoxic conditions, VHL, 
through the recruitment of an E3 ubiquitin ligase complex, ubiquitinates hypoxia-inducible 
factor 1-alpha (HIF-1α) thus inhibiting the transcription of genes involved in angiogenesis, 
glycolysis, invasion and EMT. However, under stress conditions, including hypoxia, VHL 
cannot bind HIF-1α which is then free to promote glycolysis and angiogenesis. Interestingly, 
a recent study in kidney cancer cell lines showed that the VHL protein directly interacted 
with and positively regulated p53 by inhibiting Mdm2-mediated ubiquitination, and by 
subsequently recruiting p53-modifying enzymes. Furthermore, VHL-deleted kidney cancer 
cells showed abnormal cell-cycle arrest or attenuated apoptosis following DNA damage, but 
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became normal when VHL was restored.
428,429
 This suggested that the VHL protein played a 
critical role in tumor suppression by participating actively as a component of p53 
transactivation complex during DNA damage response. We also found that, following DOX 
treatment, the p53-independently upregulated miR-4435 targeted a number of mRNAs 
involved in co-ordinating the DNA damage response including Tripartite Motif Containing 
28 (TRIM28) and High Mobility Group AT-Hook 1 (HMGA1). TRIM28 acts predominantly 
as an inhibitor of transcription but also plays a direct role in suppressing apoptosis. It inhibits 
E2F1 activity by stimulating the formation of the E2F1-HDAC1 complex and inhibiting 
E2F1 acetylation and can function to prevent E2F1-mediated apoptosis in the absence of 
RB1.
430-433
 Furthermore, TRIM28 is an important regulator of CDKN1A/p21(CIP1) and can 
promote the ubiquitylation and proteosomal degradation of p53/TP53 through a direct 
interaction with Mdm2.
434,435
  HMGA1 is a non-histone protein involved in many cellular 
processes, including regulation of inducible gene transcription, integration of retroviruses into 
chromosomes, and the metastatic progression of cancer cells. However it is also an important 
regulator of p53 activity that can suppresses p53-mediated mitochondrial-apoptosis through 
its interaction with Bcl-2,
436
 and inhibit p53 activity by promoting the cytoplasmic re-
localisation of the pro-apoptotic activator Homeodomain Interacting Protein Kinase 2 
(HIPK2).
437
 Furthermore, HMGA1 can also inhibit the function of the p53 homologues p63 
and p73 suggesting the importance of regulating the activity of this protein in the p53-
independent response to DNA damage.
438
 
 
Figure 33 illustrates the top GO-term and KEGG analyses of genes identified by PAR-CLIP 
to be targeted by miRNAs that were down-regulated in a p53-dependent manner in the RNA-
seq or that were identified as being loaded less onto AGO2 in the combined RIP-seq/RNA-
seq analysis. Again enriched genes were shown to be involved in cellular pathways that 
regulated cell proliferation and cell division as well as DNA repair and programmed cell 
death. Interestingly, other pathways including those that coordinated the response to estrogen 
and steroid hormone stimulation were also amongst the top GO-terms (Figure 9 A). This was 
not surprising given that many of the proteins involved in these signaling pathways are also 
important in the cellular response to DNA damage including CCND1, CDKN1A, cyclin A2 
(CCNA2) and mitogen-activated protein kinase 1 (MAPK1). Furthermore, although the 
oestrogen receptor-alpha (ERα) is not expressed in HCT116 cells,439 functional ERβ is, and 
coordinates estrogen-mediated effects on cell growth and proliferation.
439,440
 As one might 
have expected, mRNAs targeted by miRNAs down-regulated in a p53-dependent manner 
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following DOX treatment included many of those involved in suppressing the cell cycle and 
promoting apoptosis or DNA repair such as CDKN1A, CCNA2, SWI/SNF-Related Matrix-
Associated Actin-Dependent Regulator Of Chromatin Subfamily A, Containing DEAD/H 
Box 1 (smarcad1), Eukaryotic Translation Initiation Factor 5A (EIF5A), and Ubiquitin C 
(UBC), but also anti-apoptotic and pro-proliferative targets such as CCND1, MAPK1, 
NACC1/2. Remarkably, we also demonstrated that genes targeted by miR-142-5p, such as 
Dickkopf Homolog 1 (DKK1) were negative regulators of the Wnt-signalling pathway 
(Figure 33D). Canonical Wnt signaling controls cellular processes such as cell cycle 
regulation, cell fate determination, EMT, cell motility and metabolism, and pathologic 
increases in Wnt signalling are frequently implicated in tumorigenesis.
441-443
 p53 suppresses 
Wnt activity through a number of mechanisms including the induction of miR-34a that 
targets positive regulators of the Wnt signalling pathway such as WNT1, WNT3, Low 
Density Lipoprotein Receptor-Related Protein 6 (LRP6), β-catenin and Lymphoid Enhancer-
Binding Factor 1 (LEF1).
278,444
 Our results demonstrated that miR-142-5p was also involved 
in the p53-dependent negative regulation of Wnt signalling but that, in this case, p53 
mediated its control through a reduction in loading of a miRNA onto AGO2 rather than a 
transcriptional induction and hence the release of mRNAs involved in suppressing Wnt 
signalling rather than the targeting of those involved in promoting it. 
 
The GO-term analyses of the mRNAs identified by PAR-CLIP to be targeted by miRNAs 
that were down-regulated in a p53-independent manner in the RNA-seq are illustrated in 
Figure 34. These networks generally relate to metabolic and biosynthetic signaling pathways, 
nucleic acid synthesis and the negative regulation of Wnt signalling that was also 
demonstrated with miRNAs down-regulated in a p53-dependent manner. Although these 
pathways are less prominant in the cellular response to double-strand break DNA damage 
they do have a role particularly in the repair of DNA damage. Interestingly, miR-548d-5p 
was shown to target chromobox homologue 3 (CBX3) which is a component of 
heterochromatin that binds to DNA and is recruited to sites of DNA damage and double-
strand breaks.
445-447
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Figure 32: Top GO-term analyses of genes identified by PAR-CLIP to be targeted by miRNAs that were upregulated 
in a p53-independent manner in the RNA-seq 
A) GO term analysis showing the function of genes identified by PAR-CLIP to be targeted by any of the miRNAs 
upregulated in a p53-independent manner in the RNA-seq. B) GO term analysis showing the function of genes identified by 
PAR-CLIP to be targeted by miR-3065-3p.  
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Figure 33: Top GO-term and KEGG analyses of genes identified by PAR-CLIP to be targeted by miRNAs that were 
downregulated in a p53-dependent manner in the RNA-seq or that were identified as being loaded less onto AGO2 in 
the combined RIP-seq/RNA-seq analysis 
A) GO term analysis showing the function of genes identified by PAR-CLIP to be targeted by any of the miRNAs 
downregulated in a53-dependent manner in the RNA-seq. B) KEGG pathway analysis illustrating the cellular signalling 
pathways that genes targeted by any of the downregulated miRNAs are involved in. C) GO term analysis showing the 
function of genes identified by PAR-CLIP to be targeted by miR-301a-3p and miR-301b. D) GO term analysis showing the 
function of genes identified by PAR-CLIP to be targeted by miR-142-5p. 
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Figure 34: Top GO-term analyses of genes identified by PAR-CLIP to be targeted by miRNAs that were 
downregulated in a p53-independent manner in the RNA-seq   
A) GO term analysis showing the function of genes identified by PAR-CLIP to be targeted by any of the miRNAs 
downregulated in a53-independent manner in the RNA-seq. B) GO term analysis showing the function of genes identified by 
PAR-CLIP to be targeted by miR-548d-5p D) GO term analysis showing the function of genes identified by PAR-CLIP to be 
targeted by miR-561-3p. 
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3.1.11 Luciferase reporter assays confirm that CCND1 and POGZ are 
targeted by let-7a, let-7d, miR-23a and miR-34a and validate our 
PARCLIP approach for defining targets of miRNAs regulated upon DNA 
damage 
 
Next, we performed luciferase reporter assays to validate our PARCLIP approach for 
defining mRNA targets of miRNAs regulated following DOX treatment. The PARCLIP 
analysis revealed many genes involved in the DNA damage response that were targeted by 
miRNAs that were also regulated following DOX treatment. We selected 2 of those genes 
(CCND1 and POGZ) that are well described as regulators of either cell cycling, mitosis, cell 
proliferation, DNA repair or programmed cell death and performed 3’UTR luciferase reporter 
assays (Figure 35). Under conditions of gain-of-function for let-7a, let-7d, miR-23a and 
miR-34a, we could demonstrate the direct regulation of both of these genes by all 4 tested 
miRNAs (Figure 35). In fact, overexpression of these miRNAs in HCT116 cells resulted in a 
significant reduction in the luciferase activity of reporter constructs containing the 3’UTR of 
either CCND1 or POGZ (Figure 35).  
 
 
 
 
 
 
 
 
 
 
 
pre-let-7a       +   -    +   -       -    -    -    -       -    -    -   -        -   -     -   -  
pre-n.c. -    +    -   +      -    +   -   +       -    +    -   +       -   +   -   + 
pre-let-7d -   -    -   -        +   -    +   -        -   -     -   -        -   -    -   - 
pre-23a  -   -    -   -        -   -    -   -         +   -   +   -          -   -    -   -       
pre-34a   -   -    -   -         -   -    -   -         -   -    -   -         +   -   +   -  
**  **  **  * **  **   **    ** 
Figure 35: CCND1 and POGZ are direct targets of let-7, miR-23a and miR-34a  
Relative luciferase activity levels were measured 48h after co-transfection of HCT116 cells with CCND1 or POGZ 3’UTR-
constructs (pLightSwitch_3UTR GoClone vectors; SwitchGear Genomics, Menlo Park, CA) and the indicated miRNA 
precursors. Data are mean of three independent experiments ± s.e.m. 
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3.1.12 p53 regulates the activity of a subgroup of genes involved in the DNA 
damage response by modulating AGO2 binding on their UTR sequences 
 
We demonstrated previously (section 2.1.9) that p53 post-transcriptionally regulated 
mRNA expression through differential targeting by AGO2 and that this process was 
dependent upon p53-regulated miRNAs. Next, we wished to evaluate whether DNA damage 
modulated the binding of AGO2 on the 3’UTR of mRNAs independently of the miRNAs that 
were regulated by DNA damage. We believed it was feasible that RNA binding proteins 
modulated by DNA damage might interact with the 3’UTR of specific transcripts and 
antagonize or aid their interaction with AGO2 and hence provide an alternative mechanism of 
post-transcriptional regulation of gene expression. 
To evaluate this theory, we initially analysed our RNA-seq data to determine whether DOX 
treatment induced any significant changes in the expression of known RBPs in a p53-
dependent or –independent manner, which may have indicated a role for an RBP in this 
hypothetical process. Interestingly, we found that DOX treatment induced the differential 
expression of a number of known RBPs. We confirmed that RBM38 expression significantly 
increased in a p53-dependent manner following DNA damage (consistent with the 
literature),
299,448
 as did ZC3H7B abundance. Furthermore, there was a significant reduction in 
the expression of other RBPs including Heterogenous Nuclear Ribonucleoprotein C 
(HNRNPC) and Fused in Sarcoma (FUS).    
 
Next, we proceeded to identify whether differential changes in AGO2 loading following 
DOX treatment was associated with statistically significant differences in the amount of 
sequence overlapping clusters that constituted the PAR-CLIP signal on discrete regions of the 
UTRs. This was done in combination with a motif discovery analysis to determine whether 
particular RNA motifs were associated with these changes in either a p53-dependent or -
independent manner and whether any identified motifs corresponded to known RBPs, 
especially those we had found to be differentially expressed following DNA damage (Figure 
36 and Table 15). Remarkably, we found that, in addition to inducing or suppressing AGO2 
binding to the 3’UTR of target mRNAs, DOX treatment also induced a p53-dependent 
remodelling of this interaction. This did not occur exclusively within the miRNA-binding 
region of the 3’UTR and therefore demonstrated that this differential interaction occurred 
independently of mRNA targeting by AGO2-bound miRNAs. Figure 37 demonstrates this by 
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illustrating that DOX treatment altered the amount of sequence overlapping clusters that 
corresponded to AGO2 binding sites on the 3’UTR of various mRNAs, including CDKN1A, 
CCDN1, GADD45A GADD45B and SESN1. This occurred to a greater degree in p53
WT 
than 
p53
null 
HCT116 cell lines. Furthermore, a meme (http://meme.nbcr.net/meme/) de novo motif 
discovery analysis determined that this binding mechanism was related to a specific RNA 
motif of 10 nt on the regions of the target 3’UTR that corresponded to the sites that lost or 
gained AGO2 binding. A particular RNA motif that was highly enriched for GUC at 
positions 8 to 10 but depleted for G at positions 1 to 7 was specific to p53
WT
 cells (Figure 
36). Interestingly, a TOMTOM (http://meme.nbcr.net/meme/cgi-bin/tomtom.cgi) analysis 
suggested that this RNA motif did not correspond to any known RBP interacting motif 
(Table 15), although interesting potential candidates include the CELF1 and CELF2 binding 
proteins, which have been shown to bind to (GUC)n triplets located on  mRNA targets that 
are usually implicated in apoptosis and cell cycle pathways.
449,450
  
 
These findings demonstrated that p53 post-transcriptionally regulated mRNA expression 
through modulating the binding of AGO2 on its mRNA targets and that this mechanism was 
not only mediated by p53-regulated miRNAs bound to AGO2 but also through the reduction, 
induction and remodelling of AGO2 binding to the 3’UTR of different targets at specific 
RNA motifs independently from miRNA binding. This provided further insights into the 
complexity of the AGO2-miRNA-mRNA interaction networks involved in the DNA damage 
response and their role in modulating gene expression and regulating cellular signaling 
pathways.  
 
 
Figure 36: A meme de novo motif 
discovery analysis 
This identifies a particular RNA 
motif that is highly enriched for GUC 
at positions 8 to 10 but depleted for G 
at positions 1 to 7 that was specific to 
clusters identified  by PARCLIP to 
demonstrate differential binding to 
AGO2 following DOX treatment in 
p53
WT
 cells 
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A 
C 
B 
Figure 37: UCSC Genome Browser-adapted density plots 
They illustrate that DOX treatment altered the amount of sequence overlapping clusters that corresponded 
to AGO2 binding sites on the 3’UTR of specific mRNAs including A) CCDN1, B) CDKN1A & C) 
GADD45A. Pink (DOX treated) and purple (vehicle treated) bars illustrate the location and size of 
sequence overlapping clusters corresponding to AGO2 binding sites as derived from the PAR-CLIP 
analysis of treated HCT116
WT
 cells.  
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Cluster Characteristics and cell type 
derivation 
Enriched Motif E-value Numbe
r of 
sites 
RBP 
associated 
with motif 
Clusters located in seed or non-seed regions in 
3’UTRs of mRNAs down-regulated in a p53 
dependent manner in p53
WT
 cells 
 
 
1.7e-022 1171 Nil 
Clusters located in seed or non-seed regions in 
3’UTRs of  mRNAs upregulated in a p53-
dependent manner in p53
WT
 cells 
 
 
2.6e-014 94 
 
Nil 
Clusters located non-seed regions in 3’UTRs of 
mRNAs down-regulated in a p53 dependent 
manner in p53
WT
 cells 
 
 
5.1e-001 212 Nil 
Clusters located in non-seed regions in 3’UTRs of  
mRNAs upregulated in a p53-dependent manner 
in p53
WT
 cells 
 
- - - - 
Clusters located in seed regions in 3’UTRs of 
mRNAs down-regulated in a p53 dependent 
manner in p53
WT
 cells 
 
- - - - 
Clusters located in seed regions in 3’UTRs of  
mRNAs upregulated in a p53-dependent manner 
in p53
WT
 cells 
 
 
1.3e-008 31 Nil 
 
 
 
1.4e-057 59  
Clusters located in seed or non-seed regions in 
3’UTRs of mRNAs down-regulated in p53null cells  
 
5.4e-023 69 Nil 
 
 
3.9e-009 
 
49  
Clusters located in seed or non-seed regions in 
3’UTRs of mRNAs upregulated in p53null cells 
- - - - 
Clusters located in non-seed regions in 3’UTRs of 
mRNAs down-regulated in p53
null
 cells 
 
- - - - 
Clusters located in non-seed regions in 3’UTRs of 
mRNAs upregulated in p53
null
 cells 
 
- - - - 
Clusters located in seed regions in 3’UTRs of 
mRNAs down-regulated in a p53 dependent 
manner in p53
null
 cells 
 
 
5.0e-018 43 PUM, SNRPA 
Clusters located in seed regions in 3’UTRs of 
mRNAs upregulated in p53
null
 cells 
 
- - - - 
Table 15: A meme motif discovery analysis and TOMTOM analysis  
Illustrates the 10nt motifs associated with regions of the target 3’UTR (seed or non-seed region) whose binding 
onto AGO2 increased or decreased following DOX treatment, and describe the RBP associated with each motif. 
Abbreviations: WT: wild-type; PUM: Pumilio; SNRPA: Small nuclear ribonucleoprotein polypeptide A 
151 
 
3.2 The GAS5-derived snoRNAs are involved in the p53-
dependent cellular response to DNA damage       
 
Until very recently there has been little justification for the systematic evaluation of 
the role of snoRNAs, or snoRNA dysfunction in tumorigenesis or other pathological 
conditions. This is predominantly due to the fact that in humans, most snoRNAs have been 
shown to be encoded in the introns of protein-coding and non-protein-coding genes which 
gave rise to the assumption that these host genes acted solely as cellular housekeepers.
357,358
 
However, recently snoRNAs and their host genes have been implicated in the control of 
oncogenesis
359,360
 and a number of ‘orphan’ snoRNAs have been identified that have no 
known rRNA targets.
361
 Furthermore snoRNAs have been located in subcellular 
compartments other than the nucleolus,
361
 which supports the concept that they may regulate 
other molecules and have additional cellular functions other than as regulators of the 
ribosome.
362
 Even more strikingly, other studies have reported that mature snoRNAs may 
undergo further cellular processing to form smaller sdRNAs with miRNA-like 
functions.
347,363-366
 Additionally, snoRNA expression has been shown to be as variable as 
miRNA expression in human tumour samples and normalising miRNA PCR expression data 
to these snoRNAs introduced bias in associations between miRNAs and outcome.
367
  
 
The potential role of snoRNAs in tumorigenesis was first suggested by Chang et al. (2002) 
who demonstrated substantially lower snoRNA expression in meningiomas compared with 
normal brains.
376
 Subsequent studies have linked dysregulation in the expression of various 
snoRNAs to the development of a number of malignancies including non-small-cell lung 
cancer,
373,374
 prostate cancer
375
 and breast cancer.
360
 Interestingly, the GAS5 gene that hosts 
ten intronic snoRNAs and a lncRNA, has been implicated in oncogenesis and in the 
regulation of cell survival by inducing or sensitizing cells to apoptosis.
379-381
 GAS5 mRNA 
levels were significantly decreased in breast cancer samples compared with adjacent 
unaffected normal breast epithelial tissues which suggests a role for GAS5 as a tumour-
suppressor gene. However, little is known about whether it is the GAS5-derived snoRNAs or 
lncRNA that are responsible for these effects, although a previous study has suggested that 
three of the GAS5-derived snoRNAs (U44, U74 and U78) may also give rise to sdRNAs with 
miRNA-like function
347
 although no mechanism or specific targets were shown and there was 
no consistency across cell lines. In work related to results described earlier in this chapter, we 
discovered that expression levels of the GAS5-derived snoRNAs U44 and U47 increased in 
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colon cancer cell lines following doxorubicin treatment and that this occurred in a p53-
dependent manner. Given the previously described role of GAS5 in the regulation of 
apoptosis and the well documented role for p53 in the same process, we aimed to further 
investigate the relationship between p53 and the GAS5 snoRNAs to gain further insight into 
their potential role in cell survival and oncogenesis in colorectal cancer both in vivo and in 
vitro.  
 
3.2.1 Doxorubicin-induced DNA damage increases GAS5-deriveded 
snoRNA expression in a p53 dependent manner in colorectal cancer cell 
lines 
 
We treated HCT116 p53
WT 
and HCT116 p53
KO 
cells with doxorubicin in order to induce 
DNA damage, and used RT-qPCR to measure the changes induced in the expression levels of 
various small RNAs, particularly the GAS5-derived snoRNAs U44 and U47. Doxorubicin 
treatment in HCT116 p53
WT 
cell lines led to a significant induction in the expression of the 
GAS5-derived snoRNAs U44 (P < 0.01) and U47 (P < 0.01) when compared to treatment 
with a control vehicle, but there was no significant change in levels of the non-GAS5-
associated snoRNA U19 (Figure 38) or the snRNA U6 (data not shown). Doxorubicin 
treatment did not significantly increase GAS5-derived snoRNA expression in HCT116 p53
KO 
cells (Figure 9), suggesting that DNA damage induced the expression of the GAS5-derived 
snoRNAs in a p53-dependent manner. Doxorubicin treatment of HCT116 p53
WT 
cells also 
significantly increased the expression of miR-34a (P ≤ 0.006), used as a positive control, 
although the size of the fold change varied depending on which small RNA was selected to 
normalize expression levels to (Figure 38 & 39). Following 24 hours of doxorubicin 
treatment, miR-34a expression increased significantly by 2.8-fold and 2.6-fold (P ≤ 0.006 for 
both) when levels were normalised to U6 and U19 respectively (Figure 10). However, 
although still statistically significant, the fold-changes in miR-34a expression levels were 
much smaller (1.9-fold; P < 0.01) when the GAS5-derived snoRNAs U44 and U47 were used 
for normalisation (Figure 39). Similar differences were seen when p21 was used as a positive 
control (data not shown).  
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Figure 38: DOX induces the expression of the GAS5-derived snoRNAs 
Relative levels of (A) miR-34a, (B) U19 snoRNA, (C) U44 snoRNA and (D) U47 snoRNA were measured by RT-qPCR 
in p53
WT
 HCT116 cell lines and p53
KO
 HCT116 cell lines treated with either doxorubicin (at a final concentration 
0.2ug/ml) or vehicle for 24 hours. Levels were normalised to U6 snRNA levels and data are presented relative to the 
vehicle treated cells ± s.e.m (each of them performed in triplicate; Student’s t test: *P < 0.01, **P ≤ 0.006). 
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Figure 39: The GAS5-derived snoRNAs are not suitable housekeeping genes for use in experiments where 
DOX treatment 
Relative levels of  miR-34a normalised to (A) U6 snRNA, (B) U47 snoRNA, (C) U44 snoRNA and (D) U19 
snoRNA were measured by RT-qPCR in p53
WT
 HCT116 cell lines and p53
KO
 HCT116 cell lines treated with either 
doxorubicin (at a final concentration 0.2ug/ml) or vehicle for 24 hours. Data are presented relative to the vehicle 
treated cells ± s.e.m (each of them performed in triplicate; Student’s t test: *P < 0.01, **P ≤ 0.006). 
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3.2.2 GAS5-derived snoRNA expression varies between normal and 
malignant colorectal fresh non-microdissected tissue in a p53-dependent 
manner 
 
Having identified a relationship between p53 activity and the expression of GAS5-
snoRNAs in colorectal cancer cell lines, we wished to investigate whether a similar 
association existed in human colorectal tissue, and in particular in colorectal tumour samples. 
We collected paired samples of fresh frozen colorectal tumour tissue and corresponding 
normal colorectal tissue from 20 individual patients and used RT-qPCR to measure miR-34a 
and snoRNA expression levels in these samples. We found significant differences in the 
expression levels of the GAS5-derived snoRNAs between paired samples of fresh frozen 
normal colorectal tissue and colorectal tumour from the same patient (P< 0.01; Figure 40). 
snoRNA levels were significantly higher in tumours compared to the corresponding normal 
colorectal tissue in 85% of patient samples, but were significantly lower in 15%. There was 
no significant difference in snRNA U6 levels between paired normal and tumour samples. 
Interestingly, miR-34a levels were also significantly higher in patient tumour samples when 
compared to their corresponding normal colorectal tissue samples (P≤ 0.0006; Figure 40). 
We then measured p53 expression levels in the paired normal colorectal tissue and colorectal 
tumour samples using Western blotting (Figure 41A-C). p53 levels were significantly higher 
in colorectal tumours compared to their corresponding normal colorectal tissue samples (P< 
0.01; Figure 41D).     
Using the same samples, we calculated Pearson’s correlation coefficients, comparing p53 
expression levels with snoRNA U44 and U47 levels, to determine if any relationship existed 
between GAS5-derived snoRNA levels and p53 in vivo in humans. We found a strong 
positive correlation between p53 expression levels and the levels of both snoRNA U44 
(Pearson Correlation= 0.64; R
2
 linear = 0.41) and snoRNA U47 (Pearson Correlation= 0.69; 
R
2
 linear = 0.49) in colorectal tumour samples (Figure 42A).  We also calculated Pearson’s 
correlation coefficients to compare miR-34a expression levels with snoRNA U44 and U47 
levels, to determine if any relationship existed between the levels of GAS5-derived snoRNAs 
and p53-regulated miRNAs in humans. This was also performed to provide evidence in 
support of the use of miR-34a as a surrogate marker for p53 in this context for additional 
experiments using RNA derived from microdissected FFPE tissue samples in which p53 
levels were not measurable by Western blotting. Interestingly, we found a strong positive 
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correlation between miR-34a expression levels and the levels of both snoRNA U44 (Pearson 
Correlation= 0.73; R
2
 linear = 0.53) and snoRNA U47 (Pearson Correlation= 0.66; R
2
 linear 
= 0.43) in colorectal tumour samples (Figure 42B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    * 
      * 
    *** 
Figure 40: Expression of the GAS5-derived snoRNAs is greater in colorectal tumours than in benign colon tissue 
A Box plot comparing the relative expression levels of miR-34a, U44 snoRNA and U47 snoRNA between paired colorectal 
tumour (T) and normal colorectal (N) fresh frozen tissue samples. (Student’s t test *P < 0.01, ***P ≤ 0.0006) 
 
 * 
   *** 
      *** 
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Figure 41: A comparison of p53 expression levels between paired normal colorectal and colorectal tumour tissue 
samples 
(A & B) Western blot’s showing p53 levels in the first 10 normal colorectal (A) and colorectal tumour (B) tissue samples. 
GAPDH was used as a loading control. (C) Column chart demonstrating the fold changes in p53 expression levels shown in 
the Western blots (A & B) normalised to GAPDH and calculated using ImageJ software. (D) A box plot comparing the 
relative expression levels of p53 between all 25 paired colorectal tumour (T) and normal colorectal (N) tissue samples 
(Student’s t test *P < 0.01). 
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U44:  
• Pearson Correlation= 0.64 
• R
2
 linear = 0.41 
U47:  
• Pearson Correlation= 0.69 
• R
2
 linear = 0.49 
A 
B 
Figure 42: A positive correlation exists between GAS5-derived snoRNA levels and p53 expression in colorectal tissue 
samples 
Graphs showing Pearson correlation analyses of the relationship between (A) p53 levels or (B) miR-34a levels and the 
snoRNAs U44 and U47 in colorectal tumour tissue samples (A & B). 
 
U44:  
• Pearson Correlation= 0.73 
• R
2
 linear = 0.53 
U47:  
• Pearson Correlation= 0.66 
• R
2
 linear = 0.43 
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3.2.3 GAS5-derived snoRNA expression varies between normal, pre-
malignant and malignant microdissected FFPE colorectal tissue and levels 
correlate with miR-34a expression 
 
There is much debate as to the accuracy of RNA and gene expression studies that use 
non-microdissected tumour samples, due to the possible effects that the cellular components 
of the surrounding stroma can have on the levels of the measured molecule. We therefore 
aimed to perform further experiments in microdissected tissue samples to support the results 
above. We collected 60 unpaired FFPE colorectal tissue samples consisting of 20 normal 
mucosa, 20 adenoma and 20 tumour specimens. We microdissected the required portions 
after H&E staining, performed RNA extraction and measured small RNA expression levels 
by RT-qPCR.  We found significantly higher levels of miR-34a (P ≤ 0.006), snoRNA U44 (P 
≤ 0.0005) and snoRNA U47 (P ≤ 0.0005) in adenoma samples when compared with normal 
mucosa samples (Figure 43A). Furthermore, the expression of all 3 small RNAs was 
significantly higher in tumour samples compared to adenoma or normal mucosa samples 
(Figure 14A). In addition, p53 levels measured by immunohistochemistry and given as a p53 
score of 0-3, were higher in tumour samples (80%= score of 3, 20%= score of 2) and 
adenoma samples (50%= score of 3, 30% score of 2, 20% score of 1) than normal tissue 
(100%= score of 0).      
Using the same samples, we then calculated Pearson’s correlation coefficients to compare 
miR-34a expression levels and snoRNA U44 and U47 levels to determine if the relationship 
demonstrated in non-microdissected samples between GAS5-derived snoRNA levels and p53  
(miR-34a being used here as a surrogate marker for p53) was also seen in microdissected 
colorectal tumours. We found a strong positive correlation between miR-34a expression 
levels and the levels of both snoRNA U44 (Pearson Correlation= 0.69; R
2
 linear = 0.47) and 
snoRNA U47 (Pearson Correlation= 0.67; R
2
 linear = 0.45) in colorectal tumour samples 
(Figure 43B). 
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U44:  
• Pearson Correlation= 0.69 
• R
2
 linear = 0.47 
U47:  
• Pearson Correlation= 0.67 
• R
2
 linear = 0.45 
Figure 43: In microdissected colon samples the GAS5-derived snoRNAs are expressed more in malignant and pre-
malignant tissue than benign tissue and levels correlate with p53 expression 
A, RT-qPCR was used to measure the relative expression levels of miR-34a, snoRNA U44 and snoRNA U47 in 
microdissected human tissue samples corresponding to normal colorectal tissue (N), colorectal adenoma (A) and colorectal 
tumours (T) (Student’s t test *P < 0.05,**P ≤ 0.006,***P ≤ 0.0005). B, A Pearson’s correlation analysis was performed to 
determine the relationship between miR-34a levels and the snoRNAs U44 and U47 in microdissected colorectal FFPE tumour 
tissue samples. 
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3.2.4 The expression of GAS5-derived snoRNAs is not affected in colorectal 
cancer cell lines in which DICER has been knocked-down and therefore do 
not appear to be processed by DICER 
 
In view of the findings described in previous studies which demonstrated that 
snoRNAs can be converted to sdRNAs with miRNA-like functions and that processing by 
DICER is the most likely mechanism responsible,
347
 we wished to assess the effect of DICER 
knock-down on the expression of GAS5-derived snoRNAs following DNA damage.  To 
achieve this we used RT-qPCR to compare changes in the expression of the snoRNAs U44 
and U47 following doxorubicin treatment in the colorectal cancer cell lines DLD1 and RKO 
in their wild-type (WT) form and in a form in which DICER had been stably knocked down 
(KD). Interestingly, we found that although DICER knock-down led to a statistically 
significant reduction in miR-34a levels (P ≤ 0.006) in both DLD1 and RKO cell lines (as one 
would expect), there was no effect on the levels of snoRNA U44 or snoRNA U47 (Figure 
44). This suggests that the function of the GAS5-derived snoRNAs in the p53-regulated 
response to DNA damage does not involve their conversion into sdRNAs with miRNA-like 
function, or that if it does, DICER is not involved in this processing step.  
 
In aggregate, these findings demonstrate that a relationship exists between p53 activity and 
the expression of the GAS5-derived snoRNAs in colorectal cancer cell lines and human 
colorectal tissue. Furthermore, they suggest that transcription of the GAS5 gene is directly 
regulated by p53, although chromatin immunoprecipitation (ChIP) studies using DOX 
induced DNA damage would be required to confirm this. Interestingly, analysis of previous 
p53 chromatin immunoprecipitation sequencing (ChIP-seq) experiments performed in 
HCT116 cells
451
 indicates the presence of a significant peak of p53 interaction in two 
independent experiments involving p53 activation induced by Nutlin3 or 5’fluorouracil 
(5FU), at the same position, approximately 800bp away from the GAS5 transcriptional start 
site (TSS), indicating that p53 does directly control GAS5 transcription. Although no 
functional studies have been performed, these findings suggest an important role for the 
GAS5-derived snoRNAs in the p53-regulated cellular response to DNA damage in colorectal 
cancer cell lines and in p53-associated signalling pathways in human colorectal tissue and 
colorectal cancer. It appears that their role is not related to a miRNA-like function, as in our 
studies, they did not appear to be processed by DICER into sdRNAs. Furthermore, our results 
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demonstrate that the GAS5-derived snoRNAs are not appropriate for use as ‘housekeeping 
genes’ for normalisation of RT-qPCR measurements of small RNAs in experiments involving 
DNA damage because fold changes will be lower than their true relative value which would 
lead to inaccurate results. Our data suggest that the snRNA U6 or snoRNA U19 would be 
more appropriate for normalisation in such experiments. 
 
 
 
 
 
 
 
Figure 44:The GAS5-derived snoRNAs are not processed by DICER 
Relative levels of U44 snoRNA (red), U47 snoRNA (blue) and miR-34a (purple) were measured by RT-qPCR in DLD1 
DICER
WT
 cell lines, DLD1 DICER
KD
 cell lines, RKO DICER
WT
 cell lines, RKO DICER
KD
 cell lines treated with either 
doxorubicin (at a final concentration 0.2ug/ml) or vehicle for 24 hours. Data are presented relative to the vehicle treated 
corresponding cell lines (dotted line) ± s.e.m (each of them performed in triplicate; Student’s t test: *P < 0.01, **P ≤ 0.006). 
  
   ** 
  ** 
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3.3 Optimisation of experimental techniques 
3.3.1 PAR-CLIP protocol modifications 
 
The original PAR-CLIP protocol published by Hafner et al. (2010)
332
 involved the use of two 
RNA digestion steps to reduce the size of the RBP-bound RNA and thus to enable 
sequencing of the bound fraction and determination of its identity and binding sequence. 
Firstly, the cell lysates underwent an RNA digestion step using RNase T1 (Fermentas 
1,000U/u) at a final concentration of 1U/ul, followed by incubation at 22
0
c for 15 minutes. 
The second RNA digestion step which followed the IP stage of the protocol used RNase T1 
(Fermentas 1,000U/u) at a final concentration of 100U/ul followed by incubation at 22
0
c for 
15 minutes. However, although these concentrations allowed the digestion of RBP-bound 
fragments of RNA down to the appropriate size for the cell types and RBP used in the Hafner 
paper,
332 
we found that this caused overdigestion of the RNA bound to AGO2 in our PAR-
CLIP experiment so that the resulting size of the RNA fragments at the end of the small RNA 
library preparation was too small. More specifically, in our study the same RNase 
concentrations used in the original Hafner study,
332
 produced RNA fragments of only 10-13 
bp which when converted to cDNA using the Illumina Truseq small RNA library preparation 
kit could not be used for sequencing as they could not be accurately mapped to the genome 
and hence their identity could not be established with any certainty. This is illustrated by the 
bioanalyser traces in Figure 45. The final construct recovery step of the Illumina Truseq 
small RNA library protocol should produce cDNA that are 143-160 nucleotides (nt) in length 
which consist of 19-22 nt corresponding to the AGO2-bound miRNA/digested mRNA and 
125 nt corresponding to the adaptors bound to either side of the RNA during the ‘ligation of 
adaptors’ step in the library protocol that preceded the reverse transcription step. However, as 
the over-digestion of the RNA during the PAR-CLIP step led to the production of RNA 
fragments that were only 10-13 nt rather than 19-22 nt in length then the resulting fragments 
of cDNA produced during the subsequent library preparation steps were around 130 nt in 
length (Figure 45A) and could not therefore be sequenced effectively. We therefore repeated 
the PAR-CLIP protocol on a number of occasions, modifying the concentrations of RNase 
used in each of the RNA digestion steps, as well as the length of incubation times. 
Furthermore, in case the over-digestion was the result of RNase activity due to unintentional 
contamination of the RNA samples with RNase during the various steps of the procedure, we 
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were also increasingly vigilant to ensure all apparatus was decontaminated with RNase zap 
before use. After many repetitions of the PAR-CLIP and library protocols we found that the 
optimal concentrations of RNase to be used in our PAR-CLIP experiment using HCT116 
cells and immunoprecipitating for AGO2 were 1U/ul in the first digestion step and 10U/ul 
(rather than 100U/ul) in the second digestion step. This enabled the production of RNA 
fragments that were predominantly 19-30 nucleotides in length, that could then be used 
successfully to produce a small RNA library that was enriched for cDNA that was 143-160 nt 
in length and that could therefore be successfully sequenced and then after adaptor stripping 
could allow the resulting fragments to be mapped to the genome and identified (Figure 45B). 
 
3.3.2  Modifications to the small RNA and mRNA library preparation 
protocols for AGO2 IP and PAR-CLIP derived RNA 
 
The Illumina Truseq small RNA library preparation protocol states that the starting quantity 
of RNA should be 1ug diluted in 5ul of RNAse free water. The Illumina Truseq mRNA 
library preparation states that the starting quantity of RNA should be 1-4ug diluted in 50ul of 
RNAse free water. However there was no guidance in either protocol on the amount of RNA 
that was required as a starting concentration for RNA derived from an AGO2 IP or PAR-
CLIP experiment. Therefore we initially performed a number of library preparations starting 
with increasing concentrations of RNA derived from both the AGO2 IP and PAR-CLIP 
protocols and assessed the resulting yield of cDNA using a bioanalyser (Figure 46). We 
found that for the small RNA libraries and mRNA libraries produced using RNA from the 
AGO2 IP, the minimum amount of RNA required as a starting quantity was 250ng. Lower 
concentrations of RNA did not allow an effective reverse transcription step and therefore 
there was no detectable cDNA or insufficient amounts of cDNA at the end of the library to 
allow efficient sequencing to be performed. This is because the RNA produced from AGO2 
IP experiments is more enriched for miRNAs and mRNAS and more deplete in tRNA and 
rRNA than total RNA or RNA derived from the input samples of an IP experiment. 
Therefore, for the cDNA library preparation for RNA derived from our experiments we used 
4ug of starting material for the total RNA or input samples and 250ng of RNA for samples 
derived from the AGO2 IP experiments. For the small RNA seq library this meant that we 
required a final concentration of RNA from the AGO2 IP of at least 50ng/ul to enable a 
165 
 
quantity of starting RNA of 250ng as the volume required in the first step of the small RNA 
library is 5ul. The quantities of reagents, including the number of cells used and the quantities 
of sepharose beads and AGO2/IgG antibodies, described in the methods section of this thesis 
that describes the AGO2 IP protocol are those that we found were required to most 
consistently yield a concentration of at least 50ng/ul of RNA that is required for the small 
RNA library preparation step.      
The PAR-CLIP experiment created another conundrum with regards to the starting amount of 
RNA required for the subsequent small RNA library preparation step prior to next generation 
sequencing. The PAR-CLIP experiment produces a final RNA product that is heavily 
degraded due to the RNase digestion steps used during the protocol. The concentration of 
RNA in each sample is quantified using a nanodrop measurement at the end of the PAR-
CLIP experiment prior to the library preparation. However, we found that the concentration 
of starting RNA required for the small RNA library to allow an effective reverse transcription 
and hence to yield sufficient cDNA to allow effective sequencing was far higher for the PAR-
CLIP experiment than for the AGO2 IP experiment. In order to ensure the RNA sample at the 
end of the PAR-CLIP experiment was as concentrated as possible, we dissolved the final 
RNA pellet in only 6ul of RNase free water. This allowed 1ul to be used for a nanodrop 
measurement to ensure RNA was present and of good quality and the remaining 5ul to be 
used for the small RNA library preparation that requires a 5ul starting volume. The starting 
number of cells used in our PAR-CLIP experiments as well as the amount of dynabeads and 
antibody used were calculated through a number of experiments performed to determine 
exactly what was required to enable a sufficient yield for effective library preparation and 
sequencing.    
We also had to optimise the Truseq mRNA protocol by performing an additional 
modification step after the final PCR stage. Despite very careful use of the ‘clean up beads’ 
during the mRNA library preparation that aims to ensure that no significant adaptor 
contamination was present in the final cDNA sample, we had difficulties in ensuring that all 
the samples were free of adaptor contamination. The adaptors are used during the library 
preparation but if free adaptors (unbound to RNA) are left in the sample at the PCR stage 
then these are also amplified along with the cDNA. This means that a significant amount of 
DNA within the samples will have derived from the adaptors and not from reverse 
transcription and PCR of the RNA produced in the AGO2 IP that we wished to measure by 
Next-generation sequencing. If adaptor dimers are sequenced with the cDNA derived from 
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the RNA we wish to measure then they absorb a large number of reads during the sequencing 
process which leads to inaccurate and often uninterpretable results. Therefore it is imperative 
to keep the concentration of adaptor dimers to below 10% of the concentration of cDNA 
derived from the RNA produced in the AGO2 IP. The levels of adaptors can be seen by 
bioanalyser analysis and compared with the levels of cDNA derived from mRNA during the 
same process. In order to ensure that the adaptor concentration was as low as possible, we 
performed an additional gel cutting procedure followed by a cDNA gel extraction step. We 
ran the samples of RNA derived from the AGO2 IP on a 150ml 1% agarose gel and then cut 
the band at 200-500bp that corresponded to the mRNA but ensured that we did not cut any 
bands at 120-130bp that corresponded to adaptor dimers. This ensured that there was no 
adaptor contamination in our samples prior to sequencing and is illustrated in Figure 47. 
Interestingly, but perhaps unsurprisingly, we found that adaptor contamination was a 
particular issue in the AGO2 IP samples and not the input or total RNA samples. This can be 
explained by the fact that the AGO2 IP samples contained significantly less quantities of 
starting RNA that the input or total RNA samples but the same amount of adaptors were used 
in all the library preparations. Therefore in the AGO2 IP samples, there was less material to 
‘mop up’ the unbound adaptors during the library preparation and so more adaptor dimers 
formed.  
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Figure 45: Bionanalyser traces of cDNA derived from RNA produced in the PAR-CLIP experiment 
that was then used to create a cDNA library of small RNAs. (A) cDNA library produced from a PAR-
CLIP experiment using RNase at a concentration of 1U/ul followed by 100U/ul that demonstrates an 
average bp peak of 132 bp. (B) cDNA library produced from a PAR-CLIP experiment using RNase at a 
concentration of 1U/ul followed by 10U/ul that demonstrates an average bp peak of 141-158bp. The peaks 
at 35 and 10380 nt (bp) correspond to the marker peaks used in the bioanalyser protocol.  
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Figure 46: Bionanalyser traces of cDNA derived from RNA produced in the AGO2 IP experiment 
that was then used to create a cDNA library of small RNAs. (A) cDNA library produced from an 
AGO2 experiment that used 100ng as a starting quantity of RNA and did not therefore produce a peak of 
cDNA at 143-160 bp demonstrating that no cDNA corresponding to miRNAs (19-22nt) had been 
produced in the library. (B) cDNA library produced from an AGO2 experiment that used 250ng as a 
starting quantity of RNA and did produce a peak of cDNA at 143-160 bp demonstrating that cDNA 
corresponding to miRNAs (19-22nt) had been produced in the library. The peaks at 35 and 10380 nt (bp) 
correspond to the marker peaks used in the bioanalyser protocol. The peaks at 101 and 123 bp correspond 
to adaptor dimers. 
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Figure 47: Bionanalyser traces of cDNA derived from RNA produced in the AGO2 IP experiment 
that was then used to create a cDNA library of mRNAs. (A) cDNA library produced from an AGO2 
experiment following which no gel clean up procedure was used prior to performing a bioanalyser 
measurement of the yielded products. (B) cDNA library produced from an AGO2 experiment following 
which a gel clean up procedure was used prior to performing a bioanalyser measurement of the yielded 
products. The peaks at 128 bp correspond to the adaptor dimers and are not present in the sample after gel 
cutting (B). The peak between 200 and 500 bp correspond to the mRNA product. 
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4.1 The p53-regulated small RNA network and its role in the 
DNA damage response 
 
4.1.1. We identified a novel group of miRNAs regulated by DNA damage 
and found that this stress stimulus induced the differential loading of 
specific miRNAs onto AGO2, although the mechanism responsible requires 
further evaluation 
 
We selected an RNA-seq approach rather than a microarray approach in order to 
identify novel DNA-damage induced or supressed miRNAs. Although informative, a 
microarray approach would not have allowed the most detailed analysis at the transcriptome 
wide level because such platforms suffer from a fundamental ‘design bias’ in that they can 
only return results from those regions for which probes have been constructed and 
consequently are only as good as the databases from which they are devised. The list of 
known miRNAs on the database, miRBase, is continually updated and therefore even the 
most up-to-date array platform would not have enabled the detection of every known 
miRNA.  Conversely, RNA-seq provided a tool by which the whole transcriptome could be 
studied. We confirmed the p53-dependent up-regulation of miR-34a, miR-143, miR-200 and 
miR-107, consistent with previous findings
239,243,260-262
 and which indicated the reliability of 
our methods, however we were not able to confirm a significant fold-change for the 
previously described p53-regulated miRNAs miR-15a and miR-16.
258
  This may be the result 
of different cell lines used in our experiments than in some previously described studies or 
the use of a different DNA damaging agent but most likely the result of certain minor biases 
in our analytical techniques. However, on the whole our results were very consistent with 
published data and were validated by RT-qPCR and are therefore reliable in our view. Our 
approach enabled us to identify a group of miRNAs not previously demonstrated to be 
regulated by DNA-damage including the p53-dependently up-regulated miR-135b-3p, miR-
4485 and a host of down-regulated miRNAs including miR-4417, miR-548d-3p and miR-
1266-5p. Prior to our study, there was a paucity of data surrounding those miRNAs that were 
down-regulated in a p53-dependent manner following DNA damage, and strikingly many 
were found to be negative regulators of the DNA damage response. Interestingly, our RNA-
Seq approach permitted us to identify for the first time, miR-3065-3p and miR-3065-5p as the 
miRNAs most significantly up-regulated by DNA damage, and this occurred in a p53 
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independent manner, indicating that it could be very important in the DNA damage response. 
It is possible that the p53 family members, p63 and p73 are involved in the transcriptional 
regulation of miRNAs such as miR-3065-3p that are differentially expressed following DNA 
damage in a p53-indpendent manner. By combining these results with our PAR-CLIP data we 
were then able to illustrate in more detail the role of these identified miRNAs in the 
regulation of gene networks responsible for mediating the DNA damage response. 
In addition, we demonstrated that DNA damage induced the differential loading of certain 
miRNAs, such as the let-7 family members, onto AGO2 and that this occurred in a p53-
dependent manner. Furthermore, it was only demonstrated in p53
 
wild-type cell lines 
(HCT116 p53
WT
 and RKO) but not in DLD1 cells that are known to express one allele that 
encodes a mutant form of p53 (a missense C > T mutation at position 241 that results in a Ser 
> Phe substitution) and one p53 allele that is silenced. Due to time constraints, we were not 
able to perform further experiments to determine the mechanism involved here and this is 
discussed in the ‘future work’ chapter of this thesis, however we were able to hypothesise on 
potential mechanisms responsible for these findings. Initially, we postulated whether this 
phenomenon may have been due to an increase in AGO2 protein abundance following DNA 
damage that might have occurred in a p53-dependent manner. Potential mechanisms 
responsible included a p53-mediated increase in transcription of the AGO2 gene, EIF2C2, or 
a p53-regulated decrease in degradation of AGO2 through autophagy. Previous studies have 
demonstrated that both DICER and AGO2 were selected for autophagy by the selective 
autophagy receptor, NDP52, and that this could affect miRNA abundance and function.
452,453
 
Although autophagy has been shown to be a process regulated by p53 in response to DNA 
damage, we could not find any evidence in the literature that demonstrated a p53-dependent 
reduction in autophagy regulation of AGO2 following DNA damage. Furthermore, we could 
find no evidence of a p53-dependent regulation of AGO2 transcription either in the literature 
or our RNA-seq analysis. Crucially, our Western blot analysis demonstrated that DOX did 
not induce a change in cellular AGO2 expression at the protein level suggesting the AGO2 
loading affect was not related to a change in AGO2 abundance. Furthermore, it would have 
been very unlikely that an increase in AGO2 expression would have resulted in a selective 
rather than global increase in miRNA loading. A more probable explanation was that there 
was a p53-dependent change in AGO2 loading of certain miRNAs due to either a specific 
conformational change in AGO2 or the specific binding of these miRNAs to another 
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molecule.  We postulated that RNA-binding proteins (RBP) were the most likely candidates 
here. 
RBPs have been shown to have a role in modulating miRNA processing and function.
75,454-456
 
The heterogenous nuclear ribonucleoprotein A1 (hnRNP A1) was the first miRNA-binding 
protein to be identified.
454
 Previous studies demonstrated hnRNP A1 was involved in the 
packaging, splicing and nucleocytoplasmic transport of pre-mRNA, but further work showed 
that it could also bind to the stem loop of pri-miR-18a and facilitate its processing by 
DROSHA to pre-miR-18a.
454
 LIN-28 has been shown to impair let-7 processing at both the 
DROSHA and DICER levels by interacting with the pri-let-7 stem loop
75
 and by inducing 3’-
terminal uridylation of pre-let-7,
455
 respectively. The KH-type splicing regulatory protein 
(KSRP) binds with high affinity via its KH3 domain to G-rich stretches in the terminal loop 
of many pri- and pre-miRNAs (e.g. let-7a-d, miR-21, miR-16) and also binds to and serves as 
a component of DROSHA and DICER complexes, thereby increasing DROSHA and DICER 
processing by optimising the positioning of miRNA constructs with these RNAse III 
enzymes.
456
 We did not find a significant change in the abundance of any of the mRNAs 
corresponding to these proteins in our RNA-seq analysis making a role for them in the AGO2 
loading affect less likely. Conversely, it is possible that such RBPs may in fact have been 
involved here but that they were activated by p53-induced post-translational modifications 
rather than a p53-dependent change in their abundance, as the p53 signaling pathway has 
been shown to induce many post-transcriptional changes on proteins. Interestingly, stress 
stimuli have been shown to alter the phosphorylation status of hnRNP K and SUMO 
modification of hnRNP C/M led to conformational changes.
457
 Strikingly, a recent study used 
a PARCLIP analysis followed by fluorescence anisotropy-based binding assays to 
demonstrate that HUR interacted with let-7 and functionally affected the association between 
AGO2 and let-7 loading.
458
 To our knowledge, this study and our data were the first to 
demonstrate a mechanism whereby the loading of miRNAs onto AGO2 can be modulated 
and we were the first to demonstrate this within the context of the p53-mediated response to 
DNA damage. Whether HUR is involved in this process demonstrated herein remains to be 
seen.  
 
Subsequently, we reviewed whether p53 itself could be a direct mediator of the increased 
loading of miRNAs onto AGO2 in response to DNA damage. Although historically, p53 has 
been considered to be a sequence-specific DNA-binding transcription factor, reports over 
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recent years have described protein-protein and protein-RNA interactions involving p53 as 
well. p53 has been shown to regulate miRNA processing through protein-protein interactions 
at the DROSHA level through binding with DDX5
243
 and the p53 family members, p63 and 
p73, also appear to regulate components of miRNA processing (i.e. Drosha-DGCR8, Dicer-
TRBP2, and Argonaute proteins).
295,459
 p53–RNA interactions have been shown to be 
mediated by a p53 nucleic acid-binding domain independent of the sequence-specific core 
domain responsible for DNA recognition.
460,461
 For example, p53 interacted with RNA via 
sequence-specific and sequence-nonspecific mRNA binding,
460,462,463
 covalent complexes
464
 
and sequence-nonspecific RNA annealing,
465
 however, some have argued whether 
interactions between p53 and RNA are in fact physiologically relevant.
460,461
 We felt it was 
unlikely that p53 bound directly to the let-7 miRNAs to facilitate their loading onto AGO2, 
but rather that p53 interacted with a protein that enabled this process. Furthermore, we 
postulated that p53 might interact with AGO2 itself and induce a conformational change to 
facilitate the loading of specific miRNAs. In support of this hypothesis, a recent study in 
Drosophila used a genome-scale in vitro expression cloning approach to identify previously 
unreported p53 interactors, and found 91 candidates including both AGO1 and AGO2.
466
 
Although this interaction between p53 and AGO2 was demonstrated in Drosophila and not 
human cell lines, the authors went on to analyse for evolutionary conservation of the p53-
interacting proteins and tested 41 mammalian orthologs and found that 37 bound to one or 
more p53-family members when overexpressed in human cells.
466
 These data support a 
possible direct role for p53 in the AGO2 loading effect that we demonstrated and suggest that 
following DNA damage p53 bound directly to AGO2 and induced a conformational change 
that encouraged the loading of certain miRNAs such as the let-7 family members. Another 
possibility was that p53 bound indirectly to AGO2 through an interaction with a protein able 
to bind to the RISC complex. A potential candidate protein is the Activator of PKR (PACT), 
a 250 kDa Ring-finger containing DICER-associated RBP that along with TRBP was shown 
to be a key regulatory factor involved in substrate and cleavage specificity during miRNA 
and siRNA production.
467,468
 Interestingly, recombinant forms of PACT bound to wild-type 
p53, interfered with its binding to DNA and acted as a negative regulator, but was unable to 
interact with mutant forms of p53.
469,470
 It is possible that in our experiments, DNA damage 
activated wild-type p53 to interact with the RISC complex through its ability to bind to 
DICER-associated PACT and induced a conformational change that modulated the loading of 
certain miRNAs onto the RISC. In keeping with this theory, our finding that the mutated 
form of p53 in DLD1 cells was unable to induce an increase in AGO2 loading might be 
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explained by its inability to bind to PACT on the RISC complex. Interestingly, we are not 
alone in demonstrating that p53-dependent post-transcriptional regulation of miRNA 
processing and function occurred only in cells expressing wild-type p53 and not in those 
expressing a mutant form or that the effect of the mutant differed from that of the wild-type.   
Suzuki et al. (2009) found that although p53 bound to and enhanced the interaction of DDX5 
with the microprocessor and promoted the cleavage of pri-miRNAs to pre-miRNAs, a 
transcriptionally inactive mutant p53 had the opposite affect and augmented this interaction 
leading to a reduction in miRNA processing.
243
 In this study, the mutant forms of p53 that 
were investigated were described as being the transcriptionally inactive mutants C135Y, 
R175H and R273H (although some studies have shown gain-of-function activity for some of 
these mutants) rather than the S241F mutation in the DLD1 cell lines that we used.
243,471
  
 
Somatic mutations in p53 occur in around 50% of all human cancers. The majority are found 
between codons 125-300 corresponding predominantly with the DNA binding region, and 
over 80% of these involve missense mutations whereas most of those occurring outside of 
this zone are non-sense or frameshift mutations.
472
 Most (90%) involve single base 
substitutions, but base insertions and deletions are also demonstrated.
472
 Mutations may be 
functional, non-functional/inactivating, partially functional, or ‘supertrans’ and can cause 
changes in the transcriptional or transactivational properties of p53 as well as its ability to 
interact with other molecules such as RNA or proteins.
473
 Some mutations (e.g. N210Y)  
cause a loss of transcriptional activity, whereas others (e.g. R175H, D281G) activate gain-of-
function (GOF) capabilities leading to the transcription of a set of genes that are not 
necessarily induced or supressed by wild-type p53 but that often have net oncogenic 
effects.
472,473
  Based on work by others, the function of the S241F p53 mutant expressed in 
DLD1 cells used in our experiments appears to be stimulus specific.
474
 Sur et al. (2008) 
demonstrated that in wild-type DLD1 cells that expressed one S241F mutant allele and a one 
silenced allele (S214F/SIL), the DNA damaging agent 5-fluorouracil (5-FU) induced an 
increase in p53 but not CDKN1A.
474
 However, when the mutant S241F allele of was replaced 
with a wild-type allele, the level of p53 protein was reduced and p21 was induced following 
5-FU treatment suggesting that the S241F mutant was transcriptionally inactive (at least in 
the context of CDKN1A).
474
 However, treatment with ionizing radiation did induce the 
differential expression of a number of genes in the S214F/SIL DLD1 cells, mainly those 
involved in G2/M transition or spindle assembly checkpoints, suggesting that this mutant 
form of p53 did regulate transcription to some degree.
474
 Our results supported this view as 
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we showed an increase in miR-34a expression in DLD1 cells following DOX treatment in the 
same manner as that demonstrated in HCT116 and RKO cells that expressed wild-type p53. 
Interestingly, there is some evidence in the literature that the R241F p53 mutant is not 
capable of forming interactions with other proteins which could affect its ability to regulate 
cellular processes in a non-transcriptional manner.  The tumour suppressor, BARD1, and the 
mRNA 3’ processing factor, cleavage-stimulation factor 1 (CstF1) interact with the C-
terminus of p53 following DNA damage induced by ultraviolet-radiation (UV) and this 
inhibits the mRNA 3’ cleavage step during polyadentylation.475 Nazeer et al. (2011), 
elegantly demonstrated that in p53 wild-type cell lines, p53 coexisted in complexes with 
CstF1 and BARD1 following UV-treatment, but that in DLD1 cell lines the interaction of p53 
with these proteins was significantly reduced, as was UV-induced inhibition of 3’ 
processing.
475
 Although the DNA damaging agent here was different to that used in our 
experiments, this paper provides support for our hypothesis that the AGO2 loading effect 
might be lost in DLD1 cells due to the inability of the R241F mutant to interact with the 
relevant proteins involved in this process, but further work is required to confirm this.  
 
4.1.2 How does p53 mediate the remodelling of AGO2 binding to the 3UTR 
of different targets at specific RNA motifs? 
 
Having demonstrated a p53-depedent effect on the loading of specific miRNAs onto 
AGO2 following DOX treatment, we investigated whether DNA damage also modulated the 
binding of AGO2 on the 3’UTR of mRNA targets independently of the miRNAs regulated 
following this damage. We found that, in addition to inducing or suppressing AGO2 binding 
to the 3’UTR of target mRNAs, DOX treatment also induced a p53-dependent remodelling of 
this interaction that did not occur exclusively within the miRNA-binding region of the 
3’UTR. Therefore, this differential interaction appeared to occur independently of mRNA 
targeting by AGO2-bound miRNAs and suggested that RBPs modulated by DNA damage 
might interact with the 3’UTR of specific transcripts and antagonize or aid their interaction 
with AGO2 and hence provide an alternative mechanism of post-transcriptional regulation of 
gene expression. Remarkably our de novo motif discovery analysis showed that this 
remodelling of AGO2 binding to the 3UTR of different targets was related to a specific 10nt 
RNA motif on the regions of the target 3’UTR that corresponded to the sites that lost or 
gained AGO2 binding. This suggested that DOX treatment lead to an increase or decrease in 
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the interaction between an unidentified RBP and mRNAs at this specific RNA motif and that 
this lead to a reduction or augmentation in the binding of the mRNA onto AGO2, 
respectively. A particular RNA motif that was highly enriched for GUC at positions 8 to 10 
but deplete for G at positions 1 to 7 was specific to p53 wild-type cells, which suggested that 
this motif was selected for by a p53-dependent mechanism and that this process probably 
involved a p53-regulated RBP. Unfortunately, our TOMTOM 
(http://meme.nbcr.net/meme/cgi-bin/tomtom.cgi) analysis was unable to identify an RBP 
interacting motif that corresponded to this RNA motif and we have therefore been unable to 
determine with certainty which RBP may be responsible for this process. However, following 
an extensive literature search we were able to identify a number of potential candidates of 
which the CELF family binding proteins appeared the most interesting.  
The CELF family comprises of 6 (CELF1-6) evolutionarily conserved RNA-binding proteins 
that contain 3 highly conserved RNA-Recognition Motifs (RRM), 2 of which reside in the N-
terminal and 1 of which is found in the C-terminal. The RRMs confer RNA binding activity, 
and it has been suggested that a divergent linker domain that bridges the RRMs is crucial for 
functional regulation.
476-480
 CELF1 and 2 are ubiquitously expressed in humans and mice, 
whereas CELF3-6 are found almost exclusively in the nervous system.
476-480
  CELF1 and 2 
have been shown to play essential roles in post-transcriptional gene regulation through their 
ability to bind to mRNAs and affect splicing, deadenylation, mRNA translation and mRNA 
decay,
476,481-483
 but we could not find any studies that demonstrated a role for these proteins in 
the regulation of mRNA loading onto the RISC complex. Initial studies illustrated that 
CELF1 and 2 bound to mRNAs containing (CUG)8 repeat sequences in their 3'UTRs,
484,485
 
and subsequent work revealed that whilst both bound preferentially to GU-rich RNA 
sequences,
486 CELF1 also bound to UG repeats in yeast.487 RIP-ChIP approaches in HeLa 
cells, human T cells, and mouse myoblasts demonstrated an over-representation of the GRE 
sequence, UGUUUGUUUGU, and a GU-repeat sequence, UGUGUGUGUGU in the 3’UTRs 
of CELF1 target mRNAs and both sequences were shown to function as mRNA decay 
elements.
488-490 Furthermore, CELF1 and 2 were demonstrated to bind to (GUC)n triplets 
located on a number of mRNA targets that are known to be involved in apoptosis and cell 
cycle pathways (e.g. CDKN1A, p27, oskar).490,491 Interestingly, CELF1 has been shown to 
undergo post-translational modification, mainly through phosphorylation at various sites, 
which regulates its ability to bind its target mRNAs. The fact that we identified an RNA 
motif that was highly enriched for GUC at positions 8 to 10 but deplete for G at positions 1 to 
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7 within mRNAs bound to AGO2 in a p53-dependent manner, and that p53 activation is 
known to mediate post translation modifications to many proteins suggests that CELF1 may 
be the RBP involved in the remodelling of mRNA binding to AGO2 that we identified. 
However, further experiments are again required to validate this hypothesis. A RIP-seq and 
PAR-CLIP approach, immunoprecipitating for CELF1 in the presence and absence of DOX 
in p53 wild-type and null cells, may hold the key to achieving this.  
4.1.3 Feedback and feed-forward loops provide the means for p53 to survey 
and coordinate the cellular response to DNA damage and complex 
miRNA:mRNA regulatory networks enable fine-tuning of this response 
 
Our experimental approach outlined in Chapter 3.1 allowed us to determine the 
miRNA-mRNA interaction networks involved in the response to DNA damage both in the 
presence or absence of p53, and to do so on a larger scale than previous studies have 
described.  This allowed us to understand in greater detail how miRNAs can function as 
cellular rheostats through their ability to target multiple genes involved in many response 
pathways induced by DNA damage and can assist a cell in switching from one fate to another 
or to be primed to alter its response once a stimulus had resolved. Furthermore, we also 
showed that the miRNAs whose cellular abundance or differential loading onto AGO2 was 
regulated by p53, were involved in an intricate network of regulatory feedback and 
feedforward circuits that fine tune gene expression levels in response to DNA damage to 
permit the repair of DNA damage or initiation of programmed cell death.  
 
A striking finding was that the gene networks controlled by a specific up-regulated or down-
regulated miRNA or a miRNA that was loaded more onto AGO2, could simultaneously 
involve genes that were suppressors or promoters of the cellular process co-ordinated by that 
gene network. This was exemplified by the fact that some of the genes loaded more onto 
AGO2 following DNA damage were pro-apoptotic and others were anti-apoptotic. In the 
same way, some promoted DNA repair and others inhibited it. We found that whilst miR-
143-3p targeted a number of anti-apoptotic genes and genes that promoted cell 
cycling/division such as CCND1, it also targeted pro-apoptotic genes such as BCL2 Binding 
Component 3 (BBC3; also known as PUMA: p53 up-regulated modulator of apoptosis) which 
encodes a member of the BCL-2 family of proteins. BBC3 cooperates with direct activator 
proteins to induce mitochondrial outer membrane permeabilization and apoptosis.
492
 It can 
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bind to anti-apoptotic Bcl-2 family members to induce mitochondrial dysfunction and 
caspase activation and is thus an essential mediator of p53/TP53-dependent and p53/TP53-
independent apoptosis.
493,494
 This was also the case for miRNAs that were up-regulated in a 
p53-independent manner. For example miR-3065-5p targeted pro-apoptotic and anti-
proliferative mRNAs such as BBC3 and PTEN whilst simultaneously targeting anti-apoptotic 
and pro-proliferative mRNAs such NACC1 and PIM1.   
 
Furthermore, a miRNA could also target multiple mRNAs involved in conflicting cellular 
responses to a specific stimulus. Following DNA damage, p53 usually either co-ordinates a 
process of DNA repair or programmed cell death. However we found that following DNA 
damage a miRNA could target genes that negatively regulated apoptosis and hence induced 
cell death, whilst also targeting genes that suppressed DNA repair or senescence and 
therefore promoted the repair of DNA. For example, increased loading of let-7 onto AGO2 
led to increased targeting of SMC1A, a protein involved in DNA repair via its interaction 
with BRCA1, as well as suppression of TUSC2 and CCND1 to promote G1 arrest and 
apoptosis. These findings were not completely unexpected given that, following DNA 
damage, p53 can act to provide damaged cells the opportunity for repair whilst concurrently 
or subsequently promoting the death of mutated or irrevocably damaged cells. 
   
Additionally, p53-dependent miRNAs were found to target genes that were also 
transcriptionally regulated in a p53-dependent manner following DNA damage. We found 
that cell cycle genes such as CCND1 were transcriptionally up-regulated by p53, but at the 
same time were co-targeted by a number of p53 up-regulated miRNAs that inhibit their 
translation. Furthermore, SESN1 expression was induced by p53 following DNA damage and 
this gene was demonstrated to be targeted by the p53-dependently up-regulated miRNA, 
miR-24-3p. Sestrins are known to play a role in the cellular response to DNA damage and 
oxidative stress, and SESN1 mediates p53-regulated inhibition of cell growth by activating 
AMP-activated protein kinase, which leads to an inhibition of the mammalian target of 
rapamycin protein.
495
 The story of CDKN1A in this context was even more interesting. We 
demonstrated (as previously shown) that p53 transcriptionally up-regulated CDKN1A 
expression but we also found that the mRNA corresponding to this gene was targeted by a 
number of p53-dependently up-regulated miRNAs such as miR-200a-3p. Furthermore, 
CDKN1A was also found to be targeted by miRNAs that were down-regulated in a p53-
dependent manner such as miR-301a-3p and miR-301b which, in isolation, might result in an 
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increase in CDKN1A activity. Adding further intricacy to the regulation of CDKN1A 
expression, we found that miR-185-5p, whose loading onto AGO2 increased following DNA 
damage, targeted RBM38 (Figure 45). This RNA-binding protein is transcriptionally induced 
by p53 and specifically binds to the 3'UTR of CDKN1A and maintains its stability, thereby 
promoting cell cycle arrest in G1 following DNA damage.
299,448
 Interestingly, RBM38 is also 
required to decrease miRNA accessibility on a number of p53-induced transcripts, allowing 
an optimal target gene induction and cell cycle control.
299
 However, targeting of RBM38 by 
miR-185-5p would lead to a reduction in CDKN1A stability which could lead to a reduction 
in its abundance and hence a potential increase in cell cycling. Another example of a complex 
p53-dependent feedback loop that we identified following DNA damage involved CCND1, as 
mentioned above. We showed that this gene was transcriptionally up-regulated in a p53-
dependent manner following DOX treatment but that it was also targeted by miRNAs that 
were up-regulated in a p53-dependent manner. Furthermore, we also showed that CCND1 
was targated by miRNAs that were down-regulated in a p53-dependent manner. This 
suggested that the activity and function of CCND1 following DOX induced DNA damage 
was regulated by a complex network of feedback and feedforward loops that acted to fine 
tune expression of this gene and ensure it functioned appropriately at different stages of the 
DNA damage response. 
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Figure 48: Complex network involved in p53-mediated regulation of CDKN1A 
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We found further complex regulatory loops involving genes targeted by miRNAs that were 
regulated in a p53-independent manner following DOX treatment. We demonstrated that 
PTEN was a target of miR-3065-5p and it has been shown that this protein functions as a 
tumour suppressor by dephosphorylating and hence antagonizing components of the PI3K-
AKT/PKB signalling pathway, thereby suppressing cell proliferation. However, PI3K-
AKT/PKB signalling also promotes the phosphorylation and movement of Mdm2 into the 
nucleus where it down-regulates p53.
30,31
 So, by inhibiting the activation of Akt, PTEN 
restricts Mdm2 to the cytoplasm and promotes p53 function. Furthermore, following DNA 
damage p53 acutely induces Mdm2 transcription, providing damaged cells the opportunity 
for repair, but subsequently induces PTEN transcription by interacting with a p53-binding 
element directly upstream of the PTEN locus thereby favouring the death of mutated or 
irrevocably damaged cells.
421,496
 In aggregate these results suggested the existence of a 
complex interaction network involving p53, Mdm2, PTEN and miR-3065-5p. 
  
Another interesting finding from the joint analysis of the PARCLIP and RNA-seq data was 
that in some cases the interaction network for certain miRNAs contained a combination of 
both up-regulated and down-regulated genes as classified by the RNA-seq, whilst in other 
cases the miRNA in question only targeted genes shown to be down-regulated. This 
suggested that the mRNA targeting and translational repression mediated by certain miRNAs 
was stronger than others and that in some cases the miRNA could be the most dominant 
factor in suppressing the expression of certain genes, even over that of transcriptional 
regulation. For example, let-7 targeted genes such as  CCND1 whose abundance in the RNA-
seq analysis was shown to be increased following DOX treatment, but that it also targeted 
genes such as Polymerase DNA directed lambda (POLL), HMGA2 and pyruvate 
dehyrogenase phosphatase catalytic subunit 2 (PDP2) whose expression decreased. 
Conversely, miR-3065-5p whose expression was so strongly induced following DNA damage 
in the RIP-seq was shown only to target genes that were down-regulated in the RNA-seq. 
This suggested that the 3-fold increase in the level of miR-3065-5p that occurred following 
DOX treatment was sufficient to ensure that all the expression of all the genes it targeted 
were supressed.       
 
These findings added further complexity to our understanding of the mRNA;miRNA 
interactome following DNA damage and demonstrated that the effects of miRNA-mediated 
post-transcriptional regulation of gene expression can depend on a balance between the 
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magnitude of the variation in the expression of miRNAs that co-target that specific gene 
through direct or indirect mechansims. Taken together, these findings suggested that 
following DNA damage miRNAs are involved in multiple feedback and feed-forward loops 
and that they have the ability to fine-tune gene expression and regulate fluctuations in, and 
maintain the fluidity of, the balance between suppression and promotion of cellular response 
mechanisms following such a stress. Thus, following DOX induced DNA damage, 
oncogenes, tumor suppressor genes and miRNAs are networked through p53-dependent and 
p53-independent mechanisms to promote normal cell function and eliminate mutated or 
damaged cells. 
 
4.1.4 DNA damage induces the expression of the GAS5-derived snoRNAs in 
a p53-dependent manner in colorectal cancer cell lines, and a positive 
correlation exists between p53 and the same snoRNAs in normal, pre-
malignant and malignant colorectal tissue 
 
Until Chang et al. (2002)
376
 first described the potential role of snoRNAs in 
tumorigenesis, there had been little justification for the systematic evaluation of the role of 
snoRNAs in this or any other pathological condition. However data are accruing that link a 
dysregulation in the expression of various snoRNAs to the development of a number of 
malignancies.
360,373-375
 As the GAS5 gene hosts ten intronic snoRNAs and a lncRNA and has 
been implicated in oncogenesis and the regulation of cell survival and apoptosis,
379-381
 and 
given the well documented role for p53 in the same processes, we aimed to further investigate 
the relationship between p53 and the GAS5 snoRNAs to gain further insight into their 
potential role in tumorigenesis. We found that, in colorectal cancer cell lines, the GAS5-
derived snoRNAs were induced in a p53-dependent manner following DOX stimulated DNA 
damage but that this affect was not lost when DICER was functionally knocked down. This 
suggested that these snoRNAs were not processed into sdRNAs with miRNA-like function as 
had been suggested by a previous study,
347
 and that their role in the DNA damage response 
did not require them to be further processed in this manner. This implied that these snoRNAs 
might be involved in coordinating the p53-mediated response through their role in regulating 
the ribosome. snoRNAs are crucial for ribosomal function and the effective regulation of 
translation,
346
 and p53 is a key mediator of ribosome biogenesis especially in response to so-
called nucleolar stress.
497
 Furthermore, p53 has been shown to mediate the signaling link 
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between ribosome biogenesis and the cell cycle.
498
 It seems logical therefore that the GAS5-
derived snoRNAs might be directly induced by p53-mediated transcription following DNA 
damage in order to ‘streamline’ the post-transcriptional maturation and modification of 
rRNAs and to ensure a more efficient translation of genes required to coordinate a response 
to such a stress. This theory clearly requires significant further experimental evaluation not 
least by proving that there is an increase in the localization of these snoRNAs to the ribosome 
rather than an alternative cellular compartment following DNA damage. It is possible that 
these snoRNAs do act at a location other than the ribosome and that they may have sdRNA 
type function but do not require DICER processing to enable this. A DICER-independent 
miRNA biogenesis pathway has been identified, whereby a pre-miRNA formed following 
DROSHA processing is loaded directly onto AGO and cleaved by its catalytic centre to 
generate an intermediate 3’-end that is then trimmed.499 A similar DICER-independent 
processing pathway may exist for snoRNAs, but again further studies are required to validate 
this. Whether these DNA damage induced GAS5-derived snoRNAs simply function to 
accommodate an increase in gene translation at the ribosome or whether they are indeed 
processed to sdRNAs and have miRNA-like function, their effect on gene expression could 
be assessed through over-expression experiments followed by RNA sequencing. This would 
enable us to determine their relevance in terms of facilitating the p53-dependent response to 
DNA damage through the post-transcriptional regulation of gene expression. 
 
Following on from the cell line experiments, we wished to determine whether a correlation 
existed between p53 levels and GAS5-derived snoRNA expression in normal, pre-malignant 
and malignant human tissue samples which might have suggested a role for these snoRNAs 
in tumorigenesis. Interestingly, we did find a strongly positive correlation between p53 and 
the GAS5-derived snoRNAs in all three tissue types and in both the micro-dissected FFPE 
samples (where miR-34a was used as a surrogate marker for p53) and the fresh non-micro-
dissected samples. This provided further evidence in support of a role for p53 in the induction 
of the GAS5-derived snoRNAs and suggested a significance for this process in vivo. 
Interestingly U44 and U47 levels were found to be higher in tumour samples than in normal 
or pre-malignant tissue which is most likely the result of higher p53 expression in these 
tumours. Remarkably, and some would argue paradoxically, p53 is overexpressed in up to 
50% of colorectal cancers and this has been associated with a favourable prognosis in some 
studies.
500,501
 This paradox may be explained by the fact that in many cases it is mutant rather 
than wild-type p53 that is overexpressed and hence the effect on cell phenotype will vary 
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based on the function of the mutation variant.
501-503
 In fact, the survival for patients with 
colorectal cancers expressing mutated p53, has been shown to be significantly worse than for 
those patients with tumours that expressed the wild-type protein and this was most striking 
when mutations occurred outside the evolutionarily conserved regions.
503,504
  We did not 
specifically differentiate between mutant and wild-type p53 expression in our study and it 
would be interesting to investigate in future work whether the same correlation exists 
between mutant p53 and the GAS5-derived snoRNAs in human tumour samples. It is likely 
that this will be dependent on the specific p53 mutation as many do retain transcriptional 
activity although often the gene set varies from that regulated by wild-type p53. Interestingly, 
in our cell line work we saw an induction in GAS5-derived snoRNA expression following 
DOX treatment in the DLD1 cells which are known to contain the R241F p53 mutant, and 
this demonstrated that this mutant form of the protein was capable of transcriptionally 
activating the GAS5 gene.  It would also have been interesting to correlate GAS5-derived 
snoRNA levels with outcome in these patients, however as these samples were all taken from 
patients with resectable Dukes Stage A-C tumours there has not been a significant gap since 
their diagnosis to accrue statistically meaningful results as the data are too immature.    
 
Another important finding from our experiments was that the GAS5-derived snoRNAs were 
not appropriate to be used as housekeeping genes for normalising RT-qPCR experiments that 
used DOX to induce DNA damage.  We found that the relative expression of p53-regulated 
miRNAs significantly differed depending on whether GAS5-derived snoRNAs or alternative 
housekeeping genes such as U6 snRNA or U19 snoRNA were used to normalise results. This 
implies that the use of the GAS5-derived snoRNAs as normalising genes in the context of 
DNA damage experiments would lead to an inaccurate interpretation of the results. This is in 
keeping with the finding of others who have shown that in experiments involving human 
tumour samples, snoRNA expression was as variable as miRNA expression and that 
normalising miRNA PCR expression data to these snoRNAs introduced bias in associations 
between miRNAs and outcome.
367
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4.1.5 The potential role of p53-regulated non-coding RNAs in cancer 
therapeutics 
 
p53 is commonly dysfunctional across many tumour types either due to deletion of one or 
both alleles or genetic mutations and therefore provides a uniquely attractive target for drug 
development. However, drugs that target proteins normally inhibit rather than restore their 
function and therefore, like many other tumour suppressor genes, p53 is not a simple 
‘druggable’ target. Furthermore, as the cellular effects of the various mutant forms of p53 can 
vary greatly, some having GOF and others having loss-of-function capabilities, one type of 
therapy that targets tumours expressing a particular form of p53 may not be suitable for those 
expressing an alternative mutant or deletion variant. It has therefore been challenging to 
develop molecules that restore wild-type p53 function to cells lacking any form of the 
protein, or to restore normal transcriptional activation to mutant p53 proteins, although some 
promising agents have been developed
505-508
 and complex animal models have shown that 
activation of the p53 response can be curative even in advanced tumours.
509-511
 Gene therapy 
approaches have also been implemented to try and restore p53 function to tumour cells and 
wild-type p53 delivered by adenovirus vectors is now in widespread use in China.
505
 
Contusugene ladenovec (Advexin; INGN-201; Introgen Therapeutics Inc) is a replication-
impaired, non-integrating, serotype 5 adenoviral vector that carries the p53 gene under the 
control of the CMV promoter and has consistently demonstrated a tolerability and clinical 
efficacy as a monotherapy or in combination with chemotherapy or radiotherapy.
512
 Additive 
or synergistic effects have been observed in a variety of tumour types, including squamous 
cell carcinoma of the head and neck, colorectal, hepatocellular carcinoma, glioma, breast, 
prostate, and lung cancers.
512
 Other biologic approaches include the development of antisense 
RNAs or siRNA that activate p53 by inhibiting the function of its negative regulators 
including HPV E6, MDM2 and MdmX. Furthermore, oncolytic viruses designed to replicate 
and selectively destroy p53 defective cells are also in the pipeline and p53-based vaccines 
that can activate an immune response to abnormally processed p53 in tumour cells are in the 
clinical trial phase. A number of small molecules that directly or indirectly activate the p53 
response have also reached the clinic, of which the most advanced are the p53 MDM2 
interaction inhibitors such as the Nutlins and the sirtuin inhibitors.
513-517
 Interestingly, Nutlin-
3a has been shown to reactivate the expression of CDKN1A, PUMA, p73, E2F1 and the miR-
34 family of miRNAs in p53 deficient tumour cells and induce apoptosis and senescence.
513-
515
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However, difficulties with designing effective p53-based therapeutics have not only centred 
around problems with replacing inactive p53 or reprogramming mutant p53, but in the often 
unpredictable response to such therapies usually in combination with DNA-damaging agents. 
These issues are likely to result from the very complex role that p53 plays within cells and 
the fact that even a small alteration in its function can have a significant effect on a finely 
balanced system that allows cells to switch between cell cycle arrest, senescence and DNA 
repair, and apoptosis. For example, the retention of wild-type p53 was demonstrated to 
protect breast cancers from the cytotoxic effects of some forms of chemotherapy most 
probably by increasing resistance to DNA damaging agents through the promotion of G2/M 
arrest and DNA repair rather than cancer cell death.
518
 Given the complex balance involved 
in the p53 response, for therapeutic purposes, it may be more useful to try to target specific 
elements in the pathways that p53 regulates, rather than p53 itself, in order to perhaps 
regulate the rheostat in favour of cell death and achieve a better response to therapy. p53-
regulated small non-coding RNAs may hold the key to such a strategy and the information 
derived from studies like ours provide a vital source from which miRNA-based therapeutics 
could be selected for delivery to tumours and tip the balance in such a way as to promote 
cancer cell death rather than repair. Such strategies might also be employed to drive cell 
specific effects so as to maximise cell death in tumour cells but minimise such a response in 
normal tissue and avoid toxicities.  miRNA-based therapeutics are becoming a reality in 
certain diseases and by knowing the network of genes targeted by a specific miRNA or group 
of miRNAs, the delivery of single or multiple miRNAs through specialised delivery systems 
may provide the answer to controlling the complex signalling network regulated by p53 and 
manipulate it effectively and provide a novel and potent form of cancer therapy.  
 
4.1.6 Future Directions 
 
In light of the results presented in this thesis, several mechanisms involved in the interaction 
between p53 and small non-coding RNAs remain to be addressed. 
We describe for the first time a p53-dependent process that regulates the loading of specific 
miRNAs onto AGO2 following DNA damage. We hypothesise that the mechanism 
responsible most probably involves a direct or indirect interaction between p53 and the RISC 
complex. This theory is supported by our findings that this loading affect is lost in a cell line 
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expressing a mutant form of p53. To address this hypothesis further it would be necessary to 
assess: 
 The presence or absence of an AGO2 loading affect in cells expressing other p53 
mutants. In order to achieve this we would need to transfect pCMV-Neo-Bam 
plasmids containing the p53 mutants R248W, R175H or R273H (and a null plasmid) 
into HCT116 p53
null
 cell lines for 48 hours and subsequently treat them with DOX or 
vehicle.  It would then be necessary to perform an AGO2 IP experiment to yield 
RNA from the transfected cells and use RT-qPCR to analyse the levels of the 
miRNAs (e.g. let-7) that demonstrated differential AGO2 loading following DOX 
treatment in the p53
WT
 cell lines. It is possible that certain p53 mutants maintain the 
ability to regulate AGO2 loading whilst others may not, but this remains to be 
shown.  
 Whether p53 does in fact bind to AGO2 in the cell lines used in our experiments. To 
achieve this it would be necessary to perform a co-immunoprecipitation experiment 
to investigate the molecular interaction between p53 and AGO2. This would involve 
ectopically expressing AGO2 and p53 in HCT116
null
 cells and performing an AGO2 
and p53 IP with the protein derived from these cells. If there is an association 
between AGO2 and p53 (ad vice versa) then this would suggest an interaction 
between these two proteins might be responsible for the p53-dependent AGO2 
loading. Furthermore, it would also be interesting to ectopically co-express mutant 
forms of p53 with AGO2 in the same cell lines and observe whether the association 
between the two proteins is lost or reduced. If this were the case it would provide an 
explanation as to why the AGO2 loading affect was lost in the p53-mutant cell line.  
 Which region or domain in p53 is responsible for its potential association with 
AGO2. To achieve this is would be necessary to co-transfect Flag-tagged AGO2 into 
HCT116
null
 cells with Myc-tagged p53 constructs that contain deletions in various 
domains including the transactivation domain, proline-rich domain, DNA-binding 
domain and the C-terminus. A co-immunoprecipitation with anti-Flag antibody 
followed by Western blotting for p53 would enable us to determine whether any 
particular domain was responsible for the association between AGO2 and p53.  
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We also demonstrated another previously undescribed process whereby DNA damage 
modulated the binding of AGO2 on the 3’UTR of mRNA targets independently of the 
miRNAs regulated following this damage. This appeared to occur independently of mRNA 
targeting by AGO2-bound miRNAs and suggested that RBPs modulated by DNA damage 
might interact with the 3’UTR of specific transcripts and antagonize or aid their interaction 
with AGO2. Our de novo motif discovery analysis showed that this remodelling of AGO2 
binding to the 3’UTR of different targets was related to a specific 10nt RNA motif on the 
regions of the target 3’UTR that corresponded to the sites that lost or gained AGO2 binding. 
A particular RNA motif that was highly enriched for GUC at positions 8 to 10 but deplete for 
G at positions 1 to 7 was specific to p53 wild-type cells, but our TOMTOM analysis was 
unable to identify an RBP interacting motif that corresponded to this RNA motif however we 
hypothesise that the CELF family of binding proteins may be responsible. In order to address 
this further we would wish to: 
 Use siRNAs to knockdown the CELF family of binding proteins in HCT116 p53WT 
and p53
null 
cells and subsequently treat with DOX or vehicle. We would then 
perform protein extraction and use Western blotting to measure whether CELF 
knockdown led to an increase in the protein levels of specific genes that contained 
GUC at positions 8 to 10 but were deplete for G at positions 1 to 7. This is based on 
the theory that following DOX treatment, the binding of CELF proteins to the 
mRNA of these genes increases and hence their targeting by AGO2 reduces. This 
leads to an increase in the expression of these genes at the protein level. Hence, 
CELF knockdown would be expected to cause an increase in AGO2 targeting of 
these genes and hence a reduction in the expression at the protein level.           
 
 If these above experiment demonstrates a functional effect of CELF knockdown on 
the protein expression levels of these genes we would then perform a RIP-seq and 
PAR-CLIP experiment, immunoprecipitating for CELF1 and CELF2 to further 
prove that this RBP binds to those genes. 
We also demonstrate that DNA damage induces the expression of the GAS5-derived 
snoRNAs in a p53-dependent manner in colorectal cancer cell lines, and that a positive 
correlation exists between p53 and the same snoRNAs in normal, pre-malignant and 
malignant colorectal tissue. This suggests a role for these snoRNAs in the p53 response to 
DNA damage but our results suggest that they may not function as sdRNAs with miRNA-like 
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functions as they are not processed by DICER. In order to investigate their role more fully we 
would aim to: 
 Perform nuclear, nucleolar and cytoplasmic separation experiments in HCT116 p53WT 
and p53
null
 cell lines following treatment with DOX or vehicle and then use RT-qPCR 
following RNA extraction to analyse whether a differential expression of the GAS5-
derived snoRNAs exists between the different cellular components. If DOX treatment 
induces an increase in levels of these snoRNAs in a particular compartment, this 
would suggest a role for them in that particular cellular region and would help to 
further hypothesize what their role may be in the DNA damage response. 
 Analyse our AGO2 RIP-seq data to determine whether expressed/transcribed 
fragments corresponding to the GAS5-derived snoRNAs are loaded onto AGO2 
following DNA damage in a p53-dependent manner. The presence of such fragments 
on AGO2 would provide evidence for a miRNA-like role for these snoRNAs and 
would suggest they are processed by a DICER-independent pathway. 
 Produce plasmids expressing the GAS5-derived snoRNAs individually and transfect 
these plasmids into HCT116 cell lines in order to overexpress their transcripts. We 
would then perform RNA extraction, produce a cDNA library and sequence this to 
determine whether these snoRNAs are involved in the regulation of gene expression, 
particularly with respect to p53-regulated genes.   
 
4.1.7 Conclusions 
 
p53 earned its status as ‘the guardian of the genome’ following early studies 
identifying its role as a potent tumour suppressor able to regulate cell growth, DNA repair 
and apoptosis in response to DNA damage or oncogenic activation. However, over time, it 
has become clear that p53 also contributes to a cells response to numerous other normal and 
pathological conditions, and can mediate processes involved in senescence, metabolism, 
macromolecular synthesis, and cell differentiation and development. Hence the complexity of 
its function is only just beginning to be fully appreciated.  Mutations or inactivation in p53 
are the most frequent abnormalities observed in cancer cells. On the other hand miRNAs and 
snoRNAs are often dys-regulated in cancer and we felt that by refining our knowledge of the 
role of these small non-coding RNAs in p53-signalling networks and by gaining a better 
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appreciation of the genes that they target, we would achieve a greater understanding of their 
role in tumorigenesis. Although it is clear that p53’s ability to transcriptionally regulate the 
expression of many different coding genes is key to its function, it is apparent that its ability 
to act as a cellular rheostat is far more complex and to only study its effect on coding gene 
expression at the transcriptional level would have simply scratched the surface in terms of 
defining its true role. Therefore we specifically aimed to investigate, on a genome wide scale, 
the relationship between p53 and the non-coding RNAs that it regulated. In doing so, our 
work enabled us to characterise the role of non-coding RNAs in the post-transcriptional 
regulation of gene expression in response to DNA damage and to better understand how they 
interacted within the complex signalling pathways that mediated this response. We 
determined the miRNA-mRNA interaction networks involved in the response to DNA 
damage both in the presence or absence of p53 and found that cell cycle genes such as 
CCND1 were transcriptionally up-regulated by p53, as well as being co-regulated by various 
p53 up-regulated miRNAs that in turn inhibited their translation. This exemplifies how our 
work allowed us to illustrate, in great detail, the intricate network of feed-forward and 
feedback loops involved in the DNA damage response and added further complexity to our 
understanding of this regulatory process. Furthermore, our work enabled us to appreciate 
better the multiple levels at which genes were regulated by p53-depedent and -independent 
processes in response to DNA damage. Importantly, we demonstrated a previously 
undescribed mechanism by which p53 controlled gene expression through its ability to 
selectively regulate the loading of certain miRNAs onto the RISC complex and that this was 
relevant in the DNA-damage response and in uncontrolled cancer proliferation.  In addition, 
we showed that those miRNAs whose differential loading onto AGO2 was regulated by p53, 
were also involved in intricate networks of regulatory feedback and feed-forward circuits that 
fine-tuned gene expression levels in response to DNA damage to permit DNA repair or the 
initiation of programmed cell death. Furthermore, by a combined AGO2 RIP-Seq and PAR-
CLIP approach we showed a process by which p53 modulated a reduction, induction and 
remodelling of AGO2 binding to the 3’UTR of different gene targets at specific RNA motifs 
which demonstrated another novel mechanism by which p53 could control gene expression in 
response to DNA damage. We also showed that the GAS5-derived snoRNAs were regulated 
in p53-dependent manner following DNA damage and that this relationship appeared to be 
relevant in human tumours as well as cancer cells lines. Although we are yet to define this 
further, we hope that future work will illustrate the role of these snoRNAs in the DNA 
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damage response and in tumorigenesis, as it is becoming clear that this class of small non-
coding RNAs function as more than simple regulators of the ribosome.  
 
p53, through the range of cellular processes that it regulates, clearly plays a vital role in 
protecting cells from damage that may ultimately lead to their uncontrolled growth and 
evolution into a malignant phenotype. However strategies employed to utilize p53 clinically, 
and particularly therapeutically, have been surprisingly unsuccessful and this is probably due 
to the complexity of p53’s function and the intricate manner by which it enable cells to 
oscillate between one state and another.  However, some recent breakthroughs have provided 
much hope and the majority of these have focused on manipulating the network of molecules 
that mediate or regulate p53 function rather than on p53 itself. However, the response to such 
therapeutic agents can be unpredictable and in some cases may have undesirable affects in 
terms of stemming cancer growth by upsetting the balance of the p53 response 
inappropriately. In order to avoid this and achieve greater efficacy and predictability, we need 
a more sophisticated understanding of the regulatory processes involved in the p53 response 
and a more precise insight into how each ‘player’ contributes to the overall balance of a cells 
response in a context and tissue specific manner. Although our work does not provide any 
clear answers to these questions it does provide a novel insight into the complexities 
surrounding the p53 response and can act as a solid platform upon which future work can be 
designed. Small RNA-based therapeutics and biomarker approaches are now becoming a 
reality in the cancer clinic, and dissecting the importance of the relationships between small 
RNAs and p53 identified here, might allow a better understanding of the role of p53 in 
different tumour types and enable a more selective and strategic approach to selecting the 
drugs to most effectively manipulate this complex pathway.    
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